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Microbial infections cause a major health threat and the growing incidence of 
invasive and opportunistic infections is usually associated with high rates of 
morbidity and mortality. Approximately 300,000 patients a year in England are 
affected by a healthcare-associated infection as a result of care within the NHS 
and the NHS cost is estimated at approximately £1 billion a year. The treatment 
of infectious diseases is one of the most challenging problems in medicine due 
to the emergence of microbial resistance, side effects and spectrum of activity. 
Therefore, there is an obvious and urgent need to develop new and effective 
antimicrobial strategies. A possible alternative to traditional antimicrobial drugs is 
photodynamic therapy (aPDT), which depends on the activation of a 
photosensitiser (PS) by a visible light source to produce reactive oxygen species 
(ROS) and singlet oxygen, which can inactivate and kill microbial cells.  
 A library of novel photoactivatable compounds, based on acridine, flavin, 
acridine-isoalloxazine and anthraquinone dyes, has been characterised to 
quantify singlet oxygen release following activation by blue light for 10 and 20 
minutes. Candidate compounds were then screened, using the European 
Committee for Antimicrobial Susceptibility Testing (EUCAST) microbroth dilution 
method, for antimicrobial activity against a range of clinically important fungi, 
including Candida albicans (C. albicans), Saccharomyces cerevisiae (S. 
cerevisiae) and Aspergillus spp., and medically important bacteria, including 
Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus).  
The chemical results demonstrated the ability of the studied compounds to 
generate singlet oxygen upon exposure to blue light. Determination of the 
minimum inhibitory concentration (MIC) has identified a number of novel 
candidate compounds with activity against fungi and bacteria. These compounds 
were further investigated to determine their mechanism of action using a hog1 
and msn2/4 genomic deletion strain of S. cerevisiae. The findings suggest that 
the general stress HOG pathway (High-osmolarity glycerol) has a limited role in 
the cellular response to the compounds. However, msn2/4 deletion strains, which 
encode key transcription factors for the oxidative stress response, showed an 
increase in sensitivity suggesting these compounds are inhibiting microbial cell 
growth via oxidative stress. Further characterisation of the compounds indicates 
iii 
 
that these photo-activated compounds do not develop resistance in fungal and 
bacterial species following three repeated exposures. Additionally, a significant 
effect against Candida albicans biofilm was shown for three tested PDT 
compounds. Finally, the tested compounds showed toxicity against HeLa cells in 
the absence and presence of light. This suggests that, in their current form, they 
are not ideal compounds for clinical use. 
The results from this project support ongoing work in this field which may help in 
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NADPH β-nicotinamide adenine dinucleotide phosphate 
EEHEC Enterohemorrhagic Escherichia coli 
FAD Flavin adenine dinucleotide 






RFU Relative Fluorescence Unit 
VVC Vulvovaginal candidiasis 







An infection is defined as the pathological state resulting from the invasion of the 
body by pathogenic microorganisms, such as bacteria, fungi and viruses. 
Infectious diseases can be mild or develop into more serious diseases which may 
result in long-term consequences or death (Admassie, 2018).  
Infectious diseases are a significant health and financial burden in the UK, 
causing a mortality rate of 7% and annual costs of £30bn (Fisher et al., 2018). 
There is still a rise in infectious pathogens due to the increasing number of 
immunocompromised patients, older people, and diabetics. Despite the 
introduction of vaccination programmes and antimicrobial agents, infections 
remain a primary cause of high rates of morbidity and mortality worldwide (Peleg 
et al., 2010). Treatment of infectious diseases is one of the most challenging 
problems in medicine due to the increased capability of infectious agents to 
develop resistance to existing antimicrobial agents and those agents’ side-effects 
and spectrum of activity. Thus, there is a need to develop new and effective 
antimicrobial strategies (Denning et al., 2015; Fisher et al., 2018). 
A possible alternative to traditional antimicrobial drugs is photodynamic therapy 
(aPDT), which depends on the activation of a photosensitiser (PS) by a visible 
light source, to produce reactive oxygen species (ROS) and singlet oxygen, which 
can inactivate and kill microbial cells. The main advantages associated with PDT 
are: activity against drug-resistant microorganisms and wide spectrum of activity 
(Macdonald et al., 2001; Hamblin et al., 2004). A library of novel photoactivated 
compounds based on acridine, flavin, acridine-isoalloxazine and anthraquinone 
has been characterised photochemically and subsequently screened for 
antimicrobial activity against a range of fungi, including: Saccharomyces 
cerevisiae (S. cerevisiae) Candida albicans (C. albicans) and Aspergillus 
fumigatus (A. fumigatus) and bacteria, including: Staphylococcus aureus (S. 











Fungi are eukaryotic, which means that they contain a membrane-bound nucleus 
and several types of organelles that are common to animal cells. There is a wide 
variety of fungi ranging from the smallest unicellular fungi such as yeast, to large 
multicellular fungi capable of forming hyphal threads. The majority of fungal 
infections affect the skin or mucosa, and can be treated readily, however 
substantial minority are invasive or chronic, and can be difficult to treat (Denning 
et al., 2015). An estimated 1.5 to 2 million people die of fungal infections every 
year, mainly caused by species belonging to four genera of fungi: Aspergillus, 
Candida, Cryptococcus and Pneumocystis (Denning et al., 2015).  
The fungal cell wall fulfils important functions: it offers a rigid and mechanical 
barrier, plays a pivotal role in cell recognition and acts as a site for several 
extracellular enzymes (Vandeputte et al., 2012). 
 
1.1.1 Fungal cell structure 
1.1.1.1 Fungal cell wall 
Fungal cell wall is a dynamic structure, which is fundamental for cell viability, 
morphogenesis and pathogenesis (Gow et al., 2017). It is unique and considered 
a key target for antifungal drugs. It is typically a mutilayered structure comprised 
of glucans, the predominant glucan component being β-1,3-glucan, which forms 
around 50-60% of the total cell wall. A minor, but important, component is chitin 
(1-2%), while mannans (phosphopeptidomannan) are composed of 
mannoproteins and account for 35-40% of the cell wall structure (Figure 1.1; 
Bowman et al., 2006). The β-1,3-glucan and chitin components are largely 
responsible for offering the cell wall strength and can be oserved as an inner 
layer. The outer cell wall layer is composed of mannoproteins and is 
predominantly responsible for determining the porosity of the cell wall 





Figure 1.1 Structure of the fungal cell wall (Klepser, 2001). 
 
1.1.1.2 Fungal cell membrane 
The fungal cell membrane is predominantly composed of sterols and lipids. The 
mains sterol in fungi is ergosterol, which possesses a rigid and compact structure, 
in contrast to cholesterol found in mammalian cells (Rella et al., 2016). Ergosterol 
is biosynthesised by lanosterol 14 alpha-demethylase, and is considered an 
attractive target for antifungal treatment, which can affect cell membrane integrity 
(Maertens et al., 2000; Sant et al., 2016). 
 
1.1.2 Medically important fungi 
Opportunistic fungal pathogens are an increasing problem in human health, 
leading to superficial or serious invasive infections. As described previously, the 
main reasons behind mortality associated with fungal infections are four genera 
of fungi: Aspergillus, Candida, Cryptococcus and Pneumocystis. 
The most common fungal infections are caused by C. albicans and A. fumigatus; 
major burdens in terms of mortality and morbidity in critical care settings and 
leading causes of nosocomial and opportunistic infections.  
Candida is normally present on the skin, intestinal tract and in the genital area 
(Mayer et al., 2013). They can cause skin and mouth infections in healthy people; 
however it is are more common or persistent in people with diabetes, cancer or 
AIDS. A few forms of candidiasis can be serious: 
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- Invasive candidiasis: can spread to other body organs, such as brain, kidneys 
and eyes. It is one of the most common infections acquired in hospital (Reboli 
et al., 2007).  
- Candidemia: a serious infection of the bloodstream; often causing death if not 
promptly treated (Pappas et al., 2004). 
 
The most common species is C. albicans (Figure 1.2), a yeast like fungi 
responsible mainly for candidemia which cause a high mortality rate in the UK 
(approximately 50%) (Miceli et al., 2011; Denning et al., 2015). There are other 
important Candida species such as C. glabrata and C. krusei, which are 
responsible for around 14% and 2% of candidemia infections, respectively (Sardi 
et al., 2013). Both C. glabrata and C. krusei are intrinsically resistant to azole 
compounds. 
Fungal biofilm is frequently found on artificial surfaces. Infections related to 
biofilm are difficult to eliminate; particularly with the conventional antifungal 
treatment (Ramage et al., 2001). The biofilm-forming ability of C. albicans 
contributes to the high resistance of biofilms to antimicrobials and to high rates of 
nosocomial infections (Casalinuovo et al., 2017). 
 
Figure 1.2 C. albicans (Klepser, 2001). 
The Aspergillus mould genus comprises spore-bearing fungi; some of the mould 
of this genus are pathogenic to humans, such as A. fumigatus and A. nidulams. 
They can cause diseases, such as pulmonary aspergilloma, Aspergillus 
pneumonia, or development of bronchial asthma. The most common fungus 
among them is A. fumigatus (Figure 1.3), a life-threatening pathogenic fungus, 
whose conidium is the infectious agent of aspergillosis (Fuller et al., 2013). This 
fungus can grow in conidial and hyphal forms, however hyphae are the 
morphological form observed in tissue during invasive A. fumigtatus infections 
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(Rhodes, 2006). The most common infection route is inhalation of the conidia, as 
inhaled conidia survive and infect the lungs of immunocompromised patients, 
however they are treated in the healthy host’s lung by phagocytes (Liu et al., 
2013). Unfortunately, 30-50% of invasive aspergillosis patients usually die, due 
to late diagnosis, and infections of parts of body such as brain that are left 
untreated with drugs (Denning et al., 2015). 
 
 
                           Figure 1.3 A. fumigatus (Klepser, 2001). 
 
In recent years, there has also been an increase in the number of fungal 
infections in immunocompromised patients related to the budding yeast, 
Saccharomyces cerevisiae (S. cerevisiae; Figure 1.4; Petrikkos et al., 2007). This 
yeast can be found naturally in many niches in the environment, however recently 
the number of cases of diagnosed infections has increased, probably as a result 
of the increased numbers of immunocompromised patients. S. cerevisiae has 
been related to a wide variety of infections, which range from vaginitis and 
cutaneous infections, to systemic bloodstream infections and infections of 
essential organs in immunocompromised and critically ill patients (Pérez-Torrado 
et al., 2016). 
 
 




1.1.3 Antifungal therapy 
The increasing rates of morbidity and mortality caused by fungal infections are 
also associated with the current limited antifungal drugs and their associated 
elevated toxicity. Furthermore, searching for novel antifungal drugs is a difficult 
task, due to the similarities between fungi and human cells (Sucher et al., 2009). 
Currently there are only four groups of antifungal drugs that are used for 
treatment of fungal infections and their antifungal targets, which include fungal 
RNA synthesis and cell wall and cell membrane (Figure 1.5; Odds et al., 2003). 
 
Figure 1.5 Antifungal targets (Odds et al., 2003). 
 
1.1.3.1 Flucytosine (5-FC) 
5-FC was synthesised in 1957, however its antifungal activity was not discovered 
until 1964. Its mechanism of action is related to the inhibition of nucleic acid 
synthesis. 5-FC is rapidly taken up by fungal cells through specific cellular 
transporters, such as cytosine permease (Andriole, 1999). 5-FC (Figure 1.6) is 
converted to 5-fluorouracil (5-FU) by the enzyme cytosine deaminase, which is 
unique to fungal cells (Vermes et al., 2000). 5-FU is utilised to produce 5-
fluorouracil monophosphate (5-FUMP) which is either converted into 5-
fluorouracil triphosphate, which combines into RNA instead of uridylic acid and 
disrupts protein synthesis, or is converted into 5-fluorodeoxyuridine 
monophosphate, which inhibits thymidylate synthase, a key enzyme of DNA 
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synthesis. 5-FC possesses potent activity, mainly against fungi, particularly 
Candida and Cryptococcus species (Sobel et al., 2003). 
 
 
                           Figure 1.6 Structure of 5-FC (Vermes et al., 2000). 
 
1.1.3.2 Polyenes 
Polyenes are a large family of compounds, most of which were derived from 
Streptomyces bacteria. Only three compounds are known to possess clinical 
antifungal activity: amphotericin B (AmB), nystatin and natamycine. All polyenes 
target the fungal cell membrane by binding to the major sterol, ergosterol. This, 
in turn, results in formation of pores in the plasma membrane, which induces 
membrane destabilisation, destroying the fungal cell (Carrillo-Munoz et al., 2006). 
AmB was discovered in 1956 and is considered the gold standard due to its 
broad-spectrum activity against the majority of medically important mould and 
yeast. AmB (Figure 1.7) is widely used in systemic infections therapy for Candida 
and Aspergillus (Vandeputte et al., 2012). 
 
 





All azole derivatives prevent formation of the fungal membrane sterol ergosterol, 
by inhibition of a key enzyme, lanosterol 14 alpha-demethylase (Carrillo-Munoz 
et al., 2006). This causes a block in the production of ergosterol, leading to the 
accumulation of a toxic sterol. This toxic sterol exerts a severe membrane stress 
causing cell death (Maertens, 2004). There are two classes of azoles, imidazoles 
and triazoles. Imidazoles, which have two nitrogen atoms, were synthesised first, 
however their use remained limited to superficial use due to their high toxicity 
(Maertens, 2004). The first imidazole antifungal, ketoconazole, was used in 1981 
but then banned from clinical use for systemic fungal infections due to the risk of 
hepatic damage and risk of decreased human steroid synthesis. Further research 
led to the development of triazoles, having three nitrogen atoms, such as 
fluconazole (Figure 1.8), itraconazole and voriconazole. Triazoles bind more 
specifically to the fungal membrane compared to imidazoles. However, due to 
issues related to drug resistance, a second-generation of triazoles has been 
developed (Vandeputte et al., 2012). Fluconazole is known to have activity 
against Candida species including C. albicans. However, development of 
resistance to fluconazole has become an issue. Additionally, fluconazole lacks 
activity against Aspergillus, while itraconazole and voriconazole are still being 








Echinocandins were discovered in 1974 and were considered to be a significant 
addition to clinical use. Echinocandins are synthetic lipopetide compounds, which 
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target the fungal cell wall, these compounds have no equivalent in humans. This 
property reduces the possibility of attacking the host tissues (Sucher et al., 2009). 
These agents inhibit β(1-3)-glucan synthase, the enzyme responsible for 
production of β(1-3)-glucan, one of the key elements responsible for fungal cell 
wall rigidity. Therefore, inhibition of β(1-3)-glucan synthase causes cell wall 
destabilisation, resulting in cell rupture (Carrillo-Munoz et al., 2006). 
Echinocandins, such as caspofungin (Figure 1.9), are used to treat candidemia, 
invasive candidiasis and aspergillosis and are usually recommended following 
unsuccessful fungal treatment with azoles or AmB (Vandeputte et al., 2012).  
 
Figure 1.9 Structure of caspofungin, an example of an echinocandin (Carrillo-
Munoz et al., 2006). 
 
1.1.4 Problems with current antifungals 
There are several limitations associated with current antifungal agents including 
their resistance, side effects and spectrum of activity, which warrant an intensive 
search for more effective and safer drugs. 
All invasive fungal infections need appropriate antifungal treatment to achieve 
successful clinical outcomes. Since only a few classes of antifungal agents are 
available, the development of resistance to single drug classes and, recently, 
multidrug resistance mainly affect patient management. One of the greatest 
difficulties in achieving clinical success is azole resistance amongst Candida and 
Aspergillus species, followed resistance to echinocandins and multidrug 
resistance amongst Candida species (Perlin et al., 2017). Treatment failure 
occurs when a patient either fails to respond, or no longer responds to antifungal 
agent administered at standard doses. Many hosts and drugs lead to such 
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failures; for example, immunocompromised patients are more likely to fail to 
respond to treatment because the antifungal agents do not combine with the 
assistance of a robust immune system in the fight against fungal infection. 
Additionally, long-term treatment is often associated with the development of 
resistance. Primary drug resistance has emerged naturally among various fungi 
without previous treatment (Fuentefria et al., 2018). 
There are four major mechanisms contributing to development of fungal 
resistance to antifungal drugs. Firstly, the induction of the efflux pump, which 
decreases drug concentration inside the cell, is the most common mechanism of 
drug resistance. In fungi, two different drug efflux systems modulate azole 
resistance, the ATP-binding cassette (ABC) superfamily and the major facilitator 
superfamily (MFS) (Prasad et al., 2014). Frequently, increased number of drug 
efflux pumps reduces the intracellular accumulation of azoles. This mechanism 
is based on overexpression of the Candida drug resistance CDR1 and CDR2 
genes, which encode transporters, Cdr1p and Cdr2p, of the ATP-binding cassette 
(ABC) family. Upregulation of both CDR1 and CDR2 mediates azole resistance 
by enhanced drug efflux and reduced azole accumulation (Vandeputte et al., 
2012; Holmes et al., 2016). The multidrug resistance MDR1 gene, which encodes 
for a major facilitator transporter, Mdr1p, is also crucial in the regulation of 
transporter-mediated efflux pump to confer resistance to azoles.  
Gain-of-function mutations in the transcription factors TAC1 and CgPDR1 can 
result in greater gene expression of drug efflux pumps (Spettel et al., 2019). 
TAC1, a Candida albicans transcription factor, is necessary for the upregulation 
of the ABC-transporter genes CDR1 and CDR2, which mediate azole resistance. 
Since the CgPDR1 gene is one of the major regulators of efflux pump genes, 
deletion of CgPDR1 results in a loss of transcriptional control of the major 
transporters involved in azole resistance and, consequently, decreased 
resistance to these antifungals (Prasad et al., 2014). Expression of ABC genes 
is often associated with azole resistance in S. cerevisiae and C. neoformans 
(Holmes et al., 2016). Secondly, target alteration such as a point mutation in 
FUR1, a gene which encodes an enzyme responsible for 5FU metabolism, results 
in an entire resistance to both 5FC and 5FU in fungal cells (Perlin et al., 2017). 
Thirdly, through a metabolism modification mechanism, some yeasts have the 
ability to grow in high echinocandin concentrations (i.e. greater than the MICs). 
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This phenomenon, called the echinocandins paradoxical effect, is due to the 
metabolic adaptation of the microorganism and is mediated by the cell wall 
integrity signalisation pathway (Vandeputte et al., 2012). This response is the 
direct consequence of the β(1-3)-glucan synthesis inhibition and the subsequent 
cell wall composition modifications, upon echinocandin administration 
(Vandeputte et al., 2012). Finally, both yeast and filamentous fungi can form 
biofilm structures which ensure fungal cell integrity, survival and resistance to 
most available antifungals. Biofilms are sessile cells, which strongly adhere to 
surfaces and to each other, offering protection by a polymetric extracellular matrix 
(ECM) composed primarily of polysaccharides. Pathogenic fungi can also adhere 
to abiotic surfaces such as catheters; in particular, yeasts take advantage of this 
property to gain access to blood circulation, reaching internal organs of patients 
(Desai et al., 2014; Costa-Orlandi et al., 2017). 
With regard to side effects, some antifungal drugs exhibit various side effects, 
which limit their clinical use; 5-FC for example, may cause hepatotoxicity or bone 
marrow injury. The most serious side effect of amphotericin B therapy is 
nephrotoxicity; in this the patient develops some abnormalities in renal function. 
Ketoconazole possesses hepatotoxic properties and does produce an endocrine 
abnormality by suppression of testosterone and ACTH-stimulated cortisol 
synthesis (Roemer et al., 2014; Vermes et al., 2000). It should be noted that 
resistance to one antifungal often causes cross-resistance to others within the 
same class due to various pathways influencing multidrug resistance (Gulshan et 
al., 2007). 
Another example of a medically important fungus is Cryptococcus neoformans, 
which is a major cause of infection in immunocompromised patients and can 
cause a severe form of meningitis in patients with AIDS. Infections by 
Cryptococcus neoformans are common in the lungs and can lead to clinical 
manifestations in the skin, soft tissue and bones. Pneumocystis jirovecii is 
another example of fungus responsible for Pneumocystis pneumonia. It can infect 







Bacteria are prokaryotes consisting of a single cell with a simple internal 
structure. Unlike eukaryotic DNA, which is included inside the nucleus. Bacterial 
DNA is free within the cytoplasm, in a twisted thread-like mass referred to as the 
nucleoid. Bacterial cells also contain separate, circular pieces of DNA called 
plasmids. Bacteria lack membrane-bound organelles, which are designed to 
execute a range of cellular functions from energy production to the transport of 
proteins (Huang et al., 2008). However, both bacteria and eukaryotic cells contain 
ribosomes where proteins are assembled. In regard to bacteria, they are termed 
70S ribosomes, composed of a small 30S subunit and large 50S subunit. On the 
external surface, bacterial cells are generally surrounded by two protective 
coverings: an outer cell wall and an inner cell membrane. However, certain 
bacteria, such as mycoplasmas do not have a cell wall at all (Hacker et al., 1997).  
 
Bacteria are often classified into two groups, as Gram-negative or Gram-positive 
bacteria. This classification is based on the work of Hans Christian Gram, who in 
1884 discovered that there was a difference between some bacteria. Some of the 
bacteria would stain and exhibit a blue-violet colour when he added crystal violet 
complexed with iodine to the bacteria and then washed them with alcohol; these 
bacteria he called Gram-positive bacteria. Other bacteria would not stain but were 
counterstained with safranin or carbolfuchsin to gain a pink colour, these bacteria 
were called Gram-negative bacteria (Yazdankhah et al., 2001). The difference 
between these bacteria is their cell wall and the arrangement of the wall (Figure 
1.6). 
 
1.2.1 Bacterial cell structure 
The spectrum of activity is highly reliant on the sructural difference of the bacterial 
membrane between Gram-negative and Gram-positive bacteria (Figure 1.10). 
Despite antimicrobials passing through the bacterial membrane via passive 
transport through porin or other transporters, it is generally accepted that Gram-
negative bacteria are more difficult to kill using antimicrobials because of their 
outer membrane. The bacterial cell membrane is a bilayer made up of 
phospholipids such as phosphatidylglycerol (Tommasi et al., 2015). Gram-
negative bacteria possess both an inner and an outer membrane, in periplasmic 
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space a thin layer of peptidoglycan (cell wall) is connected to the outer membrane 
via lipoproteins (murein lipoprotein) (Silhavy et al., 2010). Peptidoglycan is a 
polymer consisting of disaccharides and short peptide chains and is synthesised 
via a series of enzymatic steps including the key biosynthetic enzyme, DD-
transpeptidase (Scheffers et al., 2005; Vollmer et al., 2008). DD-transpeptidase 
is a penicillin-binding protein (PBP), responsible for the final stages of bacterial 
cell wall assembly and is a target of β-lactam antibiotics.This enzyme carries out 
the cross-linking of the cell wall, which gives the structural rigidity to the cell wall 
(Silhavy et al., 2010; Malanovic et al., 2016). The outer membrane of the Gram-
negative bacteria is on the inward facing side composed of phospholipids similar 
to the inner membrane, whereas the outer facing side contains 
lipopolysaccharide (LPS) (Sarkar et al., 2017). On the other hand, Gram-positive 
bacteria do not contain an outer membrane, however, they do have a thick cell 
wall (peptidoglycan), through which lipoteichoic acids and wall teichoic acids 
traverse (Malanovic et al., 2016).  
 
Figure 1.10 A comparison of the cell walls of Gram-negative and Gram-positive 





1.2.2 Medically important bacteria 
Bacterial pathogens cause a high rate of mortality around the world, particularly 
in developing countries due to unavailability of antibiotic therapy for resistant 
bacteria (Devasahayam et al., 2010). Most bacterial infections are caused by 
particular microorganisms; Staphylococcus aureus and Escherichia coli 
(Bannerman et al., 2004). 
S. aureus (Figure 1.11) is a Gram-positive bacterium, present in the nose of about 
30% of healthy people and on the skin of about 20% of them. The percentages 
are higher for people who are patients in a hospital or even work there. Bacteria 
can spread from person to person through direct contact with contaminated items 
or by inhalation of infected droplets dispersed by sneezing or coughing 
(Malachowa et al., 2018). The most common S. aureus infections on the skin, 
can however travel through bloodstream ( a bacteraemia) and infect any part of 
the body, particularly heart valves (endocarditis) and bones (osteomyelitis) (Tong 
et al., 2015). These bacteria also tend to accumulate on medical devices in the 
body, such as artificial heart valves or joints, and catheters inserted through skin 
into blood vessels. Various strains of S. aureus produce toxins, which can cause 
food poisoning and toxic shock syndrome. In recent years, the development of 
methicillin-resistant S. aureus (MRSA) has caused a number of medical issues, 
especially in hospitals. (Nixon et al., 2006). In the UK the estimated cost of 
treating MRSA is £13,972 per patient (Nixon et al., 2006). 
 
                                Figure 1.11 S. aureus (van Belkum, 2003). 
E. coli (Figure 1.12) is a Gram-negative bacterium and is one of the most common 
microorganisms isolated in clinical laboratories (Russo et al., 2000; Van Belkum, 
2003). This bacterium is commonly found in the gut of humans and warm-blooded 
animals. This bacterium can be spread from one person to another by hand-to-
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mouth contact. E. coli causes many infections, including cholangitis, neonatal 
meningitis and pneumonia. E. coli, particularly species of extended-spectrum β-
lactamase (ESBL)-producing E. coli, cause many infections such as blood stream 
and urinary tract infections (Rodriguez-Bano et al., 2006). 
 
                                   Figure 1.12 E. coli. (Van Belkum, 2003). 
 
1.2.3 Bacterial therapy 
The majority of the known antibiotics inhibit relatively few pathways in the 
bacterial cell including folic acid synthesis, transcription, DNA replication, protein 
synthesis and cell wall synthesis (Figure 1.13; Lange et al., 2007).. 
 




Current bacterial therapy depends on a number of broad classes of antibiotics: 
1.2.3.1 Penicillin 
Penicillin (Figure 1.14) was isolated from the Penicillium fungi and was the first 
bacteriocidal antibiotic identified. Penicillin binds to the enzyme transpeptidase, 
which is required for the development of the bacterial cell wall. By inhibiting the 
cross-linking activity of the enzyme, peptidoglycan chains are no longer linked, 
preventing new cell wall formation. This causes cell lysis and results in cell death 
(Miller, 2002). Penicillin is mainly effective against Gram-positive bacteria, such 
as Streptococci, Enterococci and some Staphylococci. 
 
                       Figure 1.14 Structure of penicillin (Antunez et al., 2006). 
1.2.3.2 Cephalosporins 
Cephalosporins are a set of bacteriocidal antibiotics originally derived from the 
fungus Acremonium and are structurally similar to penicillin (Figure 1.15). As 
such, these compounds have the same mode of action as penicillin. 
Cephalosporins possess greater efficacy than penicillin against Gram-negative 
bacteria and resistant bacterial strains because they are less susceptible to 
inhibition by β-lactamase (Demain et al., 1999). 
 




The aminoglycoside family (Figure 1.16) are bactericidal, wide-spectrum 
compounds with activity against a number of infectious pathogens, particularly 
Gram-negative bacteria such as E. coli, Pseudomonas and Salmonella species. 
Aminoglycosides bind to the prokaryotic 30S small ribosomal subunits, resulting 
in inhibition of ribosome translocation and therefore protein synthesis (Mingeot-
Leclercq et al., 1999). There are a number of issues associated with using 
aminoglycosides including the toxicity profile, due to unspecific binding to 
mammalian ribosomes, and resistance (Hermann, 2007). 
 
Figure 1.16 Structure of amikacin (Kotra et al., 2000). 
1.2.3.4 Fluoroquinolones 
Fluoroquinolones, such as ofloxacin (Figure 1.17), are synthetic bactericidal 
agents, possessing outstanding activity against various species of Gram-
negative and positive bacteria including gastrointestinal, urinary and respiratory 
bacterial pathogens (Scheld, 2003). Fluoroquinolones inhibit bacterial DNA 
gyrase, which is necessary for initiation of DNA synthesis, thereby preventing 
normal DNA replication and leading to bacterial cell death (Blondeau, 2004). 
 





Tetracyclines (Figure 1.18) are bacteriostatic compounds, which prevent 
bacterial protein synthesis by blocking the attachment of aminoacyl-tRNA with 
the ribosomal acceptor (A) site of the large ribosomal subunit. Consequently, this 
leads to disruption of protein synthesis. These agents display activity against both 
Gram-negative and Gram-positive bacteria (Chopra et al., 2001) . 
 
Figure 1.18 Structure of tetracycline (Chopra et al., 2001). 
 
1.2.3.6 Macrolides 
Macrolides (Figure 1.19) are an important group of naturally occurring antibiotics, 
used mainly to treat lower respiratory infection. These agents bind reversibly to 
the 50S large subunit of the bacterial ribosome, stopping peptide bond formation 
by inhibiting peptidyltransferase activity. This leads to inhibition of bacterial 
protein synthesis (Zotchev, 2003). 
 





1.2.4 Problems with antibiotics 
Bacteria have a natural process that encourages resistance to antibiotics. The 
resistance process occurs via gene level mutations. Antibiotics induce selective 
pressure, and genes act in association with the induced pressure (Admassie, 
2018). Bacteria have the ability to directly transfer genetic material between each 
other by transferring plasmids, which signifies that natural selection is not the only 
mechanism by which resistance evolves. Broad-spectrum antibiotics are 
prescribed in hospitals as a solution for nosocomial infections, however they 
increase emergence of resistance (Zaman et al., 2017). The emergence of 
bacterial resistance has instigated researchers to look for effective alternative 
treatments. These resistant bacterial strains, such as MRSA and vancomycin-
resistant enterococci (VRE), are important causative agents of nosocomial 
infections (Cosgrove et al., 2003; Hurley, 2005). 
Bacterial resistance can develop through three main mechanisms: 
I. Inactivation of the antibiotic by secretion of bacterial hydrolytic enzymes, 
as seen in resistance to β-lactam antibiotics (Walsh et al., 2005). 
II. Bacterial modification of the antibiotic target so that it is no longer 
recognised. In methicillin-resistant S. aureus (MRSA) the mobile genetic 
element SCCmec (staphylococcal cassette chromosome mec) harbouring 
the mecA gene that encodes an alternative penicillin-binding protein 
(PBP2a) induced by β-lactams and with low affinity for β-lactams 
antibiotics (Walsh et al., 2005; Munita et al., 2016). 
III. Upregulation of cellular efflux pumps to limit antibiotic accumulation inside 
the bacterial cell. This is the most frequent mechanism of the development 
of antibiotic resistance (Blair et al., 2015). 
Additionally, as resistance has evolved into multidrug resistance, this has 
resulted in increased global morbidity and mortality. Bacterial pathogens 
belonging to the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter, Pseudomonas aeruginosa and 
Enterobacter) often carry MDR determining genes. 
In addition, many bacterial species are able to form biofilms by adhering both to 
each other and surrounding themselves with an extracellular polymeric 
substances (EPC). This in turn protects the bacterial cells from the effects of the 
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antibiotic. The formation of biofilms occurs in many steps. It requires a special 
type of signalling, known as quorum sensing between bacterial cells (Wu et al., 
2015). Also, it requires transcription of different set of genes compared to those 
planktonic forms of the organisms. In addition, there are channels in the biofilm 
that separate the microcolonies. Mechanical stability of a biofilm is related to the 
viscoelastic features of the EPS matrix (Jamal et al., 2018).  
Further issues associated with antibiotics include host toxicity. For example, 
penicillin and cephalosporin may cause allergic reactions leading to allergic 
symptoms or serious anaphylaxis in rare situations (Antunez et al., 2006). In 
general, the most common side effects affect the digestive system and cause 
vomiting, nausea and abdominal pain. 
 
1.2.5 Tackling antimicrobial resistance issue 
Considering the increasing number of pathogens resistant towards commonly 
used antimicrobial drugs and the rise in opportunistic microbial infections in 
immunocompromised patients, there is a pressing need for antimicrobial 
approaches that are capable of inactivating pathogens efficiently without the risk 
of developing resistance. 
In a report on antimicrobial resistance published on 22 October 2018, the UK 
Parliament Health and Social Care Committee said that the Government must 
make this issue a “top five policy priority” and must urgently improve the market 
for drug companies to focus on developing and introducing new antibiotics. 
Without effective antimicrobial treatments, the risk of death from infectious 
disease would become substantially higher. In 2050 it is estimated that 
antimicrobial resistance will kill 10 million people per year, more than cancer and 
diabetes combined. Therefore, a dedicated budget should be made available to 
enable work and research to find alternative antimicrobial therapies and 
photodynamic therapy could be one of these promising tools to combat microbial 





1.3 Photodynamic therapy 
The basis of photodynamic therapy (PDT) is the initiation of toxic photochemistry 
in the target tissue. This involves a combination of two steps, the first being the 
injection of a photosensitiser followed by light illumination of the sensitised target 
tissue at a specific wavelength which is appropriate for absorbance by the 
photosensitiser (Abrahamse et al., 2016). Although the exact biological 
mechanisms underlying PDT may vary with the nature of photosensitiser, its 
distribution in the tissue, the intracellular localisation sites and other parameters, 
the primary photochemistry involved in PDT-induced damage is similar for all 
photosensitisers. 
 
1.3.1 Historical overview 
In 1801 ultraviolet (UV) rays were discovered and scientists began to understand 
the therapeutic effect of the sunlight. Later, during the 19th century, the use of 
therapy with sunlight increased in the scientific community to treat a variety of 
diseases including rachitis, peritoneal tuberculosis and lupus vulgaris (Weishaupt 
et al., 1976). 
Towards the end of the 19th century, Lahmann constructed and used the first 
artificial light sources in Germany. His construction was made from a carbon arc 
lamp in combination with a parabolic mirror. He successfully treated a patient with 
lupus vulgaris of the nose and recorded an improvement in another patient that 
had the same condition. At the beginning of the 20th century, Niels Finsen 
received the Nobel Prize for his therapeutic results in treating lupus vulgaris with 
concentrated doses of UV radiation from a carbon arc lamp. This was regarded 
as the beginning of modern phototherapy (Roelandts, 2002). 
In the mid-20th century scientists and doctors started using artificial light sources 
for treating neonatal jaundice, psoriasis, and several different skin conditions 
(Macdonald et al., 2001). It was not until the 1990s when the first photosensitisers 
were approved for clinical use (Macdonald et al., 2001; Konopka et al., 2007; 
Ormond et al., 2013). Nowadays, phototherapy can be used with or without the 
use of a photosensitiser. When used together with a photosensitiser, 
phototherapy is known as photochemotherapy (Ormond et al., 2013). 
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Photodynamic therapy (PDT) is a type of photochemotherapy, which involves 
three components: light, a photosensitiser and oxygen.  
Currently photodynamic therapy is mostly used in the treatment of cancers, as 
reviewed by (Allison et al., 2005; Allison et al., 2010), however, there are 
numerous recent studies that have shown that photodynamic therapy also has 
an antimicrobial effect (Cieplik et al., 2014; Cieplik et al., 2018).       
 
1.3.2 General photochemistry of photodynamic therapy 
The PSs are activated by a UV/visible light source of a specific wavelength to 
produce reactive oxygen species (ROS) (Maisch, 2007). During PDT the 
irradiation process transfers electrons of the PS to another orbital, changing the 
ground state of a PS (S0) to an unstable form (excited singlet state, S1). The 
phosphorescence emission, via intersystem crossing that involves a change in 
the spin rotation of an electron, allows S1 to convert to an excited triplet state, 
which is the major factor in the photodynamic treatment (Figure 1.20) (Baltazar 
et al., 2015). 
Photodynamic treatment includes two types of reactions. In the Type 1 
photochemical mechanism, the excited triplet form of PS depends on direct 
electrons or hydrogen transference to a biomolecule (Castano et al., 2004). This 
yields free radicals, which will readily react with oxygen to form cytotoxic species, 
such as; hydroxyl radicals, superoxide O2− and peroxide. The availability of 
oxygen is not necessary in Type 1 as free radicals can induce direct cell death. 
Conversely, Type 2 reactions require transfer of energy from the triplet form of 
PS to the ambient molecular oxygen (Dai et al., 2012; Cieplik et al., 2018). This 
produces singlet oxygen 1O2 by shifting the external O2 electron into the orbital 
with the other electron (Figure 1.20). This resulting singlet oxygen is powerful, 
short-lived and difficult to destroy by enzymes. Consequently, the resultant 
reactive species leads to cell death by apoptosis, necrosis and autophagy 






Figure 1.20 Schematic illustration of photodynamic therapy including the 
Jablonski diagram. The PS firstly absorbs photons that excite it to unstable excited 
singlet state, then this is converted to an excited triplet state. This triplet PS can act in 
two pathways, Type 1 and Type 2, resulting in formation of reactive oxygen species 
(ROS) and singlet oxygen respectively, adapted from (Dai et al., 2012). 
 
 
1.3.3 Oxygen in photodynamic therapy 
The ground state of oxygen has two unpaired electrons, which are positioned on 
the outermost orbitals. Depending on the presence or absence of a magnetic 
field, these electrons can have three different configurations: both spins aligned 
up, both spins aligned down, or in opposite directions. Because of these three 
possible configurations, the ground state of oxygen is also called a triplet state 
(Macdonald et al., 2001). 
 
The predominant agents produced from photodynamic therapy are .OH and 1O2. 
They are highly reactive forms that happen as a result of the photosensitising 
process. The lifetime of both species is very short due to their reactiveness, and 
as a result of this short lifetime the energy created and the oxidative damage 
induced by PDT is highly localised (Ormond et al., 2013; Jiang et al., 2018). 
 
1.3.4 Photosensitisers in photodynamic therapy 
The first photosensitisers used for photodynamic therapy were porphyrins, 
chlorins and bacteriochlorins. These dyes have the strongest light absorption in 
the red portion of the electromagnetic spectrum. They differ in the absorption 
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spectra ranging from around 400 nm to around 800 nm (Macdonald et al., 2001). 
These photosensitisers are highly efficient singlet oxygen generators. The 
production efficiency of singlet oxygen is called singlet oxygen quantum yield (Φ) 
(Mathai et al., 2007; Konopka et al., 2007). 
 
The first commercial photosensitiser was Photofrin®. It belongs to the porphyrin 
group of photosensitisers and absorbs at 630 nm. Initially, it was approved only 
for treating bladder cancer, but later was approved for treating many other 
cancers, including oesophageal, lung, head, neck and abdominal cancers 
(Pushpan et al., 2002). In an attempt to create a better photosensitiser, many 
new compounds have been synthesised such as 5-aminolevulinic acid (ALA), 
benzoporphyrin derivative (BPD), lutetium texaphyrin, temoporfin (mTHPC), 
tinethyletiopurpurin (SnET2) and talaporfin sodium (LS11). These compounds 
are more potent than the first-generation compounds by releasing more ROS. As 
a result of their potency they can cause pain and lead to severe skin 
photosensitivity (Macdonald et al., 2001; Ormond et al., 2013). 
 
Additionally, there are also several non-porphyrin photosensitisers, which are 
organic dyes and aromatic hydrocarbons. These compounds are effective 
photosensitisers as they possess a triplet state of appropriate energies for 
sensitisation of oxygen including acridines, flavines, antharquinones, 
phenothiazines, xanthenes and cyanines (DeRosa et al., 2002; Babanzadeh et 
al., 2018). 
 
1.3.5 Light sources 
The first light sources used for PDT were argon-pumped dye lasers, potassium 
titanyl phosphate (KTP)- or neodymium:yttrium aluminium garnet (Nd:YAG)-
pumped dye lasers, and gold vapour or copper vapour-pumped dye lasers. All 
these devices are expensive and complex, which is why diode laser systems are 
now predominantly used. Diode lasers are easy to handle, portable and less 
expensive compared to previously used devices (Kübler, 2005; Zhu et al., 2005). 
Recently, non-laser light sources, such as light-emitting diodes (LED), have also 
been applied in PDT procedures. These light sources are much less expensive 
and are small, lightweight, and highly flexible (Haas et al., 1997; Steiner, 2006).     
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For an effective PDT treatment, the light source should be capable of activating 
the photosensitiser at a specific wavelength. The penetration of light within skin 
relies on its wavelength, which means that depending on the pathology treated, 
the PDT can be applied superficially, interstitially, intra-operatively, and 
intracavitary (Figure 1.21; Hill et al., 2014). The shorter the wavelength the more 




Figure 1.21 Representation of the electromagnetic spectrum, with regions of 
interest discussed in the text above. Current applications of certain wavebands also 
shown (Gwynne et al., 2018). 
 
1.3.6 Antimicrobial photodynamic therapy (aPDT) 
The antimicrobial potential of PDT has been known since the beginning of the 
last century. However, it was not until the emergence of antibiotic-resistant strains 
of bacteria that scientists were motivated to look for alternative treatments, 
especially for localised infections of the skin and oral cavity (Konopka et al., 2007; 
Davies et al., 2010; Malik et al., 2010).     
It has been illustrated that PDT is effective against a number of microorganisms 
including Gram-positive and negative bacteria including multidrug-resistant 
(MDR) Pseudomonas aeruginosa (Tseng et al., 2009), Staphylococcus aureus 
(Rosa et al., 2014), Listeria monocytogenes and Bacillus subtilis (Yin et al., 2013). 
In addition, it has shown activity against a number of fungal species including 
Candida species, dermatophytes (Lyon et al., 2011) and A. fumigatus (Friedberg 
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et al., 2001). It is unlikely that these microorganisms can develop resistance to 
aPDT. This is due to the fact that singlet oxygen and the free radicals interact 
with several cell structures and different metabolic pathways at the cellular level 
(Wainwright, 2004). As such, antimicrobial photodynamic therapy (aPDT) is a 
possible substitute for traditional antimicrobial drugs. 
 
The products of photodynamic therapy cause damage to various components of 
the microbial cells or they can alter the metabolic activity irreversibly. This results 
in microbial elimination. This mechanism of action is based on the energy 
absorbed through intracellular photosensitisation which is transferred to the 
oxygen molecule in order to damage the oxidative reaction pathways in the 
plasma membrane and the genetic material of the microbial cells (Munin et al., 
2007; Hamblin et al., 2002).   
With regards to the uptake pathways of anionic and cationic photosensitisers, it 
has been reported that the uptake of anionic PSs by microbial cells may be 
mediated through a combination of electrostatic charge interaction, while the 
uptake of cationic PSs is mediated by electrostatic interactions and self-promoted 
uptake pathways (George et al., 2009).  
The localised action of radicals and 1O2 produced during PDT, implies that the 
PS is more effective if it is taken up into its target cell before light is delivered 
(George et al., 2009). Subsequently, these released species are better able to 
oxidise important cellular targets such as membrane, enzymes and lipids which 
leads to microbial killing. However, membrane barriers of the microbial cells limit 
the penetration of PSs into the microbial cell.  
  
In relation to the mechanism of photodynamic inactivation, two pathways - Type 
1 and Type 2 - can be involved in antimicrobial PDT, however one reaction may 
occur to a greater degree than the another due to PS structure and groups 
substituted on it. Some studies investigated the action of a set of acridine, 
thiazine, xanthene and phenazine dyes towards E. coli (Martin et al., 1987), 
concluding that radicals were primarily responsible for the oxygen-dependent 
toxicity of the dyes examined. 
On the other hand, other studies have implicated the Type 2 reaction (via energy 
transfer and 1O2) in the inactivation mechanism of several cationic porphyrins 
against different S. aureus and E. coli species, concluding that the killing was 
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mediated predominantly by 1O2 (Maisch, 2007). Although the microbial 
inactivation by aPDT mainly involves either Type 1 or 2 reactions, participation of 
the another reaction type could not be neglected (Ergaieg et al., 2008). 
 
With respect to the cytotoxic damage, two basic mechanisms have been studied 
in both bacteria and fungi to explain the lethal effect of radical species (Type 1) 
and singlet oxygen (Type 2) caused to microbial cells after PDT treatment 
(Hamblin et al., 2004; Castano et al., 2004): 
 
1- Damage to DNA. DNA modification, breaks in both single- and double-
stranded DNA and photomodification or disappearance of the plasmid 
supercoiled fraction of cytoplasm have been detected in both kinds of 
bacteria upon PDT using structurally different types of photosensitisers 
(Nitzan et al., 1992; Malik et al., 1990; Bertoloni et al., 2000). Guanine 
residues were found to be the most easily oxidised. 
 
2- Damage to the cytoplasmic membrane followed by a leakage of cellular 
contents or inactivation of membrane transport systems and enzymes 
(Valduga et al., 1993). 
 
These mechanisms achieve the cellular damage necessary for the success of 
aPDT, leading to cell lysis and, consequently, to its death. 
Furthermore, the type of microorganisms determines difference in response to a 
PDT. Gram-positive bacteria, for example, can easily take up molecules such as 
neutral or anionic PS used for PDT and can be easily photoinactivated by them, 
especially when compared to Gram-negative which have a unique LPS-
containing outer membrane, that excludes compounds from penetrating into the 
cell (Hamblin et al., 2004; Zgurskaya et al., 2015). Regarding Gram-negative 
bacteria, photoinactivation is not so easy since they are relatively impermeable 
to neutral or anionic drugs due to their highly negatively charged surface and 
when compared to Gram-positive (Zgurskaya et al., 2015). Positively charged 
photosensitisershave been shown to be active against both Gram-positive and 
negative bacteria and fungi.  
Due to the continuous need for new alternatives to antimicrobial therapy, narrow-
wavelength light has been used alone as antimicrobial treatment (Gwynne et al., 
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2018). This wavelength (blue light 400-450 nm) has the ability to activate 
intracellular photosensitisers such as porphyrins, and thus cause cell death by 
the production of toxic reactive oxygen species (Halstead et al., 2016; Zhang et 
al., 2016). 
 
1.3.7 Advantages and disadvantages of photodynamic therapy 
1.3.7.1 Advantages of aPDT 
Antimicrobial photodynamic therapy has shown a reduction of emergence of 
photoresistant strains due to the absence of a specific target (Jori et al., 2006), 
as the short-lived species related to the photodynamic effect have a multi-target 
impact property affecting different components of microbial cells (Giuliani et al., 
2010; Tavares et al., 2010). Additionally, many possible PS compounds have 
been shown to possess aPDT action against bacterial and fungal biofilms, which 
are often untreated by traditional antimicrobial drugs (Yin et al., 2013; Chabrier-
Rosello et al., 2005). The produced ROS species relating to PDT usually have 
irreversible effects on bacterial and fungal cells which hinder the microbial 
recovery after application (Jori et al., 2006; Tavares et al., 2010).  
There are also many different applications of aPDT against a wide range of 
pathogenic microorganisms. As aPDT has a broader therapeutic window than 
other traditional antimicrobial agents, and thus it can be applied to several 
different localised infectious diseases (Donnelly et al., 2008). An important 
observation about cationic antimicrobial PSs concerns their selectivity for 
microbial cells compared to host mammalian cells. It is thought that these PSs, 
such as porphyrin-based compounds, are only slowly taken up by host cells by 
the process of endocytosis, while their uptake into bacteria is relatively rapid 
(Demidova et al., 2004).  
 
1.3.7.2 Disadvantages of aPDT 
In order for PDT to be effective, it requires the light to be directed to the 
appropriate site and tissue depth. Optimal light delivery with lasers and the 
coordination between different clinicians is complex, and sometimes the 
availability of the light sources is a major issue. Currently there are portable light 
sources, which have simplified the process. PDT in general is an ablative 
procedure and the treatments do not provide material for histopathological 
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diagnosis. That is why prior to the application of PDT, a treatment diagnosis 
should be made by other methods. Another limitation of PDT is the inability of the 
light to penetrate deeply, which reduces treatment effectiveness (Jin et al., 2010). 
The extent of light penetration relies on the wavelength and the higher the 
wavelength the more penetration depth. If the target site of action is the skin, it is 
preferred to use shorter wavelengths which are absorbed mainly in the skin (Hill 
et al., 2014; Gwynne et al., 2018).  
Photosensitivity is another issue that can last for some time after the application 
of certain photosensitisers. It is dependent on the method of application of the 
photosensitiser. When administered systemically, skin photosensitivity may last 
for several days or weeks. Patients are instructed to avoid exposure to sunlight, 
to protect the skin and the eyes until the drug is completely eliminated (Konopka 
et al., 2007). 
 
1.4 Aims 
In the last decade, the rise in opportunistic microbial infections in 
immunocompromised patients and the reduction in efficiency of currently 
available treatments has resulted in an unmet medical need, which requires 
focus. Antimicrobial photodynamic therapy has already been identified as a 
promising treatment for microbial infections including resistant species. 
The main aim of this thesis is to identify novel effective photoactivated 
antimicrobial compounds that may target clinically important fungi including S. 
cerevisiae and C. albicans and A. fumigatus and the bacteria S. aureus and E. 
coli. Due to the fact that acridine, flavine and anthraquinone compounds have 
photosensitising activity, it is hoped that synthesised photoactivated compounds 
based on their structures will show activity against several medically important 
microorganisms. Chapters 3, 4, 5, and 6 measure the amount of reactive oxygen 
species released in vitro from acridine, flavine, acridine-isoalloxazine and 
anthraquinone compounds under blue light illumination and determine the 
antimicrobial activity. A further aim was to identify a shortlist of compounds based 
on their antimicrobial activity. 
Chapter 7 investigates the development of resistance by the microbial species to 
the shortlisted photoactivated compounds. Additionally, Chapter 7 examines the 




Data within this thesis investigates the mechanism of action of the shortlisted 
photoactivated antimicrobial compounds and assesses their effects against 
microbial biofilms. Another important aim was to determine whether the novel 
photoactivated antimicrobial candidate compounds are cytotoxic to host 
mammalian cells. Finally, it is hoped that this work will suggest methods to 
































2. Materials and methods 
2.1 Photosensitiser characterisation 
A library of novel photosensitisers, based on acridine, acridine-isoalloxazine, 
flavine and anthraquinone structures, has been previously synthesised by Dr 
Robert Smith, School of Physical Sciences and Computing, University of Central 
Lancashire, Preston, UK (UCLan). 
 
2.1.1 Determination of wavelength of maximum absorbance λmax 
The compounds were dissolved in dimethyl sulfoxide (DMSO), at a concentration 
of 0.5 mg/ml, and the absorption spectrum between the wavelengths 250-800 nm 
was taken using a UV-Visible spectrophotometer (Shimadzu-UV-3600). The 
wavelength of maximum absorbance, λmax, was determined for each of the 
compounds tested.  
The blue light source used in this study was blue light LED (light-emitting diode) 
bulbs giving a peak wavelength of 470 nm and a light fluence rate of 96 mW/cm2 
at 5 cm distance. 
 
2.1.2 Singlet oxygen release analysis 
o TPCPD assay 
Singlet oxygen release by the compounds was assayed using the decolourisation 
of the marker 2,3,4,5-tetraphenylcyclopentadienone (TPCPD) in DMSO (Cincotta 
et al., 1987). Initial stock concentrations of the candidate compounds and the 
marker (TPCPD) were prepared in DMSO (0.5 mg/ml). The candidate 
compounds were added, in a ratio of 1: 1, with the marker TPCPD and the 
absorbance, at a wavelength 506 nm, was monitored over time using a UV-
Visible spectrophotometer (Shimadzu-UV-3600) in the presence or absence of 
blue light. The path length for best illumination was determined to be 5 cm from 
the blue light source and the standards used were aminoacridine, alloxazine, 10-
phenylisoalloxazine, anthraquinone, anthrone and bianthrone. These standards 
were considered to be more likely to release singlet oxygen species due to their 
molecular structures typified by conjugated double bonds containing a 
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delocalised system of π-electrons (Wainwright et al., 1997; Wu et al., 2006). By 
assuming that the drop in TPCPD absorption at 506 nm is directly proportional to 
the reaction with singlet oxygen 1O2, the decrease in absorption caused by tested 
derivatives compared to that of the corresponding standard when exposed to blue 
light under identical conditions thus gives a measure of its photosensitising 
effectiveness.  
The Relative 1O2 yield = Actual reduction of absorption (Standard) / Actual 
reduction of absorption (compounds). 
 
2.1.3 Free radical release studies 
o DPPH assay 
2,2-Diphenyl-1-picrylhydrazyl (DPPH) assay was performed according to Brand- 
Williams et al., (1995) with some modifications. The DPPH• is a stable radical in 
solution, absorbing at 515 nm in either DMSO or methanol. DPPH• accepts a 
hydrogen (H) atom and is reduced to DPPH, resulting in a colour change and a 
decrease in absorption at 515 nm (Brand-Williams et al., 1995).  
Initial stock concentrations of the test compounds 0.5mg/ml and equivalent 
concentration of DPPH were prepared in DMSO to give an OD of approximately 
1.1 +/- 0.02 at 515 nm. The candidate compounds were added to DPPH solution 
at a ratio of 1:1 and the absorbance was monitored over time at 515 nm. 
o ABTS assay 
This assay depends on the reaction between 2,2′-Azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS) and potassium persulphate in order 
to generate ABTS•+ solution as described by (Re et al., 1999). ABTS•+ solution, 
which has a maximum absorption at 734 nm, is reduced by antioxidants to ABTS. 
The extent of this decolourisation depends on the antioxidant activity and the 
amount of free radical species release. ABTS•+ was produced by reacting 7 mM 
ABTS, prepared in water, with 2.45 mM potassium persulphate (final 
concentration) and stored in the dark for 12-16 h. 
The solution was then diluted with phosphate buffered saline (PBS) [0.8% NaCl, 
0.02% KCl, 0.144% Na2HPO4, 0.024% KH2PO4] to give an absorbance of 
approximately 0.7 at 734 nm. The test compounds were added, and the 
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absorbance was monitored over time spectrophotometrically at 734 nm after 
exposing the candidate compound to blue light. 
 
2.2 Microorganisms and growth media 
Details of the yeast species and strains utilised are detailed in Table 2.1. 
The fungal species utilised in the present study are Saccharomyces cerevisiae 
(S. cerevisiae), Candida albicans (C. albicans) and Aspergillus fumigatus (A. 
fumigatus).  
These fungal species were maintained on agar plates, either yeast extract 
peptone dextrose (YPD) [2% dextrose, 1% peptone, 1% yeast extract] (S. 
cerevisiae and C. albicans) containing 2% agar or Sabouraud dextrose (SD) [4% 
dextrose, 1% peptone] (A. fumigatus), containing 1.5% agar. The bacterial 
species utilised were Staphylococcus aureus (S. aureus) and Escherichia coli (E. 
coli), which were maintained in Luria broth (LB) [1% tryptone, 0.5% yeast extract, 
1% NaCl] containing 2% agar. 
The fungal species, S. cerevisiae and C. albicans, were incubated in YPD at 30oC 
with shaking at 180 rpm. A. fumigatus (spore-forming mould) was grown on solid 
medium Sabouraud dextrose agar (SDA) at 35oC because it readily pellets in 
liquid. While the bacterial species, S. aureus and E. coli, were incubated in LB at 
37oC with shaking at 180 rpm. 
Microbial growth was measured via optical density (OD) using a 










Table 2.1 Microbial species and strains utilised in the present study. Strain 
information for fungal and bacterial species and strains used in the present study. () 
means deletion yeast species. NBRP: National BioResource Project (Japan). 
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2.3 Growth analysis 
Growth curves were conducted on fungal and bacterial cells by pre-culturing cells 
overnight in the corresponding media at 30oC and 37oC, respectively, before 
diluting in new media to OD of approximately 0.1. Growth was monitored at hourly 
intervals via OD using a spectrophotometer at either 595 nm, for fungi, or 600 
nm, for bacteria. Analysis of the data enabled the time to reach mid-exponential 
phase for each species to be determined.   
To determine the relationship between optical density (OD) and cell number, 
viable cells were plated onto the corresponding plates at a variety of dilutions. 
The number of colonies were counted after 24 h incubation and related back to 
the starting OD. Density of 5 x 106 cells/ml for S. cerevisiae and 10 x 106 cells/ml 
for C. albicans were related to OD595 approximately 0.1 and density of 15 x 107 
cells/ml for S. aureus and 45 x 107 cells/ml for E. coli were related to OD600 
approximately 0.1. For A. fumigatus, conidia density of 2.5 x 105 cfu/ml was 
related to OD530 approximately 0.01. 
 
2.4 Effect of blue light on microbial growth 
The effect of visible light alone on fungal and bacteria cell growth was studied by 
determining the effect on cell growth with and without exposure. 
3-(N-morpholino) propanesulfonic acid (MOPS) (Sigma-Aldrich) at a final 
concentration of 0.165 M pH 7 was the recommended buffer for preparation of 
RPMI 1640 Medium (HyClone, USA) [2.08% RPMI 1640, 6.906% MOPS, 3.6% 
glucose] was prepared by dissolving the components in distilled water and 
adjusting pH to 7 with 1 M sodium hydroxide [4% NaOH].  
RPMI was then filter sterilised using a 0.22 µm pore size filter (Stericup Filter Unit) 
to reduce the media’s insoluble particle content. Exponentially growing fungal 
cells were diluted and a final inoculum of 2.5 x 105 cfu/ml, prepared in sterilised 
distilled water, was added to each well. Conidia suspension 2.5 x 105 cfu/ml of A. 
fumigatus was prepared in sterilised distilled water and was shaken in a vortex 
mixer if clumps were detected. Cells were then exposed to blue light for either 0, 
10, 20, 30 and 60 min before being incubated overnight at 30⁰C for S. cerevisiae 
and 35⁰C for C. albicans and A. fumigatus. Optical density readings at 530 nm 
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were taken to measure the growth of cells in the absence and presence of blue 
light for S. cerevisiae and C. albicans. For A. fumigatus the growth inhibition was 
determined by visual inspection. These experiments were done three times in 
triplicate, n=3.  
The effect of visible light alone on bacterial cells was studied by measuring the 
optical density (OD600) for S. aureus and E. coli in the absence and presence of 
blue light exposure. Similar volumes of 100 μl Mueller-Hinton [beef extract 0.2%, 
acid hydrolysate of casein 1.75%, starch 0.15%] and an inoculum of 1 x 106 cfu/ml 
bacterial cells (resulting in a final inoculum of 5 x 105) were dispensed in 96-well 
plates. Cells were then exposed to blue light for either 0, 10, 20, 30 and 60 min 
before being incubated overnight in a 35⁰C static incubator. Optical density 
readings at 600 nm were taken to measure the growth of cells in the absence and 
presence of blue light for S. aureus and E. coli. The experiment was repeated 
three times in triplicate, n=3. 
 
2.5 Photoantifungal susceptibility test 
The EUCAST microbroth dilution method (EUCAST 7.3: Arendrup et al., 2015a) 
for yeast was used to evaluate the susceptibility of S. cerevisiae and C. albicans 
to the compounds. The susceptibility of A. fumigatus was measured using 
(EUCAST 9.3: Arendrup et al., 2015b) for moulds. For each compound, the 
minimum inhibitory concentration (MIC) in µg/ml was determined in the absence 
and presence of blue light. 
Cultures of S. cerevisiae and C. albicans were grown in YPD broth at 30⁰C with 
shaking at 180 rpm until they reached the mid-exponential phase. Varying 
concentrations (0-250 µg/ml) of the compounds were prepared in DMSO ( ≤ 5%) 
and RPMI 1640 culture medium and dispensed into 96-well plate before 
inoculation with the same volume of cells, 5 x 105 cfu/ml. The final drug 
concentration and inoculum density was half the starting amount i.e. final 
inoculum = 2.5 x 105 cfu/ml. Plates were illuminated for either 10 or 20 min using 
blue light (470 nm) giving a light irradiance of 96 mW/cm2 and, as a control, in the 
absence of blue light. 
The plates were incubated for 24 h at 30⁰C for S. cerevisiae and 35⁰C for C. 
albicans, before the optical density at a wavelength of 530nm for each well was 
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determined. The MIC values of the compounds were determined to be the well 
showing growth inhibition of ≥ 50% of that of the drug-free control. In contrastfor 
A. fumigatus, the culture was incubated for 48 h at 35 ⁰C and the MIC value 
considered as the concentration of compound providing no visible growth by eye. 
The standard antifungal drug fluconazole was used against S. cerevisiae and C. 
albicans and amphotericin B against A. fumigatus. Experiments were either 
performed twice, in duplicate (n=2), if no effect on growth was observed or three 
times, in duplicate (n=3), if an antimicrobial effect was observed. Where possible 
the resulting MIC values were analysed using two-way ANOVA with Tukey’s post-
hoc test to calculate significant difference, with results found to be significant 
when p ≤ 0.05. 
To determine whether the compounds had a static or cidal effect, 100 µl of sample 
was removed from wells which showed complete inhibition of growth and sub-
cultured into fresh YPD broth medium and incubated for 24 h at 30 ⁰C. The static 
or cidal effect was identified by investigating their growth visually and was 
repeated on three separate occasions. 
 
2.6 Photoantibacterial susceptibility test 
The EUCAST microbroth dilution method (EUCAST 5.1: EUCAST, 2003) for 
bacteria was used to evaluate the susceptibility of Gram-positive S. aureus and 
Gram-negative E. coli to the candidate compounds. For each compound, the 
minimum inhibitory concentration (MIC) was determined in the absence and 
presence of blue light. 
Cultures of S. aureus and E. coli were grown in LB broth at 37⁰C with shaking at 
180 rpm until they reached the mid-exponential phase. Varying concentrations 
(0-256 µg/ml) of the compounds were prepared in DMSO ( ≤ 5%), PBS and 
Mueller-Hinton culture medium and dispensed into 96-well plate before the 
inoculation with the same volume of 1 x 106 cfu/ml. The final drug concentration 
and inoculum density is half the starting amount i.e. final inoculum = 5 x 105 
cfu/ml. Plates were illuminated for either 10 or 20 min using blue light (470 nm) 




The plates were incubated for 16-20 h at 35⁰C for both bacteria, before the optical 
density at a wavelength of 600 nm for each well was determined. The MIC values 
of the compounds were determined to be the first well showing no visible growth. 
Experiments were either performed twice, in duplicate (n=2), if no effect on 
growth was observed or three times, in duplicate (n=3), if an antimicrobial effect 
was observed. Where possible the resulting MIC values were analysed using two-
way ANOVA with Tukey’s post-hoc test to calculate significant difference, with 
results found to be significant when p ≤ 0.05. 
 To determine whether the compounds had a static or cidal effect, 100 µl of 
sample was removed from wells which showed complete inhibition of growth and 
sub-cultured into fresh LB broth media and incubated for 20 h at 35 ⁰C. The static 
or cidal effect was identified by investigating their growth visually and was 
repeated on three separate occasions. 
 
2.7 Mechanism of action of photoactivated antimicrobial 
compounds 
To investigate the mechanism of action of the five shortlisted compounds, which 
showed maximal growth inhibition following initial testing, they were tested 
against two mutant strains of S. cerevisiae deleted for either HOG1 or MSN2/4 
genes involved in the stress response (Table 2.1). The MIC values of the 
compounds were determined using the EUCAST antifungal susceptibility testing 
method against both hog1 and msn2/4 genomic deletion strains of S. cerevisiae 
and compared the wildtype S. cerevisiae. 
 
2.8 Development of resistance to photoactivated compounds 
To investigate the development of resistance by fungal and bacterial species to 
the shortlisted candidate compounds, cells were repeatedly exposed to the 
compounds. Following initial screening by the EUCAST method, surviving cell 
suspensions were grown and screened again, using the same compound and 20-
minute blue light illumination. The MIC was then determined before the assay 
was repeated again. This procedure was repeated until third exposures were 
reached. In each passage, three independent cultures were examined. The 
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resulting MIC values were analysed using two-way ANOVA with Tukey’s post-
hoc test to calculate significant difference, with results found to be significant 
when p ≤ 0.05. 
 
2.9 Effect of pH and EDTA on growth inhibition activity of 
photoactivated compounds 
2.9.1 pH effect 
The effect of pH on the growth inhibition activity of the shortlisted compounds 
against S. cerevisiae and C. albicans was tested. 
Susceptibility testing was performed using a broth microdilution method, 
according to EUCAST guidelines utilising pH 7 (EUCAST 7.3: Arendrup et al., 
2015a). Compound concentrations tested were 0-250 µg/ml and fluconazole 
concentrations range was 0-64 µg/ml. 100 µl inoculum of 5 x 105 cfu/ml (resulting 
in final inoculum of 2.5 x 105 cfu/ml) was added to the same volume of compound 
solution in each well and illuminated for 20 min with blue light. The MIC was 
determined to be the lowest compound concentration giving growth inhibition of 
≥ 50% of that of the compound-free control. Antifungal susceptibility testing was 
carried out for S. cerevisiae and C. albicans by adjusting pH to 4, 5, 6 and 8 using 
1 M sodium hydroxide [4% NaOH] or 1 M hydrogen chloride [96 ml of 32% HCl 
added to distilled water to make a total of 1 L], as required.  These experiments 
were repeated in the presence and absence of MOPS, which is a buffer used to 
minimise pH changes and the MICs values were compared at different pH values 
4, 5, 6, 7 and 8. 
2.9.2 EDTA effect 
The effect of Ethylenediaminetetraacetic acid (EDTA) on the growth inhibition 
activity of the shortlisted compounds against S. cerevisiae and C. albicans was 
tested. 
Susceptibility testing was performed using a broth microdilution method, 
according to EUCAST guidelines (EUCAST 7.3: Arendrup et al., 2015a). 
Compounds’ concentrations (0-250 µg/ml) and fluconazole concentrations (0-64 
µg/ml) were prepared with 1 mM EDTA (final concentration) at pH 7 with and 
without MOPS. 100 µl inoculum of 5 x 105 cfu/ml (a final inoculum of 2.5 x 105 
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cfu/ml) was added to the same volume of compound solution in each 
microdilution well and illuminated for 20 min with blue light. Antifungal 
susceptibility testing was carried out for S. cerevisiae and C. albicans in the 
absence and presence of EDTA and MIC was determined to be the lowest 
compound concentration giving growth inhibition of ≥ 50% of that of the 
compound-free control. MICs were compared and antifungal activity of EDTA was 
determined by analysing MICs results using two-way ANOVA with Tukey’s post-
hoc test to calculate significant difference, with results found to be significant 
when p ≤ 0.05. 
 
2.10 In Vitro antifungal susceptibility testing Of C. albicans 
biofilms 
The antifungal susceptibility test to determine MICs of planktonic cells was 
conducted using EUCAST broth microdilution (EUCAST 7.3: Arendrup et al., 
2015a). Testing was conducted in triplicate. 
Biofilms cells were prepared following method described by (Ramage et al., 
2001), a fresh culture of C. albicans was grown in YPD at 30 ⁰C to ensure growing 
cells were in the budding yeast phase. Cells were harvested by centrifugation for 
3 min at 1438 x g, washed twice in sterile PBS, and resuspended in RPMI 1640 
with L-glutamine and 0.165 M MOPS. The optical density of the culture was 
adjusted to 0.1, which is equivalent to approximately 1 x 106 cfu/ml, by dilution 
with RPMI 1640. Biofilm cells were prepared by pipetting 100 µl of 1 x 106 cfu/ml 
suspension into a flat bottom 96-well microtiter plates before incubating for 48 h 
at 37 ⁰C. Photoantifungal tested compounds were prepared in RPMI 1640 and 
added to the biofilms at varying final concentrations (0-25 µg/ml). Samples were 
exposed to blue light for 20 min before being incubated for 24 h at 35⁰C. MICs of 
compounds and fluconazole were determined using the XTT reduction assay to 
assess their effects on biofilm cells. 
XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] 
was prepared at 0.5 g/l in PBS and then filter sterilised using a stericup vacuum 
(0.22 µm pore size). Menadione (10 mM dissolved in acetone) was added to a 
final concentration of 1 µM and then 100 µl of the XTT-menadione mixture was 
added to biofilm cells and control wells. The 96-well plates were incubated in the 
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dark over a two-hour period at 37 ⁰C and a colorimetric change was examined in 
a microtiter plate reader at 490 nm to compare the metabolic activity of the biofilm 
cells, as XTT is converted only in viable fungal cells into an orange-coloured 
formazan derivative by mitochondrial dehydrogenase activity (Meletiadis et al., 
2001). 
 
2.11 Perseverance parameter measurement 
Perseverance is defined by the ability of fungal cells to grow at drug 
concentrations above the MIC, and is measured as the degree of supra-MIC 
growth (SMG) in broth microdilution assays (Rosenberg et al., 2018).  
Supra-MIC growth (SMG) was quantified as the average growth per well obtained 
after 24h and 48h above the MIC50 at 24 h normalised to growth level in the drug-
free control.  
 
SMG =
average 48 h growth above MIC50
growth without compound
 
EUCAST broth microdilution assay was used to measure MIC value, the lowest 
drug concentration that inhibits 50% of growth, in S. cereviseae and C. albicans 
strains. The plates were incubated for 24 h at 30⁰C and 35⁰C for C. albicans, 
before the optical density at a wavelength of 530 nm for each well was 
determined. MICs values were determined to be the first well giving growth 
inhibition of ≥ 50% of that of drug-free control. MICs were determined after 24 h 
and 48 h. SMG and MICs values were compared at 24 h and 48 h and analysed 
using two-way ANOVA with Tukey’s post-hoc test to calculate significant 
difference, with results found to be significant when p ≤ 0.05. 
 
2.12 Mammalian screening 
2.12.1 Cell maintenance 
HeLa cells were maintained in Eagles Minimum Essential Medium (EMEM), 
supplemented with 10 % Fetal Bovine Serum (FBS), L-glutamine (2 mM), 1 % 
Non-Essential Amino Acids (NEAA) and sodium pyruvate (1 mM). The cell lines 
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were cultured in a 37 ⁰C humidified atmosphere containing 5% CO2. When a 
maximum confluence of 80-90% was obtained in a T75 flask, cells were washed 
with phosphate buffered saline (PBS) solution, before being incubated with 3 ml 
of 1 X trypsin (0.25%) at 37oC for 3 min. The trypsin was neutralised by the 
addition of EMEM before cells were centrifuged for 5 min at 169 x g. Cells were 
then resuspended in EMEM. Cells were passaged 1:5 into flasks to maintain the 
HeLa cell line or seeded into dishes for practical analysis. 
 
2.12.2 Growth curves 
To determine the growth rate of the HeLa cell line, growth curve analysis was 
performed over a period of four days. Cells were seeded in a 12-well plate at a 
density of 2,000 cells per well. After 24, 48, 72 and 96 h incubation, three wells 
on each day were trypsinised and viable cell number was determined by counting 
cells manually using a haemocytometer and trypan blue exclusion test of cell 
viability, as cells which had taken up trypan blue staining were considered non-
viable and excluded from counting. This process was repeated three times. 
 
2.12.3 PrestoBlue® viability assay  
PrestoBlue® is a resazurin-based cell permeable viability indicator that is quickly 
reduced by metabolically active cells, changing in colour from blue to red and 
becoming highly fluorescent. PrestoBlue® assay was used to provide a 
quantitative measure of viability and cytotoxicity by changing fluorescence in the 
presence of compounds or blue light alone.  
As the greatest variable in viability assays is cell number, linearity of fluorescence 
versus cell number was determined to find a suitable working range of cell 
density. Cells were seeded at 500, 1,000, 2,000, 2,500, 5,000 and 10,000 
cells/well in EMEM in 96-well plates and incubated at 37oC for 24, 48, and 72 h 
before adding PrestoBlue® (Invitrogen) at ratio 1:10 for one hour and measuring 
the fluorescence with excitation at 535 nm and emission at 610 nm by Tecan 
GENios PRO plate reader. This process was repeated three times in triplicate.  
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To characterise the effects of blue light alone on cell viability, HeLa cells were 
seeded at 2,000 cells per well and incubated for 24 h before 20-minute blue light 
treatment. The cell viability was then measured by taking fluorescence readings 
on three consecutive days following treatment. 10 μl was withdrawn from wells 
and 10 μl PrestoBlue® added and incubated at 37oC for 2 h. Fluorescence was 
measured with excitation at 535 nm and emission at 612 nm using a 
spectrophotometer. 
To test the effect of the shortlisted antimicrobial compounds, HeLa cells were 
seeded at 2,000 cells per well, incubated for 24 h before treatment with the 
compounds alone and following exposure to blue light for 20 min. HeLa cells were 
treated with two different concentrations 25 and 32 µg/ml, which showed the 
highest MICs against fungal and bacterial species. The cell viability was 
measured using the PrestoBlue® assay by taking fluorescence readings 
throughout three consecutive days after compound treatment. The controls used 
in this experiment were HeLa cells treated with 0.625% DMSO (the highest 
DMSO concentration used in antimicrobial testing) and untreated HeLa cells. The 
experiment was conducted in triplicate, n=3. 
     
2.13 Statistical analysis 
All data are shown as means ±SEM of either two or three independent 
experiments. Comparison between tested groups was conducted by means of 
two-way ANOVA with Tukey’s post-hoc test using GraphPad Prism software. 
Significant results were determined statistically as follows: *** p ≤ 0.001,** p ≤ 













Acridine-based compounds are important small nitrogen tricyclic heteroaromatic 
agents with anti-infective properties. Acridines in general possess a high degree 
of positive ionisation and sufficient planar surface space for DNA intercalation, 
which are considered necessary for antibacterial effectiveness (Albert, 1951). 
Two aminoacridines, proflavine and acriflavine, were first developed and 
subjected to clinical uses during the First World War as antibacterials against 
sepsis in wounds and hospital infections. Another effective acridine antimicrobial 
drug, aminacrine, was used widely in dermatology, ear and eye surgery due to 
its safety in mammalian host cells. Acridines, such as mepacrine, were used as 
antimalarial drugs and, at higher doses, to treat immune system disorders such 
as lupus erythematosus (Albert, 1951). Additionally, the cytotoxic activities of 
several acridine derivatives have been intensively examined to test their ability 
as potential anticancer drugs (Lin et al., 2017). 
To improve their effectiveness as antimicrobial agents, Albert and his co-workers 
attempted to identify parameters necessary to optimise their activity, such as 
cationic ionisation. They focused on the mechanism of action of aminoacridines 
and showed that those with electronic conjugation between the ring nitrogen and 
the amino group were the most effective because of the high cationic ionisation 
of these compounds. This led Albert to find a correlation of antimicrobial efficacy 
via DNA intercalation with acridine planar area and cationic ionisation (Albert, 
1951). 
With respect to photosensitising activity, a variety of acridine derivatives such as 
proflavine, acridine orange, acriflavine and 9-aminoacridine have been 
demonstrated to be active photosensitisers by releasing reactive oxygen species 
(ROS) under irradiation with an ultraviolet (UV) lamp (Ito et al., 1978). The 
production of these species may be due to the molecular structures of these 
compounds, typified by conjugated double bonds containing a delocalised 
system of π-electrons. Therefore, the acridines exposed to visible light are likely 
to be more effective in killing unwanted clinically important microbes, compared 
to acridines without light activation (Wainwright et al., 1997).  
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Initial studies have found that photoactivated acridines have an antimicrobial 
effect across a number of microorganisms. Various acridine compounds such as 
acriflavine, proflavine and acridine orange are shown to have photodynamic 
biological activities in the haploid yeast, Saccharomyces cerevisiae. Following 
exposure to UV light (315-400 nm) for 30 min, these acridines inhibited the yeast 
cells viability more significantly significantly when compared to that of the dark 
control (lwamoto et al., 1987). 
Photoactivated aminoacridines have shown a significant increase in antibacterial 
activity under illumination with white light (a mixture of wavelengths of the visible 
spectrum) against a range of pathogenic microorganisms including both Gram-
positive (Staphylococcus aureus, Enterococcus faecalis, Bacillus cereus) and 
Gram-negative (Escherichia coli, Pseudomonas aeruginosa) bacteria 
(Wainwright et al., 1997). 
Based on the well-established in vitro photosensitising and photoantimicrobial 
activity (Iwamoto et al., 1987; Wainwright et al., 1997) and to optimise their 
potential antimicrobial activity, a library of novel aromatic substituted acridine 
compounds has been synthesised (Johns et al., 2014). The substitution pattern 
at different positions on acridine was hoped to lead to some dyes with interesting 
photophysical, photochemical and biological properties. The wavelength of 
maximum absorbance λmax of novel synthesised acridines ranged between 424-
445 nm, which corresponds with blue light. 
This study utilised these novel substituted acridines to determine their potential 
use in photodynamic therapy (PDT) for microbial infections following blue light 
illumination. To determine their antimicrobial activity, the European Committee 
for Antimicrobial Susceptibility Testing (EUCAST) microbroth dilution method was 
utilised. All compounds were screened against key microbial pathogens, 
including Staphylococcus aureus and Escherichia coli and the fungi Candida 
albicans (C. albicans) which has high mortality rate of 40% and Aspergillus 
fumigatus (A. fumigatus), which is complicated to treat and often fatal with a 
mortality rate of 50-90% (Liu et al., 2013; Miceli et al., 2011). In addition, the yeast 
model organism, Saccharomyces cerevisiae (S. cerevisiae), was also included 





Acridine moieties have been of interest to medicinal chemists for many years and 
they exhibit significant pharmaceutical importance due to their potential 
photodynamic biological activities (Wainwright, 2001). A series of novel acridine-
based compounds was previously synthesised by Dr Rob Smith (Figure 3.1, 




Figure 3.1 Chemical structures of novel acridine derivatives. 
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Table 3.1 Structures of substituted aminoacridine containing different R groups 









R1 R2 R3 R4 R5 R6 
1 H H H H H H 
2 H H OCH3 H H H 
3 H H H OCH3 H H 
4 Cl OCH3 H OCH3 H H 
6 H H H H Cl Cl 
8 NO2 H Cl H H H 
9 NO2 H CH3 H H H 
10 H H CH3 H H H 
11 H H H OCH3 Cl Cl 
12 Cl OCH3 H OCH3 Cl Cl 
13 Cl H H H H H 
15 H H H OCH3 CH3 CH3 
16 NO2 H OCH3 H H H 
17 Cl H H OCH3 H H 
18 Cl H OCH3 H Cl Cl 
19 Cl H CH3 H H H 
20 Cl H OCH3 H H H 
21 H H OCH3 H CH3 CH3 








Table 3.2 Structures of substituted phenyl-aminoacridine containing different R 







R1 R2 R3 
5 Cl H H 
7 H H H 
14 Cl CH3 CH3 
 
3.2.1 Photochemical characterisation of acridine compounds 
3.2.1.1 Singlet oxygen (1O2) data 
Firstly, the wavelength of maximum absorbance, λmax, was determined for each 
of the compounds in order to identify the corresponding visible light range for best 
excitation. As such, the absorption spectrum between the wavelengths 250-800 
nm for each of the compounds was taken (Table 3.3). For all acridine compounds, 
the λmax of the compounds ranged between 424-445 nm, suggesting that all the 
novel acridine compounds were activated by blue light (400-495 nm).  
The radical and 1O2 species released from photosensitisers, under visible light 
illumination, can give a phototoxic response against microbial infections (Hamblin 
et al., 2004; Jori et al., 2006). Therefore, to measure singlet oxygen species 
produced following the exposure of candidate compounds to blue light, they were 
assayed using the decolourisation of the marker 2,3,4,5-
tetraphenylcyclopentadienone (TPCPD) in DMSO. The absorbance of the marker 
alone and the active mixture, at a wavelength of 506 nm, was monitored over 
time using a UV-Visible spectrophotometer (Shimadzu-UV-3600) in the presence 
of blue light. It was assumed that the resultant drop in absorption of TPCPD in 
DMSO at 506 nm, due to decolourisation, is proportional to its reaction with 
singlet oxygen species. As such, the level of singlet oxygen release from each of 
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the compounds could be determined. An example set of data is shown in Figure 
3.2, where the absorbance of TPCPD decreases over a period of 20 min following 
exposure of compound 5 to blue light. By determining the gradient of the linear 
portion of the graph, the half-life of the compound can be calculated. However, in 
21 compounds the half-life was not reached, over the 20-minute monitoring 
period, instead the percentage reduction of absorption over 20 min was 
determined (Table 3.3). 
 
 
Figure 3.2 Absorbance degradation after blue light illumination. The singlet oxygen 
release of Compound 5 was monitored by absorbance reduction of TPCPD at 506 nm 
after excitation with blue light for 20 min. The half-life was reached after 15 min blue light 
exposure. Absorbance measurement was conducted three times, n=3.  
 
The illuminated compounds were ranked according to the half-life or the 
percentage reduction in absorbance resultant from blue light illumination.  It was 
assumed that the higher the actual reduction of absorption of TPCPD for the 
acridine compounds following blue light exposure, the greater their 1O2 yield 
(Table 3.3). Twenty-one acridine compounds did not show a half-life except 
Compound 5, which has a half-life t1/2 of 15 min. This data suggests that 


























tested. It was followed by Compounds 3 (43%), 17 (37%), 7 (24%) and 4 (27%), 
which showed a reduction in the percentage absorption (Table 3.3). Conversely, 
Compounds 19 and 20 did not show any measurable release of singlet oxygen 
following blue light illumination. 
By measuring singlet oxygen release following excitation with blue light over a 
60-minute period, it was noted that most singlet oxygen was released from 






















Table 3.3 Compounds characterised according to the percentage reduction in 
absorbance or half-life obtained following 20 min blue light exposure. As the 
decrease of absorption of TPCPD at 506 nm is directly proportional to singlet oxygen 
release and the lower half-life the more singlet oxygen production. λmax is determined 
to be the wavelength at which absorbance is highest. 
Compounds λmax 
Percentagereduction 







1 437 12% 83.33 1.00 
2 440 11% 90.9 0.92 
3 429 43% 23.25 3.58 
4 442 16% 62.5 1.33 
5 432  64% 15 5.33 
6 426 13% 76.92 1.08 
7 443 11%       90.9 0.92 
8 444 26% 38.46 2.17 
9 427 2% 500 0.17 
10 431 8% 125 0.67 
11 435 10% 100 0.83 
12 441 6% 166.66 0.5 
13 426 6% 166.66 0.5 
14 424 6% 166.66 0.5 
15 427 4% 250 0.33 
16 433 9% 111.11 0.75 
17 438 30% 33.33 2.5 
18 445 10% 100 0.83 
19 441 0% No half-life 0 
20 432 0% No half-life 0 
21 427 4% 250 0.33 





3.2.1.2 Radical species data 
Due to the damaging effect of ROS released during PDT on microbes, radical 
species produced from the acridine compounds were then measured in vitro. 
3.2.1.2.1 DPPH assay 
The aim of this DPPH assay is to assess the antioxidant activity resultant from 
the candidate compounds during exposure to 60-minute blue light. DPPH. is 
reduced by free radical scavenger and the decrease in absorbance is monitored 
at 515 nm (Shimamura et al., 2014). 
The DPPH. 0.1 mM and 0.2 mM dissolved in DMSO was stable in the presence 
and absence of blue light as its absorbance was not degraded. However, its 
absorbance showed far greater degradation after the addition of acridine 
compounds in the presence and absence of blue light illumination. 
After the compounds were added to DPPH., they were exposed to blue light and 
then absorbance readings were taken. It has been demonstrated that the 
absorbance of the DPPH. was degraded directly after the addition of compounds. 
For example, the DPPH. absorbance was 1.6, which decreased dramatically to 
0.045 when Compound 2 added at different points of concentration in the 
presence or absence of blue light. All the tested acridines caused dramatic 
degradation of the absorbance of DPPH. when added to it. 
To investigate whether solvents can have effect on absorbance degradation of 
the marker DPPH when compound is mixed, different solvents were used to 
solubilise the compounds. The solvents tested were methanol, chloroform, 
acetone, isohexane and acetonitrile. In all cases, degradation of the maker was 
observed in the presence of the photosensitiser regardless of the availability of 
blue light.   
 
3.2.1.2.2 ABTS assay 
This method measures the antioxidant activity resultant from the candidate 
compounds during exposure to 60-minute blue light by determining the 
decolourisation of the ABTS. + through measuring the reduction of this radical 
cation as the percentage inhibition of absorbance at 734 nm (Miller et al., 1997). 
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The ABTS assay was improved to prevent any possible effect on radical 
reduction. To achieve that, radical cation ABTS.+ was pre-generated before 
addition to the compounds, rather than the formation of the radical occurring 
continually in the presence of tested compounds (Re et al., 1999). 
Antioxidant activity was expressed using the total contribution to the antioxidant 
activity during 60-minute blue light exposure. The results in the presence of the 
compounds demonstrate that there was a drop in absorbance in the presence 
and absence of blue light, which means that the marker may be not stable when 
mixed with the acridines.  
After the compounds were added to ABTS.+, they were exposed to blue light and 
then absorbance readings taken. It has been demonstrated that the absorbance 
of the ABTS.+ was degraded directly after the addition of acridines in the presence 
and absence of blue light. For example, the ABTS.+ absorbance was 1.3, which 
decreased markedly to 0.13 when the Compound 2 added at different points of 
concentration in the presence or absence of blue light. 
 
3.2.2 Blue light alone has no effect on the growth of fungal and 
bacterial species 
Based on previous data (Table 3.3), the λmax for all the acridine compounds was 
in the blue region between 426-445 nm. In order to determine the effect of the 
photoactivated compounds, exposure of fungal (S. cerevisiae, C. albicans and A. 
fumigatus) and bacterial cells (S. aureus and E. coli) to blue light alone was 
studied. The effect of blue light alone on growth was studied following exposure 
for 0, 10, 20, 30 and 60 min. As previously studied in photochemistry experiments 
(Section 3.2.1), the maximum level of singlet oxygen was released following 10 
and 20-minute blue light exposure. Following 24 h incubation either the optical 
density was measured, or visual inspection of the plates was used to determine 
the level of microbial growth. 
The experiment was conducted in triplicate, n=3, and the values expressed by 
the mean ±SEM. Two-way ANOVA analysis of results was used to test the degree 
to which untreated cells differ from cells treated with blue light. 
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ANOVA analysis of results, showed no significant effect of the S. cerevisiae and 
C. albicans cells treated with blue light in comparison with untreated cells after 
24 h of treatment, as shown in Figures 3.3 and 3.4.  
The percentage growth of blue light treated A. fumigatus did not change visually 












































Figure 3.3 Blue light has no effect on the growth of Saccharomyces cerevisiae. 
0.5-2.5 x 105 cells/ml (corresponding to approximately OD595 0.002) of exponentially 
growing S. cerevisiae were inoculated in RPMI 1640 medium, exposed to blue light and 
incubated overnight at 30⁰C without shaking. Optical density readings at the wavelength 
530 nm were taken to measure the growth concentration of the growing cultures in 96-
well plates in the absence and presence of blue light exposure over a period of 10, 20 
and 60 min. n=3 (pooled from triplicate experiments). Values are the mean ±SEM. Data 
















































Figure 3.4 Blue light has no effect on the growth of Candida albicans. 0.5-2.5 
x 105 cells/ml (corresponding to approximately OD595 0.001) for C. albicans were 
inoculated in RPMI 1640 medium, exposed to blue light and incubated overnight at 
35⁰C without shaking. Optical density readings at the wavelength 530 nm were taken 
to measure the growth concentration of the growing cultures in 96-well plates in the 
absence and presence of blue light exposure over a period of 10, 20, 30 and 60 min. 
n=3 (pooled from triplicate experiments). Values are the mean ±SEM. Data analysed 
by two-way ANOVA test.  
 
ANOVA analysis of results, showed no significant effect of the bacterial cells 
treated with blue light in comparison with untreated cells after 24 h of treatment. 
As shown in Figures 3.5 and 3.6, the percentage growth of blue light treated S. 
aureus and E. coli strains did not change significantly when compared to the 













































Figure 3.5 Blue light has no effect on the growth of Staphylococcus aureus. 5 
x 105 cells/ml (corresponding to approximately OD600 0.0003) for S. aureus were 
inoculated in Mueller-Hinton medium, exposed to blue light and incubated overnight 
at 35⁰C without shaking. Optical density readings at the wavelength 600 nm were 
taken to measure the growth concentration of the growing cultures in 96-well plates 
in the absence and presence of blue light exposure over a period of 10, 20, 30 and 
60 min. n=3 (pooled from triplicate experiments). Values are the mean ±SEM. Data 












































Figure 3.6 Blue light has no effect on the growth of Escherichia coli. 5 x 105 
cells/ml (corresponding to approximately OD600 0.0001) for E. coli were inoculated 
in Mueller-Hinton medium, exposed to blue light and incubated overnight at 35⁰C 
without shaking. Optical density readings at the wavelength 600 nm were taken to 
measure the growth concentration of the growing cultures in 96-well plates in the 
absence and presence of blue light exposure over a period of 10, 20, 30 and 60 min. 
n=3 (pooled from triplicate experiments). Values are the mean ±SEM. Data analysed 




These results demonstrate that blue light did not inhibit the growth of the studied 
microbes significantly; therefore, the novel acridine compounds were then 
screened for photoantimicrobial activity. 
 
3.2.3 Antifungal screening 
Following photochemical characterisation of the compounds, they were then 
screened in vitro for their phototoxicity against a range of fungal species. 
The 22 acridine compounds were screened using the EUCAST microbroth 
dilution method for antifungal activity against S. cerevisiae, C. albicans and A. 
fumigatus (EUCAST 7.3, 2015a; EUCAST 9.3, 2015b; Arendrup et al., 2015). 
These species were exposed to a range of concentrations of the acridine 
compounds (0 to 250 μg/ml) in the presence and absence of blue light. Growth 
was determined by using OD at 530nm for S. cerevisiae and C. albicans and 
visually for A. fumigatus. 
The heat maps shown in Figures 3.7 and 3.8 summarise the percentage growth 
determined from the OD530nm readings for fungal growth for concentrations of 
fluconazole and compounds exposed to blue light for 20 min at 24 h incubation. 
The concentrations of fluconazole (control) used were 0 to 64 μg/ml, while 
concentrations of the compounds were 0 to 250 μg/ml. The colour in the heatmap 
indicates the percentage growth with black, indicating complete growth, and red, 
indicating no growth (100% inhibition). Yellow indicates 50% growth inhibition, 
which aligns with the minimal growth inhibition (MIC), as determined by the 
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Figure 3.7 Heatmap illustrating OD530nm levels for varying concentrations of a list of 22 compounds (0 to 250 μg/ml) against S. 
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Figure 3.8 Heatmap illustrating OD530nm levels for varying concentrations of a list of 22 compounds (0 to250 μg/ml) against C. 
albicans. The yellow bar shows 50% growth inhibition while the red bar illustrates the maximum growth inhibition. 
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The EUCAST microdilution method was used to determine the susceptibility of 
studied fungi against a series of final concentrations of compounds of 0-250 μg/ml 
and fluconazole of 0.125-64 μg/ml and to identify the minimum inhibitory 
concentration MIC (50% growth inhibition compared to the control) of the tested 
compounds (EUCAST 7.3: Arendrup et al., 2015a). To determine percentage 
growth inhibition, the optical density OD530nm readings for S. cerevisiae and C. 
albicans growth were taken for each concentration of fluconazole and 
compounds exposed to blue light for 10 and 20 min at 24 h incubation. 
The graphs show the mean ±SEM (standard error of the mean) of percent growth 
inhibition for the highest concentration of acridine compounds in the absence and 
presence of blue light, after 10 and 20-minute exposure and that for fluconazole 
at 64 (μg/ml) in S. cerevisiae and C. albicans (Figures 3.9 to 3.30). Table 3.4 
shows the determined MIC (50% growth inhibition compared to the control) of 
each of the candidate compounds in S. cerevisiae and C. albicans. Fluconazole 
was utilised as a positive control in each of the studies. In all cases, growth 
inhibition of less than 17% was seen in the no blue light control. The experiments 
were repeated on two separate occasions in duplicate, except for the active 









Figure 3.9 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 1 in absence and presence of blue light. Comparison of Compound 1 with 
fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage obtained 
in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 
Values are the mean ±SEM. 
 
Figure 3.10 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 2 in absence and presence of blue light. Comparison of Compound 2 with 
fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage obtained 
in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 























































Figure 3.11 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 3 in absence and presence of blue light. Comparison of Compound 3 with 
fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage obtained 
in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 
Values are the mean ±SEM. 
 
Figure 3.12 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 4 in absence and presence of blue light. Comparison of Compound 4 with 
fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage obtained 
in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 























































Figure 3.13 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 5 in absence and presence of blue light. Comparison of Compound 5 with 
fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage obtained 
in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 
Values are the mean ±SEM. 
 
Figure 3.14 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 6 in absence and presence of blue light. Comparison of Compound 6 with 
fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage obtained 
in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 






















































Figure 3.15 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 7 in absence and presence of blue light. Comparison of Compound 7 with 
fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage obtained 
in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 
Values are the mean ±SEM. 
 
Figure 3.16 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 8 in absence and presence of blue light. Comparison of Compound 8 with 
fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage obtained 
in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 






















































Figure 3.17 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 9 in absence and presence of blue light. Comparison of Compound 9 with 
fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage obtained 
in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
Figure 3.18 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 10 in absence and presence of blue light. Comparison of Compound 10 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 























































Figure 3.19 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 11 in absence and presence of blue light. Comparison of Compound 11 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 
Values are the mean ±SEM. 
 
Figure 3.20 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 12 in absence and presence of blue light. Comparison of Compound 12 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 























































Figure 3.21 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 13 in absence and presence of blue light. Comparison of Compound 13 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 
Values are the mean ±SEM. 
 
Figure 3.22 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 14 in absence and presence of blue light. Comparison of Compound 14 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 























































Figure 3.23 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 15 in absence and presence of blue light. Comparison of Compound 15 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
Figure 3.24 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 16 in absence and presence of blue light. Comparison of Compound 16 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=3. 






















































Figure 3.25 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 17 in absence and presence of blue light. Comparison of Compound 17 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
Figure 3.26 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 18 in absence and presence of blue light. Comparison of Compound 18 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 























































Figure 3.27 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 19 in absence and presence of blue light. Comparison of Compound 19 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
 
Figure 3.28 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 20 in absence and presence of blue light. Comparison of Compound 20 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
























































Figure 3.29 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 21 in absence and presence of blue light. Comparison of Compound 21 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
Figure 3.30 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 22 in absence and presence of blue light. Comparison of Compound 22 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 





















































Table 3.4 Summary of the minimum inhibitory concentrations (MICs) of the 
acridine compounds in S. cerevisiae and C. albicans using the EUCAST method 
after 10 and 20 min blue light exposure. MIC is the concentration at which 50% growth 
inhibition is seen. (-) means MIC value could not be determined at the maximum 
concentration tested (25 μg/ml). The rest of the candidate compounds did not show any 
minimum inhibitory concentrations against S. cerevisiae and C. albicans over both 10 


















Fluconazole 1 0.25 1 0.25 
Compound 1 4.2 4.2 4.2 4.2 
Compound 2 8.3 5.2 8.3 5.2 
Compound 3 21 21 25 12.5 
Compound 4 25 25 25 25 
Compound 5 21 21 21 21 
Compound 6 - - - - 
Compound 7 - 25 - 12.5 
Compound 8 25 25 25 25 
Compound 9 - - - - 
Compound 10 - - - - 
Compound 11 25 25 25 12.5 
Compound 12 - - - - 
Compound 13 - 25 - 25 
Compound 14 - - - - 
Compound 15 - - - - 
Compound 16 - 25 - 25 
Compound 17 - - - - 
Compound 18 - - - - 
Compound 19 - - - - 
Compound 20 - - - - 
Compound 21 - - - - 





To ensure consistency of the results, EUCAST antifungal susceptibility testing of 
S. cerevisiae and C. albicans to the control fluconazole was performed. The 
average MIC of fluconazole obtained was 0.25 μg/ml against S. cerevisiae and 1 
μg/ml against C. albicans. Regarding S. cerevisiae, the obtained MIC of 0.25 
μg/ml was in the region of published data (MIC and zone distributions and 
ECOFFs) (EUCAST 7.3: Arendrup et al., 2015a). The resultant MIC of 1 μg/ml 
against C. albicans corresponded with the EUCAST Antifungal Clinical 
Breakpoints (EUCAST 7.3: Arendrup et al., 2015a). 
Furthermore, none of the compounds exhibited a significant antifungal effect in 
the absence of blue light against both strains. As the acridine compounds showed 
no significant effect on growth of cells in the absence of blue light, any antifungal 
activity will be attributed to blue light treated compounds.  
 
A lower MIC value suggests that a lower concentration of drug is required for 
inhibiting growth of microbes, therefore the lower the MIC, the more effective the 
antimicrobial drug. By analysing the MIC results in Table 3.4, it can be noted that 
Compound 1 showed more effectiveness than other compounds with MICs of 4.2 
μg/ml over 10 and 20 min against C. albicans and S. cerevisiae. It was followed 
by Compound 2, which showed MICs of 8.3 and 5.2 μg/ml over 10 and 20 min, 
respectively against C. albicans and S. cerevisiae. The data demonstrates that, 
amongst all the screened compounds, Compound 1 and Compound 2 showed 
the lowest MIC, and were determined to be the most potent. Furthermore, none 
of the drugs showed a lower MIC than that of fluconazole. The results of 
photoactivated acridines in the presence of blue light against S. cerevisiae and 
C. albicans were significantly different from those of non-light acridines.  
Compounds 7, 13 and 16 exhibited antifungal activity against S. cerevisiae but 
demonstrated no effect on C. albicans at the maximum concentration tested. The 
remaining seven compounds showed a similar trend in activity against both 
species, except of S. cerevisiae being more susceptible to fluconazole, 
Compound 2, Compound 3 and Compound 11 compared to C. albicans (Table 
3.4).  
A. fumigatus was also screened using EUCAST antifungal MIC microdilution 
method for moulds. Due to the growth of A. fumigatus, instead of measuring the 
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optical density to determine percentage growth inhibition, a visual inspection was 
undertaken (EUCAST 9.3: Arendrup et al., 2015b). In this case, the MIC was 
determined to be the first well where the concentration of compound resulted in 
complete absence of growth. The concentration range tested for the control drug 
amphotericin B was 0-16 μg/ml. The control drug amphotericin B used in the 
EUCAST method was effective against A. fumigatus showing MIC of 0.125 μg/ml, 
which was matching the MIC EUCAST breakpoint in A. fumigatus (EUCAST 9.3: 
Arendrup et al., 2015b) The antifungal screening demonstrated that acridines, 
following exposure to blue light, did not exhibit any efficacy against A. fumigatus 
at the concentrations tested (0 to 250 μg/ml) by checking the growth visually.   
The first row of Figure 3.31 illustrates the complete growth inhibition of 
amphotericin B starting from well number 8 (0.125 μg/ml), while the rest of the 
rows illustrate the complete growth of A. fumigatus in the presence of Compounds 
1 and 2 exposed to blue light. 
 
 
Figure 3.31 Comparing the effect of amphotericin B in the first row and 
photosensitisers in the next two rows against A. fumigatus. Amphotericin B showed 
MIC of 0.125 μg/ml while no acridine compound showed MIC against A. fumigatus. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The MIC value considered as the concentration of 






3.2.4 Antibacterial screening 
Following antifungal screening of the compounds, the compounds were then 
screened in vitro for their antibacterial effectiveness under blue light exposure 
against two clinically important bacteria, Gram-positive S. aureus and Gram-
negative E. coli. 
 
The acridine compounds were screened using the European Committee for 
Antimicrobial Susceptibility Testing (EUCAST) microbroth dilution method, for 
antibacterial activity (EUCAST 5.1; EUCAST, 2003). The antibacterial drug, 
gentamicin, was used as a control due to its broad antibacterial activity against 
both Gram-negative and Gram-positive bacteria. The bacterial species were 
exposed to a range of concentrations of the compounds (0 to 256 μg/ml) in the 
presence and absence of blue light. A 20-minute illumination period was used, 
due to the release of most singlet oxygen from the compounds. The MIC was 
determined, by visual inspection, to be the lowest concentration that completely 
inhibited growth. Data of MIC of compounds and fluconazole against S. aureus 
and E. coli are shown as means of two separate occasions in duplicate, except 














Table 3.5 Summary of the minimum inhibitory concentrations (MICs) of the 
acridine compounds in S. aureus and E. coli using the EUCAST method after 10 
and 20 min blue light exposure. (-) means MIC value could not be determined at the 
maximum concentration tested. The rest of the candidate compounds did not show any 















against E. coli 
Gentamicin 0.25 0.125 0.25 0.125 
Compound 1 2 16 2 24 
Compound 2 8 32 8 24 
Compound 3 24 - 24 32 
Compound 4 32 - 16 - 
Compound 5 8 - 8 24 
Compound 6 - - - - 
Compound 7 24 - 24 - 
Compound 8 32 - 32 32 
Compound 9 - - - - 
Compound 10 - - - - 
Compound 11 8 32 8 24 
Compound 12 16 32 8 32 
Compound 13 8 - 32 32 
Compound 14 24 - 24 - 
Compound 15 - - - - 
Compound 16 8 32 8 32 
Compound 17 32 - 24 - 
Compound 18 - - - - 
Compound 19 - - - - 
Compound 20 - - - - 
Compound 21 - - - - 




EUCAST antibacterial susceptibility testing of S. aureus and E. coli to the control 
gentamicin was performed and the resultant MICs of 0.25 and 0.125 μg/ml 
corresponded with EUCAST Antibacterial Clinical Breakpoints (EUCAST 5.1: 
EUCAST, 2003), which confirms the accuracy of the assay. Since the acridine 
compounds showed no remarkable visual effect on growth in the absence of blue 
light, any growth inhibition observed following the exposure to blue light is 
attributed to photoactivation of the compounds. 
A lower MIC value is indicative that a lower concentration of drug is required for 
inhibiting growth of bacteria, therefore the lower MIC the more effective the 
antibacterial activity. By analysing the MIC results (Table 3.5) nine acridine 
compounds showed little effect on bacterial growth. Compound 1 and Compound 
2 showed the lowest MICs of all the compounds tested with 2 and 8 μg/ml 
respectively, against S. aureus and the same MIC of 24 μg/ml against E. coli. 
Compounds 4, 7, 14 and 17 only exhibited an effect following 20-minute blue light 
exposure against S. aureus but not against E. coli. This suggests that the Gram-
positive bacteria, S. aureus, is more sensitive to the activated compounds as 
compared to the Gram-negative bacteria, E. coli (Table 3.5). 
By combining the MIC values of the acridine compounds against bacterial and 
fungal species following 20-minute blue light illumination in Table 3.6, it can be 
noted that there is a marked difference in the sensitivity of fungi and bacteria to 
the light activated acridine compounds. Compounds 12, 14 and 17, for instance, 











Table 3.6 Summary of the minimum inhibitory concentrations (MICs) of the 
candidate compounds in S. cerevisiae, C. albicans and S. aureus, E. coli using the 
EUCAST method after 20 min blue light exposure. (-) means MIC value could not be 















against E. coli 
Fluconazole 1 0.25   
Gentamicin   0.25 0.125 
Compound 1 4.2 4.2 2 24 
Compound 2 8.3 5.2 8 24 
Compound 3 25 12.5 24 32 
Compound 4 25 25 16 - 
Compound 5 21 21 8 24 
Compound 6 - - - - 
Compound 7 - 12.5 24 - 
Compound 8 25 25 32 32 
Compound 9 - - - - 
Compound 10 - - - - 
Compound 11 25 12.5 8 24 
Compound 12 - - 8 32 
Compound 13 - 25 32 32 
Compound 14 - - 24 - 
Compound 15 - - - - 
Compound 16 - 25 8 32 
Compound 17 - - 24 - 
Compound 18 - - - - 
Compound 19 - - - - 
Compound 20 - - - - 
Compound 21 - - - - 







In this chapter, the aim was to investigate a series of novel synthesised acridine 
compounds for their possible use as antimicrobial photodynamic agents. 
Photochemical characterisation and antimicrobial investigations were carried out 
on these acridine compounds, in the absence and presence of blue light. Their 
antimicrobial activity was assessed against a range of clinically important fungi 
(S. cerevisiae, C. albicans and A. fumigatus) and bacteria (S. aureus and E. coli) 
using the European Committee for Antimicrobial Susceptibility Testing (EUCAST) 
method (EUCAST 5.1: EUCAST, 2003). 
To identify the visible light source required to photoactivate the acridines, the 
absorption spectrum between the wavelengths 250-800 nm was taken. The 
wavelength of maximum absorbance, λmax, was then determined for each of the 
compounds tested to choose the corresponding visible region. It has been 
demonstrated that λmax of the acridine compounds ranges between 424-445 nm, 
which corresponds with the blue light region (400-500 nm) (Table 3.3). The 
obtained values are consistent with other published acridines, which generally 
show their λmax in the range between 400-500 nm (Albert, 1951).  
The absorption of acridine-based compounds may be extended into the red or 
near infrared regions by utilising the acidic carbon functionality of 9-methyl 
quaternary acridines to produce styryl derivatives (Wainwright, 2015). It has been 
demonstrated that the selection of red wavelength in antimicrobial photodynamic 
therapy leads to significant reduction in adverse effects when compared to UV 
and blue light, which can lead to DNA cleavage and thus cause greater toxicity 
to mammalian cells (Bumah et al., 2017). Additionally, longer wavelength such 
as red and infrared have the ability to penetrate more deeply in tissues than UV 
and blue light, which allows their use in surgery and dentistry applications (Jin et 
al., 2010; Hill et al., 2014). However, limited work has been published on the 
photosensitising and photoantimicrobial activity of those acridine compounds 
absorbing in red or infrared light. In this study all the tested compounds absorb 
strongly in the blue light region. This method has not been done with any of the 




3.3.1 Acridines are photosensitised following exposure to blue 
light and release singlet oxygen 
Due to the well-characterised photosensitising activity of a variety of acridine 
compounds such as euflavine, proflavine and acridine orange (Iwamoto et al., 
1993; Iwamoto et al., 1987), set of novel synthesised acridines has been 
characterised photochemically in the present study.  
The photochemical reactions of the triplet state of photosensitisers such as 
acridines following blue light exposure can be divided into two different pathways, 
either the Type 1 mechanism involving electron transfer reaction from the PS to 
O2 and results in  O·2̄ , H2O2 and .OH, or the Type 2 mechanism involving energy 
transfer to O2 and form 1O2. It has been demonstrated that the most prevalent 
damaging ROS are .OH and 1O2, which have the ability to react with many 
molecules in microbial cells (Vatansever et al., 2013). Therefore, this present 
study has studied both .OH and 1O2 species and attempted to quantify them 
following activation by blue light over a 60-minute period. Within this study, a 
radical scavenging assay using DPPH, a stabilised radical, was used to assess 
the amount of radical species produced from blue light treated acridines by 
monitoring the absorbance at 517 nm (Brand-Williams et al., 1995). Although 
DPPH. showed stability in the solvent used, DMSO, it demonstrated instability 
following the addition of acridine compounds in the presence and absence of blue 
light. This is indicative of degradation of DPPH. when mixing with acridines. 
Following failure to measure the radical using DPPH., another popular radical 
scavenging assay was conducted using the ABTS radical. This ABTS method 
has extra flexibility, as it can be used at different pH levels (unlike DPPH, which 
is sensitive to acidic pH). Furthermore, ABTS.+ is pre-generated directly in a 
stable form prior to the addition of acridines, while DPPH. is ready to use free 
radical. Following generation of ABTS.+, it is recommended to store it in the dark 
for 12 h for completion of the radical formation reaction. Subsequently, the 
resultant decolourisation was monitored by spectrophotometer at wavelength 724 
nm. Radical cation ABTS.+ was pre-formed in order to achieve a more stable 
synthetic coloured radical. However, ABTS.+ was degraded following the addition 
of acridines and radical release data was not obtained due to its instability in the 
presence and absence of blue light. The two assays were chosen because the 
λmax of DPPH. and ABTS.+at 517 and 734 nm did not overlap with the λmax of 
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acridines (426-446 nm). The experiments in this study were conducted without 
the addition of acridines and revealed that synthetic radicals dissolved in DMSO 
were stable in the presence and absence of blue light (Floegel et al., 2011; 
Thaipong et al., 2006). 
With respect to the measurement of radical species release, the amount of radical 
released from 20-minute blue light treated acridines is not known. It may be 
possible that the radical markers used in these antiradical activity assays are 
unstable in solution with acridines, which makes radical release investigation 
challenging. Furthermore, highly reactive radical species such as hydroxyl radical 
.OH may be quite difficult to detect, due to their extremely short lifetimes. There 
are alternative methods to measure radical species such as using fluorescent 
probes such as HPF for the specific detection of hydroxyl radical with insensitivity 
to 1O2 (Price et al., 2010). Additionally, EPR spectroscopy performed by EPR 
spin-trapping is considered the method of choice to detect and identify free 
radicals in biological systems (Hawkins, 2004). This highly sensitive method 
depends on the reaction between radicals with a diamagnetic probe containing a 
nitrone function, the spin trap, to produce a stable radical adduct (a nitroxide 
derivative) that can be detected by EPR (Augusto et al., 2007). Also, the EPR 
method has the ability to identify and quantify distinct radical species such as 
O·2̄  and .OH, which could otherwise not be detected by other assays (Mitchell et 
al., 2013). However, the requirements of high cost, knowledge of operation and 
upkeep of this large complicated piece of equipment are drawbacks of this type 
of investigation (Davies, 2016). 
In the screening of the second most damaging ROS (1O2) for 60 min, it appeared 
that most singlet oxygen was released from acridine compounds after 20 min 
using the TPCPD assay. It was established in this study that 20 acridine 
compounds produced singlet oxygen upon exposure to blue light for 20 min when 
compared with the standard’s yield in the in vitro photochemical test (Table 3.3). 
The in vitro photosensitising activity of acridines and their abilities to release 
singlet oxygen upon exposure to blue light support findings by (Iwamoto et al., 
1987), who found that several acridines such as acriflavine (AF), proflavine (PF), 
acridine orange (AO) and 9-aminoacridine (AA) showed singlet oxygen activity, 
upon irradiation with an ultraviolet (UV) lamp for 30 min, which is unsurprising 
given the spectral proximity of UV and blue light. The singlet oxygen production 
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in the aforementioned study was detected and quantified by measuring the signal 
intensity of TEMPO detected by (ESR) spectrometry inside the cell, which is 
considered less sensitive than the method used in the present study (TPCPD) 
and may show misleading increase of singlet oxygen production due to the 
possibility of electron transfer interference by the excited photosensitiser as well 
as the spin trap TEMPO is considered very sensitive to pH and its penetration 
into tissue is limited (Koh et al., 2016). 
Conversely, a group of acridine compounds such as ethacidine, aminacrine, 
salacrine, acridine orange and proflavine was screened for 1O2 using in vitro 
spectrophotometric testing. None of the compounds yielded any measurable 
amount of 1O2 after one hour’s illumination by white light of 1.7 mW/cm2 
(Wainwright et al., 1997). The reason for the absence of 1O2 release in that study 
is potentially due to the insufficient irradiance dose to photoactivate the 
compounds, while the irradiance rate used in this present study was far higher at 
96 mW/cm2 for 20 min, which was sufficient to release 1O2. 
The photochemical data presented in this study demonstrated that six acridine 
compounds, 3, 4, 5, 6, 8 and 17, out of 22 compounds were more efficient singlet 
oxygen producers than the standard, aminoacridine (Compound 1). 
Aminoacridine is an unsubstituted photosensitiser, which demonstrates that 
substitutions made by adding the groups Cl, NO2, CH3 and OCH3 at C1, C2, C3, 
C4, C5 and C6 of the aminoacridine led to enhanced singlet oxygen release 
(Table 3.6). Similarly, substitutions made on toluidine blue (standard lead 
photosensitiser for the phenothiazinium group) produced analogues releasing 
more 1O2 than that of standard with relative values ranging between 1.24 and 
1.87, by replacing methyl group at C2 in toluidine blue with the groups ethyl, 
propyl, butyl and phenyl (Wainwright et al., 2016). The relative 1O2 measurements 
in this study cannot be directly compared with relative 1O2 released from the 
phenothiazinium group, which used a different standard as lead compound due 
to their missing data of half-life. 
 It has been demonstrated that acridine orange possesses photosensitising 
activity and can release both singlet oxygen and hydroxyl radicals. Investigations 
of 1O2 and radicals were conducted by using acridine orange with L-histidine 
hydrochloride monohydrate, a scavenger of 1O2, and D-mannitol, a scavenger of 
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hydroxyl radicals. The survival rate of tumour cells under ultrasonic irradiation at 
2 W/cm2 was significantly higher in the presence of two scavengers than that in 
the presence of acridine orange alone, which reveals the killing effect of both 1O2 
and hydroxyl radicals. In the previous study, L-histidine and D-mannitol both 
suppressed the antitumour effect when combined with acridine orange. 
Therefore, both singlet oxygen and hydroxyl radicals may play a role in ultrasonic 
cell damage in the presence of acridine orange, however no quantitative results 
were obtained. No published data measured radicals released from acridines. 
 
3.3.2 Acridines have no significant effect on microbial growth in 
the absence of blue light 
Acridines such as acridine orange are cell-permanent compounds that can 
diffuse into the cytoplasm of living cells to accumulate in lysosomes, mitochondria 
or to bind to the DNA and RNA (Iwamoto et al., 1987; Lin et al., 2017). The 
accumulation of AO may give us an indication of how the tested compounds in 
this study may behave. Acridines have been shown to enter the fungal and 
bacterial cell as this localisation of acridines has been facilitated by cationic 
ionisation and sufficient molecular planarity. The high cationic ionisation of 
acridines results from electronic conjugation between the ring nitrogen and the 
amino group (Albert, 1951). It has been demonstrated that all acridine 
compounds screened in this study showed limited activity in the absence of blue 
light illumination, a growth inhibition of less than 15% in the no blue light control 
against S. cerevisiae and C. albicans, measuring growth by the optical density 
method. Because there is no effect of acridines on microbial growth in the 
absence of light, this suggests they are either unable to enter the cell or the 
cellular effect is limited. For example, intracellularly they may bind to mitochondria 
or lysosomes only or they enter the nucleus without DNA intercalation and then 
release ROS under illumination, which destroys DNA. Furthermore, the 
assessment of microbial growth inhibition using the optical density method in this 
study does not reflect accurately the viable cells count and thus the effect of 




3.3.3 Blue light (470 nm with irradiance rate of 11 5 J/cm2) has no 
significant effect on microbial growth 
The novel acridine compounds in this study are activated in response to blue light 
(Table 3.3). Before biological testing of these compounds was undertaken, the 
effect of the activating light source alone on cell growth was determined. The data 
within this chapter demonstrates that 470 nm blue light alone (20 min, 115 J/cm2) 
cannot be utilised as an effective antimicrobial therapy against S. cerevisiae, C. 
albicans, A, fumigatus, S. aureus and E. coli, as no significant effect on growth 
was obtained as measured by optical density or checking visual growth (Figures 
3.3 to 3.6). The insignificant antimicrobial effect observed in this study can be 
attributed to the weak activation of endogenous photosensitisers chromophores 
such as coproporphyrin, which were not completely activated. This in turn leads 
to the release of low amounts of cytotoxic oxidative agents ROS, causing lack of 
significant growth inhibition. This result is in contrast to other studies where blue 
light alone, particularly in the wavelength range of 405-470 nm, has shown 
potential antimicrobial effects (Gwynne et al., 2018). 
Exposure of S. aureus, E. coli and C. albicans to blue light has been shown to 
have an antimicrobial effect (Halstead et al., 2016; Zhang et al., 2016; Maclean 
et al., 2009). However, although many of these studies use a similar blue light 
dose (115 J/cm2 versus 108 J/cm2), the wavelength of blue light is much shorter 
(400 – 415nm). A study by (Murdoch et al., 2013) required short wavelength and 
much higher levels of irradiance dose to achieve significant CFU inactivation in 
fungal suspensions of S. cerevisiae, C. albicans and A. niger. The previous 
results may suggest why this current study did not demonstrate a significant 
growth inhibition. These results suggest that the shorter the wavelength of blue 
light, the more effect it has on the growth of microbial cells. This suggests the 
availability of endogenous photosensitisers inside microbial cells, which can be 
photoactivated only by shorter wavelength, then produce ROS and kill the cell. 
Most of the studies undertaken on the effect of blue light on microorganisms 
concentrate on the blue/ultra violet range ˷ 405 nm. This is a significantly shorter 
wavelength than was used in this study (470 nm). Comparison of same energy 
doses but varying wavelengths indicates that a shorter wavelength is more 
effective in inactivating microbes (405 nm vs 470 nm) (Roh et al., 2016). Due to 
the use of longer wavelength of blue light (470 nm) in this study, no effect seen 
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can be interpreted. The antimicrobial blue light effect obtained by other studies 
was mainly attributed to the presence of endogenous photosensitisers 
chromophores such as coproporphyrin, which were activated and led to the 
release of cytotoxic oxidative agents ROS and thus inactivated microbial cells 
(Zhang et al., 2016). In this study the activity of 470 nm blue light was not 
sufficient to activate endogenous porphyrins, which are well known for their 
importance as if their synthesis pathway is knocked out, the susceptibility of 
microbial cells to blue light decreases significantly (Galbis-Martínez et al., 2012; 
Grinholc et al., 2015). The amount of endogenous coproporphyrin was shown to 
be different between Gram-positive and negative bacteria (Nitzan et al., 2004; 
Kumar et al., 2015). There is evidence that Gram-positive bacteria are generally 
more susceptible to blue light than Gram-negative bacteria when using a shorter 
wavelength at 405 nm (Gupta et al., 2015). This difference in susceptibility is due 
to the difference in concentration of flavins, endogenous photosensitisers present 
inside the cell, which can vary between bacterial species (Kumar et al., 2015). 
However, within this study no significant effect of blue light was observed in all 
tested microorganisms. 
There is also evidence that a higher dose of blue light can have an antimicrobial 
effect with a 60-minute blue light illumination, producing a total higher dose of 
216 J/ cm2, which inhibited growth for C. albicans (Trzaska et al., 2017). This is 
consistent with Roh et al., 2016, who utilised a similar wavelength and method 
for determining an antimicrobial effect to show that bacterial cells were 
significantly inactivated after 24 h blue light irradiation at a dose of 1,150 J/cm2. 
This suggested that the absence of effect in this study was obtained due to using 
a much lower irradiance dose when compared to the aforementioned studies. 
Furthermore, exposure time can have impact on the level of porphyrins as 
adjusting low irradiance with longer exposure exhibited a greater effect of 
antimicrobial inactivation than high irradiance with short exposure (Murdoch et 
al., 2012). It has been demonstrated that A. fumigatus spores were significantly 
inactivated by using a much longer illumination period with low irradiance Fuller 
et al., (2013). In contrast, this study used high irradiance with short exposure 
time, which may affect the result obtained. It was also reported that the 
endogenous porphyrin patterns in vitro such as porphyrin quantity and porphyrin 
species are highly affected by the whole culturing conditions such as time of 
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culturing, passaging and nature of culture media. Since porphyrin levels and 
antimicrobial activity can be affected by various factors, there is a need to find an 
antimicrobial blue light standardised method to achieve a significant effect on 
microbial cells. 
Furthermore, differences in blue light effect might have also resulted from a 
number of other factors including size of the inoculum, the endogenous levels of 
porphyrins, the method used to measure antimicrobial effectiveness and how 
cells were exposed to blue light treatment. Regarding inoculum cells, studies 
have shown that a higher concentration of cells reduces antimicrobial activity. In 
this study the cell concentration was 2 x 105 cells/ml. This is significantly less than 
that used in the study of Bumah et al., 2015 at (3 x 106 cells/ml), which would 
suggest that this would not influence the effects of blue light alone. In contrast to 
other studies, this study did not show an effect. It seems the effect seen with blue 
light exposure is due to endogenous porphyrins and the reason for not seeing the 
effect in this study could be that bacterial strains have different levels of 
porphyrins. As it has been shown that strains of P. aeruginosa Gram-negative 
bacteria showed significant difference in inactivation using the same conditions, 
possibly due to the lack of sufficient amount of flavins in the bacterial strain 
used(Abana et al., 2017). Also, the effectiveness of inactivation in log phase 
which was used in this study was less than lag phase due to the presence of 
more porphyrin inside cells in lag phase that acted as endogenous 
photosensitisers (Keshishyan et al., 2015). The previous studies conducted used 
a different method to determine antimicrobial activity by utilising the viable count 
method (colony forming unit - CFU), while the present work used optical density 
measurements or visual inspection to determine growth inhibition obtained. The 
use of CFU, where actually a significant inactivation was seen, is more accurate 
due to the measurement of viable cells. While this work determined growth 
inhibition by taking ODs or visually without measuring how many viable cells were 
there. In addition, the cells were removed from the treated samples and plated 
on agar, then incubated for 24 h before counting. In this study the cells were left 
in the treated media which have antioxidant properties. The effect of blue light 
with approximately the same wavelength and irradiance dose to this present 
study was shown to significantly reduce number of CFU of the same E. coli strain 
DH5α as used in this study (Abana et al., 2017). This dissimilarity between their 
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results and the present study is probably due to using agar plate method (Abana 
et al., 2017) while this work utilised the suspension method. It has been 
demonstrated that in vitro studies performed using the in suspension method 
require a higher irradiance dose to achieve microbial inactivation than studies 
performed on agar plates (Murdoch et al., 2012). The bacterial cells exposed to 
blue light in buffer suspensions and on agar plates were compared. It has been 
found that using suspensions required significantly more energy doses to obtain 
similar effect to that on agar, which ensures more exposure to blue light and direct 
effect on cells (Murdoch et al., 2012). Various studies have been conducted with 
using cell suspension, as this study, but to improve the antimicrobial efficacy, blue 
light should be exposed to microbial cells on agar plates (Murdoch et al., 2012). 
Therefore, there is no need for blue light to penetrate the solution. This suggests 
that using the suspension method in this study may have affected the results 
obtained in this work. 
In this study, no antimicrobial effect of blue light was seen against the spores of   
A. fumigatus. This supports the findings of Moorhead et al. (2016), who found 
previously Aspergillus species resistant at an energy dose of 504 J/cm2, which is 
higher than the dose used in this study. An increased resistance to blue light is 
also seen in bacterial endospores, which have similar hardy properties to the 
spore-forming A. fumigatus used in this study (Maclean et al., 2013). The high 
resistance of Aspergillus species is most probably due to the multilayered 
pigmented spore coat containing aspergillin (Ray et al., 1975).  
 
3.3.4 Blue light activation of acridines has an effect on microbial 
growth 
Based on blue light results and the absence of significant effect of acridines alone 
on microbial growth, any growth inhibition observed following illumination of the 
novel acridine compounds would be attributed to photoactivation of these 
compounds. Following photochemical screening of the 22 acridine compounds, 
the photoantifungal activity of these compounds under blue light illumination was 
measured against a range of fungi: S. cerevisiae, C. albicans and A. fumigatus.  
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The synthesised compounds were tested in vitro to determine growth inhibitory 
activity in the absence and presence of blue light. Minimum inhibitory 
concentration (MIC) values were measured using the EUCAST broth 
microdilution method (EUCAST 7.3: Arendrup et al., 2015a).Two different types 
of antimicrobial susceptibility test available are the solid media-based disk 
diffusion method and the liquid media-based microbroth dilution method. The disk 
diffusion method offers the ability to detect subpopulations of resistant bacteria 
that would be visualised as inner colonies in the zone of inhibition, view growth 
on the plate rather than in a well and set up easily. However, the disk diffusion 
method must be visually read and does not provide quantitative MIC values for 
the comparison of in vitro efficacy of different agents (Balouiri et al., 2016). 
Additionally, not all fastidious bacteria can be tested accurately by using the disk 
diffusion method, such as Helicobacter pylori and Brucella spp, which require 
particular cultural conditions to grow. On the other hand, the broth microdilution 
method has become a more widely referenced method for antimicrobial 
susceptibility testing. Using this method secures quantitative measurement of 
minimum inhibitory concentration (MICs) of antimicrobial drugs, reproducibility 
and result accuracy (Kahlmeter et al., 2006; Mayrhofer et al., 2008). However, 
broth microdilution as a method has its associated disadvantages as being 
relatively difficult to setup and more expensive (Reller et al., 2009).  
The most popular standardising breakpoint guidelines of broth microdilution 
method used in antimicrobial susceptibility testing worldwide are the Clinical 
Laboratory Standards Institute (CLSI) and the European Committee on 
Antimicrobial testing (EUCAST). Both the CLSI and EUCAST methods establish 
MIC breakpoints, which can identify whether the microorganism is sensitive or 
resistant to a given antimicrobial agent (Pfaller et al., 2011) . Due to the free 
availability and standardisation property of EUCAST guidelines, they were 
chosen in the present study. 
Two control bioassays with fluconazole against S. cerevisiae and C. albicans and 
amphotericin B against A. fumigatus were conducted. Fluconazole inhibits cell 
membrane formation by inhibition of a key enzyme, lanosterol 14-alpha 
demethylase, with decreasing effect against A. fumigatus due to the emergence 
of resistance (Carrillo-Munoz et al., 2006). Amphotericin B targets ergosterol, the 
essential component of fungal cell membrane, leading to cell death (Vandeputte 
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et al., 2012). No effect on the activity of fluconazole and amphotericin B was seen 
in the presence of blue light. This has not been previously investigated, 
consequently there is no literature to support this observation.    
To ensure consistency of the antifungal susceptibility testing and allow the 
obtained data to be compared across experiments, two control bioassays with 
fluconazole against S. cerevisiae and C. albicans and amphotericin B against A. 
fumigatus were carried out. The obtained MIC of 0.25 μg/ml against S. cerevisiae 
was located in the fluconazole wildtype distributions of S. cerevisiae that include 
data collected from multiple sources, geographical areas and time periods (MIC 
distributions-ECOFFs). In addition, the resultant MIC of 1 μg/ml against C. 
albicans corresponded with the EUCAST Antifungal Clinical Breakpoints 
(EUCAST 7.3: Arendrup et al., 2015a). Finally, the MIC of amphotericin B against 
A. fumigatus of 0.125 μg/ml matched the previous published MIC EUCAST 
breakpoint. 
The photoantimicrobial activity of acridine compounds was studied using the 
EUCAST broth microdilution method following 20-minute blue light (470 nm). The 
microbiological screening used in this study identified seven compounds with 
photoantifungal activity as these compounds reached MIC values against both S. 
cerevisiae and C. albicans with limited growth inhibition in the absence of blue 
light (Table 3.4). The MIC of acridines was determined using the same method 
as the reference drug fluconazole, to be the lowest concentration giving inhibition 
of growth of ≥ 50 % of that of compound-free control (EUCAST 7.3: Arendrup et 
al., 2015a). 
The spectrophotometric assay determined that five acridine compounds, 3, 4, 5, 
8, 17 were more efficient singlet oxygen producers than the standard with relative 
1O2 of 3.58, 1.33, 5.33, 2.17, and 2.5, respectively (Table 3.3). Compounds 3 and 
5 that released the highest levels of in vitro singlet oxygen compared to 
Compound 1 (Table 3.3); however, their high levels of singlet oxygen following 
blue light activation were not proportional to their respective photoantimicrobial 
effectiveness. For example, Compound 1 showed an MIC of 2 μg/ml against S. 
aureus, while the MIC of Compounds 3 and 5 was 24 and 8 μg/ml, respectively 
(Table 3.6).  Indeed, Compound 17 produced a high level of singlet oxygen, with 
a half-life of 33 min, but had limited effect on the growth of bacteria and fungi 
following blue light illumination. Additionally, although Compounds 2 and 11 
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released less 1O2 than Compound 5 in the spectrophotometric assay, they 
showed similar photoantibacterial activity (Table 3.3 and 3.5). This means that 
the increased in vitro photoantibacterial efficacy for Compounds 2 and 11 was 
not reflected in their respective singlet oxygen production (Table 3.3 and 3.5). 
This means that the in vitro photoantimicrobial efficacy for acridine compounds 
was not reflected in their respective singlet oxygen production. 
The photoantifungal data demonstrated that acridines 7, 13 and 16 showed 
antifungal activity against S. cerevisiae with no effect on C. albicans, while 
acridines 2, 3 and 11 exhibited antifungal activity against C. albicans but less than 
against S. cerevisiae. As C. albicans is a diploid microorganism, it contains two 
copies of its entire genome including genes responsible for resistance such as 
CDR1, CDR2, MDR1, which act by an efflux pumps mechanism (White et al., 
2002; Franz et al., 1998). Therefore, this genomic property may make C. albicans 
more resistant to antimicrobial acridine compounds than S. cerevisiae (Cowen et 
al., 2002). This is the same trend as with other antifungal agents, as the incidence 
of fluconazole resistance in C. albicans is higher than in S. cerevisiae (Anderson 
et al., 2004).  
No effect of acridines following blue light illumination was observed against A. 
fumigatus. A. fumigatus, in general, is more resistant than bacteria and other 
fungi. This can be attributed to the fact that A. fumigatus conidia accumulate 
trehalose and mannitol which play a protective role by scavenging reactive 
oxygen species (ROS) and preventing the aggregation of proteins (Ruijter et al., 
2003). Conversely, PDT has been shown to be effective against the conidial form 
of A. fumigatus but at a longer exposure time and higher wavelength than used 
in the study (Friedberg et al., 2001). 
In order to improve the efficacy of these compounds against microbes, the 
chemical structures should be reviewed to increase the production of singlet 
oxygen, which is considered to play the major role in microbial inactivation 
(Castano et al., 2004). The higher the singlet oxygen release the longer triplet 
excited state lifetime of a photosensitiser, which can be obtained by increasing 
intersystem crossing (ISC) efficiency. One way to increase ISC is by incorporating 
heavy atoms such as Br and I into the structure of the sensitiser. None of the 
current structures incorporate with those heavy atoms. Additionally, the cationic 
charge of molecules can make them more effective photosensitisers against 
92 
 
Gram-negative bacteria and Gram-positive bacteria as the positive charge on the 
PS molecule promotes a tight electrostatic interaction with negatively charged 
sites at the outer surface of the bacterial cells, increasing the efficiency of the 
photoinactivation process (Alves et al., 2009; Minnock et al., 1996). 
An additional way to enhance the efficacy of acridine compounds could be by 
synergism of acridines with other antimicrobial agents such as fluconazole, as 
this combination leads to a stronger effect than that of acridine alone in the 
equivalent dose (Lu et al., 2017; Cokol et al., 2011). 
The photoactivation of the 22 acridine compounds was examined against Gram-
positive bacteria (S. aureus) and Gram-negative bacteria (E. coli) using blue light. 
The obtained data showed nine acridine compounds with photoantibacterial 
efficacy against both bacterial species (Table 3.5). 
Despite singlet oxygen release being detected from the novel compounds in this 
study, this did not reflect their effectiveness against bacterial and fungal target 
cells. In photoantimicrobial therapy, the two most damaging ROS are .OH and 
1O2, which are able to react with many biomolecules in microbial cells 
(Vatansever et al., 2013). Since data in this study shows there is no correlation 
between photochemical results of singlet oxygen (Type 2) and biological results, 
this can explain that acridine compounds also tend to produce free radicals via 
Type 1 photochemistry; however, the amount of radicals could not be measured 
in this study. Consistent with the previous suggestion are the findings of a study 
by (Vatansever et al., 2013) in which non-tetrapyrrole based compounds (which 
match acridines) are more likely to undergo both Type 1 and Type 2 
photochemistry. Examples of these PS include phenothiazinium salts, such as 
toluidine blue O (TBO) (Martin et al., 1987) and methylene blue (MB) (Sabbahi et 
al., 2008). While it is thought that photosensitisers with different molecular 
frameworks (tetrapyrrole-based compounds) such as porphyrins and chlorins 
tend to undergo mainly Type 2 photochemical mechanisms (1O2 generation) 
(Maisch, 2007). This means that acridines tested in this study probably tend to 
undergo Type 1 and Type 2 reactions and thus produce radicals and singlet 
oxygen, respectively. Therefore, the absence of correlation between singlet 
oxygen release and photoantimicrobial effect in this present study could mean 
other factors, such as radical hydroxyl .OH, could be responsible. 
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 Additionally, photosensitisers in free solution may behave differently in the 
clinical environment. The composition of synthetic culture media is important for 
the behaviour of cultured cells in vitro and may affect the results of the 
photoantimicrobial experiments. The total antioxidant capacity of RPMI 1640 
medium used in photoantimicrobial screening has been estimated using the 
ABTS decolourisation assay and the ferric ion reducing antioxidant power assay 
and it has been shown that this culture medium has antioxidant properties using 
both assays (Lewinska et al., 2007). It has been found that components of the 
RPMI 1640 medium such as phenol red, cysteine, tyrosine and tryptophan are 
important contributors to the total antioxidant capacity of cell culture media (Van 
Overveld et al., 2000; Watanabe et al., 2002). Therefore, the use of RPMI 1640 
as a medium in photoantimicrobial screening within this study can weaken the 
killing effect of radicals released from acridines under irradiation. In this study it 
has been found that photoantimicrobial activity did not correlate with the amount 
of 1O2 released, which has previously been shown by Iwamoto et al., who 
measured singlet oxygen release and found that acridine and quinacrine 
produced a large amount of 1O2 but had less inactivation effect on viable S. 
cerevisiae cells than acridine yellow which produced the same amount of 1O2 
(Iwamoto et al., 1987). This supports the findings in this present study, which 
demonstrated that the resultant phototoxicity effects did not have a clear 
correlation with the related 1O2 efficiencies. 
The generation of 1O2 is very sensitive to oxygen concentration, which may play 
a role in photodynamic inactivation (Maisch, 2007). Because 1O2 originates from 
energy transfer from the excited photosensitiser to ground state oxygen, 
consuming oxygen, photoinactivation critically depends on oxygen levels 
(Kwiatkowski et al., 2018; Juzeniene et al., 2007). The measured oxygen levels 
at the site of singlet oxygen generation inside the microbial cells decreased as a 
result of normal oxygen consumption thus with decreasing oxygen concentration, 
the quantum yield of singlet oxygen released following exposure of acridines to 
blue light also decreases (Maisch, 2007). This means that the amount of singlet 
oxygen produced from acridines in microbiological screening may be less than 
that released under blue light illumination within the photochemical experiments 




To carry out PDT effectively in microbial cells, it is necessary to ensure sufficient 
light delivery to the cells with the least proportion of scatter and absorption 
scattering and absorbing (Castano et al., 2004; Castano et al., 2014). 
Additionally, the areas of photosensitiser localisation can directly affect the 
outcome of PDT in microbial cells because of the high reactivity and short life of 
both 1O2 and .OH (Moan et al., 1991).  
The discrepancies in the growth inhibition effect among the studied fungi (Table 
3.4) may be due to the fact that A. fumigatus is a spore-forming mould and its 
susceptibility testing was performed using a fungal conidial suspension. 
Compared to unicellular fungi such as S. cerevisiae and C. albicans, A. fumigatus 
fungi have supplementary mechanisms to handle ROS. For example, such 
mechanisms include a larger number of antioxidant enzymes such as the 
catalases CATA, CAT1, CAT2 and superoxide dismutases (SODs), which play 
important roles in the resistance of A. fumigatus to oxidative stress (Paris et al., 
2003; Jukic et al., 2017). Furthermore, the role of AtfA and the HOG MAPK 
pathway in stress tolerance in conidia of A. fumigatus has been reported, 
particularly AtfA, which can regulate several stress protection-related genes such 
as catT, dprA, scf1 and conJ at the conidiation stage (Paris et al., 2003; Hoi et 
al., 2011). Therefore, due to the availability of two ROS-detoxifying systems, 
catalases (CATs) and superoxide dismutases (SODs), A. fumigatus resists the 
ROS released following the exposure of acridines to blue light (Jukic et al., 2017; 
Emri et al., 2015). 
It is apparent in this study that the Gram-positive bacterium S. aureus was more 
sensitive to acridine compounds illuminated by blue light than Gram-negative 
bacterium E. coli (Table 3.5). Various studies have also reported fundamental 
difference in susceptibility to PDT between Gram-positive and negative bacteria 
(Nitzan et al., 2004; Maclean et al., 2009). Data within this chapter shows Gram-
positive bacteria are more susceptible to acridines than Gram-negative bacteria. 
This may be related to their morphology and physiology properties, as their 
cytoplasmic membrane is surrounded by a relatively porous layer of 
peptidoglycan and lipoteichoic acid that allows acridine and ROS to cross. Gram-
negative E. coli were more resistant to blue light treated acridines, which may be 
due to the existence of lipopolysaccharides (LPSs) in the extra outer membrane 
which forms a physical and functional barrier between the cell and its 
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surroundings, which may prevent penetration of acridines and ROS into the cells 
(Vatansever et al., 2013; Hamblin et al., 2004). Therefore, the different 
susceptibilities between Gram-positive and Gram-negative bacteria in this study 
can be explained by the difference in their cell wall structures. 
The data in this study demonstrated that Gram-positive bacteria are more 
sensitive to PDT than Gram-negative bacteria and this has been shown in other 
studies (Jori et al., 2006; Costa et al., 2012). In contrast, another study has 
previously shown no difference in susceptibility between Gram-positive and 
Gram-negative bacteria (Wainwright et al., 2016). The existence of more strongly 
cationic charges on molecules will increase the spectrum antimicrobial efficacy 
against Gram-negative bacteria (Vatansever et al., 2013). 
It is clear that there is a marked difference in the sensitivity of fungi and bacteria 
against our compounds. Compounds 12, 14 and 17, for instance, showed only 
antibacterial activity without any antifungal effect (Table 3.7). The higher 
resistance of fungi S. cerevisiae and C. albicans to photodynamic inactivation 
(PDI) in this study is probably due to the great difference in size and surface area 
between the bacterial and fungal cells. Because bacterial cells are significantly 
smaller than fungal cells that means fewer oxygen radicals less 1O2 are needed 
to kill them (Demidova et al., 2004). 
In conclusion, the data reported here will be important in designing experiments 
concerning antimicrobial PDT for infections. The photoantimicrobial activity of 
some compounds and the low no-light toxicity prompt future research to study 













Flavins are compounds with the basic structure of tricyclic isoalloxazine (Figure 
4.1; Knappe, 1977). They have been of interest to scientific research over the 
past decades, due to the discovery of many flavin-containing enzymes, which 
have a pivotal role in several important biological reactions. Flavin derivatives can 
absorb in the visible light range of spectrum because of the conjugation of the 
isoalloxazine ring. This absorption property allows flavins to be activated by UV-
blue light.  
 
 
Figure 4.1 7,8-Dimethylisoalloxazine structure (Knappe, 1977).  
 
 Flavin molecules act as important cofactors, which have the ability to take part 
in either one or two electron transfer reactions (Heelis, 1982). 
Flavin dependent enzymes perform a wide variety of functions in the absence or 
presence of light. For example, flavoprotein dehydrogenases and reductases 
transfer electrons between substrates in non-light conditions (Edwards, 2006). 
Another group of flavins containing enzymes such as DNA photolyase can obtain 
their catalytic functions following light exposure. This enzyme can be 
photoactivated by blue or near UV light of 360-500 nm and use its energy for the 
DNA repair function (Losi, 2007) 
Flavins such as riboflavin (RF), lumiflavin, flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN), β-nicotinamide adenine dinucleotide (NAD) and β-
nicotinamide adenine dinucleotide phosphate (NADPH) showed to have a 
photosensitising activity when excited in the ultraviolet-blue (UV-blue) spectral 
band due to the production of either hydrogen peroxide and other radical species 
via electron transfer (Type 1) or singlet oxygen 1O2 via energy transfer to oxygen 
(Type 2). The release of singlet oxygen and radical species is attributed to the 
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highly delocalised π-orbitals capable of transferring electrons or energy to 
molecular oxygen (Heelis, 1982). 
It has been further identified, in a study by (Ruane et al., 2004), that two selected 
bacterial pathogens Staphylococcus epidermidis and Escherichia coli can be 
inactivated by exposing riboflavin to 10 min UV light (Ruane et al., 2004) . 
Additionally, the antibacterial activity of photosensitising riboflavin using UV 
irradiation against Staphylococcus aureus, Staphylococcus epidermidis and 
Pseudomonas aeruginosa was evaluated by using a combination of 60 min UV 
light and riboflavin, which decreased the viable bacterial count (CFU), by an 
average of 95% in all bacteria tested (Makdoumi et al., 2010). A device known as 
Mirasol Technology was developed for the reduction of microbes by using UV 
light (280-360 nm) and riboflavin (vitamin B2) as photosensitiser to inactivate E. 
coli cells’ viability (Kumar et al., 2004). However, the negative effect of UVA 
ionisation on the biological tissues and its mutagenesis mechanism can cause 
additive effects (Ahgilan et al., 2016). 
 
It has been shown that riboflavin and two novel derivatives, FLASH-01a and 
FLASH-07a, can produce singlet oxygen and radicals following UV-blue light 
illumination, which means they are involved in two pathways, Type 1 and Type 2 
reactions under visible light illumination (380-600 nm) (Wainwright, 2009). These 
new flavin photosensitisers exhibited a phototoxicity effect upon light exposure 
duration between 10 and 180 s against multidrug resistant bacteria such as 
MRSA (methicillin-resistant Staphylococcus aureus) and EHEC 
(enterohemorrhagic Escherichia coli) (Maisch, 2007). Another study by Maisch, 
proved the photodynamic effect of these two novel riboflavin derivatives against 
Bacillus atrophaeus. Their results showed that the combination of the 
photosensitisers with blue light for 10 s effectively inactivated the Bacillus spores 
(Maisch, 2007).  
 
Due to the photosensitisation effect and phototoxicity properties of flavins under 
UV-blue light irradiation, a set of new flavin derivatives was produced to evaluate 
the antibacterial efficacy of theses photoactivated derivatives using blue light on 
clinically important microorganisms (Heelis, 2018). 
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The work presented in this chapter describes the possible photochemical 
inactivation of selected microbes using the novel flavin derivatives and blue light 
irradiation. The singlet oxygen (1O2) released from these flavin compounds was 
measured previously and these compounds were then tested to determine their 
photoantimicrobial activities. To determine their antimicrobial efficacy, the 
European Committee for Antimicrobial Susceptibility Testing (EUCAST) 
microbroth dilution method was utilised (EUCAST 7.3: Arendrup et al., 2015a). 
All flavin compounds were screened against key microbial pathogens, including 
Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) and the fungi 
Candida albicans (C. albicans), which has high mortality rate of 40%, and 
Aspergillus fumigatus (A. fumigatus), which is complicated to treat and often fatal 
with a mortality rate 50-90%. In addition, the yeast model organism, 



















Riboflavine (Vitamin B2) is a natural photosensitiser and well known to undergo 
Type 1 and 2 photosensitisation under illumination with blue light (λ = 475nm) 
(Wainwright, 2009). The reported photoantimicrobial activity of riboflavin 
demonstrates activity across a broad spectrum of Gram-positive and Gram-
negative bacteria (Kumar et al., 2004; Makdoumi et al., 2010). Inspired by this, a 
series of novel flavin compounds, based on the core alloxazine structure as 
shown in Table 4.1, was synthesised by Dr Rob Smith, UCLan (Figure 4.1). 
(Table 4.1; Johns et al., 2014). The aim was to investigate how singlet oxygen 
production and the subsequent antimicrobial effects of these compounds would 
change, if the ribose sugar unit was replaced with a p-substituted phenyl 
derivative. This is because the removal of the sugar unit could change the ability 
of the microbe to take up the flavin compounds. Indeed, it was hypothesised that 
when the substituted atom was a Cl, Br or I, the singlet oxygen yield would 
increase due to the heavy atom effect. This in turn should increase 
photoantimicrobial activity due to the higher rate of singlet oxygen production, 







     Figure 4.2 Chemical structures of novel flavin derivatives.
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Table 4.1 Structures of substituted flavins containing different R groups. 
    
                      
 






25 CO2 (CH3)2 
26 H 




















4.2.1 Photochemical characterisation of flavin compounds 
4.2.1.1 Singlet oxygen (1O2) data 
The absorption spectrum for all flavins was taken to identify the matching 
wavelength of visible light for best activation. For all flavin compounds, the λmax 
(which shows the wavelength at the highest energy peak) ranged between 260-
269 nm (Table 4.2). Two other low energy peaks were located in the blue light 
region between 425-435 nm, which can activate flavins. Following absorption of 
visible light of a specific wavelength, free radicals and singlet oxygen species are 
produced, which then cause cellular damage. The singlet oxygen produced 
following blue light exposure was measured using TPCPD assay by determining 
the half-life of these compounds. 
The half-life and singlet oxygen levels of flavins were measured following the 
exposure to blue light. All the flavins demonstrated a half-life. The data in this 
study finds that Compound 29 produced the most amount of singlet oxygen by 
showing the lowest half-life at 6 min among all flavin derivatives. It was followed 
by Compounds 24, 27 and 33 with half-life values of 6, 8 and 9 min, which showed 
decreasing values of relative singlet oxygen (Table 4.2). It was seen that the 













Table 4.2 Compounds characterised according to the half-life obtained following 
60 min blue light exposure. The lower the half-life the more singlet oxygen production. 










Alloxazine 260 100 1 
23 266 25 7 
24 267 6 27.5 
25 268 20 8.7 
26 268 13 14 
27 269 8 21.7 
28 269 60 3 
29 268 6 29 
30 266 23 8 
31 269 11 15.7 
32 263 53 3.3 
33 253 9 20.4 
34 267 12 14.4 
 
4.2.1.2 Radical species data 
The measurement of radicals released from flavins during PDT on microbes was 
not measured in this study. It may possible that the radical markers used in this 











4.2.2 Antifungal screening 
The 12 candidate compounds based on flavins were screened using the EUCAST 
microbroth dilution method for antifungal activity against S. cerevisiae, C. 
albicans and A. fumigatus. These species were exposed to a range of 
concentrations of the flavin compounds (0 to 250 μg/ml) in the presence and 
absence of blue light. The concentration range of 0 to 250 μg/ml was consistently 
chosen as higher concentrations often showed limited solubility. Growth was 
determined by measuring OD at 530 nm for S. cerevisiae and C. albicans and 
visually for A. fumigatus.  
The growth inhibition percentage for each concentration of compound, in the 
presence and absence of blue light, was calculated against the OD530nm of the 
drug-free control (100%). The well-characterised antifungal agents, fluconazole 
and amphotericin B, were used as the controls. The experiments were repeated 
on two separate occasions in duplicate. 
The heat maps shown in Figures 4.3 and 4.4 illustrate the percentage growth 
inhibition determined from the OD530nm readings for fungal growth for 
concentrations of fluconazole and compounds exposed to blue light for 20 min at 
24 h incubation. The concentrations of fluconazole (control) used were 0 to 64 
μg/ml due to the expected MIC range of fluconazole according to the EUCAST 
method, while concentrations of the compounds were 0 to 250 μg/ml. The colour 
of the table cells indicates the percentage growth, with black indicating complete 
growth (0% inhibition), and red indicating no growth (100% inhibition). Yellow 
indicates 50% growth inhibition, which aligns with the minimal growth inhibition 
(MIC), as determined by the EUCAST method. In Chapter 3 it has been 
demonstrated that there is no effect of blue light alone on the growth of fungal 
and bacterial species (Figure 3.3 to 3.6). Therefore, any antimicrobial activity will 








      Growth Inhibition % (OD530nm) 
 
Figure 4.3 Heatmap illustrating OD530nm levels for varying concentrations of a list of 12 compounds (0 to 250 μg/ml) against S. cerevisiae. 
The yellow bar shows 50% growth inhibition while the red bar illustrates the maximum growth inhibition. 
 
    
 % inhibition, as determined by  OD530nm , following 24 h incubation at 30˚C 
Compounds 250 
μg/ml 
25 μg/ml 12.5 μg/ml 6.25 μg/ml 3.125 μg/ml 1.56 μg/ml 0.78 μg/ml 0.39 μg/ml 0.195 μg/ml 0.097 μg/ml 0.048 μg/ml 0 μg/ml 
23             
24             
25             
26             
27             
28             
29             
30             
31             
32             
33             
34             
 64 μg/ml 32 μg/ml 16 μg/ml 8 μg/ml 4 μg/ml 2 μg/ml 1 μg/ml 0.5 μg/ml 0.25 μg/ml 0.125 μg/ml 0 μg/ml 
             Flu            
          4 






      Growth Inhibition % (OD530nm) 
 
Figure 4.4 Heatmap illustrating OD530nm levels for varying concentrations of a list of 12 compounds (0 to 250 μg/ml) against C. albicans. The 
yellow bar shows 50% growth inhibition while the red bar illustrates the maximum growth inhibition. 
 % inhibition, as determined by  OD530nm , following 24 h incubation at 35˚C 
Compounds 250 μg/ml 25 μg/ml 12.5 μg/ml 6.25 μg/ml 3.125 μg/ml 1.56 μg/ml 0.78 μg/ml 0.39 μg/ml 0.195 μg/ml 0.097 μg/ml 0.048 μg/ml 0 μg/ml 
23         2.95    
24         2.95 3.2  3 
25            7 
26            5 
27            3 
28           3 1 
29            2 
30            5 
31            3 
32            6 
33            8 
34            8 
 64 μg/ml 32 μg/ml 16 μg/ml 8 μg/ml 4 μg/ml 2 μg/ml 1 μg/ml 0.5 μg/ml 0.25 μg/ml 0.125 μg/ml 0 μg/ml 
             Flu            
          4 
100%     50%     0% 
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The EUCAST microdilution method was used to determine the susceptibility of 
the studied fungi against a series of concentrations to identify the minimum 
inhibitory concentration MIC (50% growth inhibition compared to the control) of 
the tested compounds. To determine percentage growth inhibition, the optical 
density OD530nm readings for fungal growth were taken for each concentration of 
compounds exposed to blue light for 20 min at 24 h incubation and compared 
with that of the compound-free control.  
The graphs (Figures 4.5 to 4.16) show the mean ±SEM (standard error of the 
mean) of the highest percentage growth inhibition which has been recorded for 
all flavin compounds at 25 μg/ml in the absence and presence of blue light and 
for fluconazole at 64 μg/ml in S. cerevisiae and C. albicans.  
 
Figure 4.5 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 23 in absence and presence of blue light. Comparison of Compound 23 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 

































Figure 4.6 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 24 in absence and presence of blue light. Comparison of Compound 24 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
Figure 4.7 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 25 in absence and presence of blue light. Comparison of Compound 25 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
























































Figure 4.8 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 26 in absence and presence of blue light. Comparison of Compound 26 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
Figure 4.9 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 27 in absence and presence of blue light. Comparison of Compound 27 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 























































Figure 4.10 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 28 in absence and presence of blue light. Comparison of Compound 28 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
Figure 4.11 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 29 in absence and presence of blue light. Comparison of Compound 29 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 























































Figure 4.12 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 30 in absence and presence of blue light. Comparison of Compound 30 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
Figure 4.13 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 31 in absence and presence of blue light. Comparison of Compound 31 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
























































Figure 4.14 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 32 in absence and presence of blue light. Comparison of Compound 32 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
Figure 4.15 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 33 in absence and presence of blue light. Comparison of Compound 33 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 






















































Figure 4.16 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 34 in absence and presence of blue light. Comparison of Compound 34 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 means no blue light exposure. The 
experiment was conducted using EUCAST broth microdilution method and standardised 
inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in duplicate, n=2. 
Values are the mean ±SEM. 
 
To ensure consistency of the results, EUCAST antifungal susceptibility testing of 
S. cerevisiae and C. albicans was performed using fluconazole as the control. 
Regarding S. cerevisiae, the resultant MIC of 0.25 μg/ml was identified to be 
within the published range (MIC and zone distributions and ECOFFs). The 
resultant MIC of 1 μg/ml against C. albicans corresponded with the EUCAST 
Antifungal Clinical Breakpoints (EUCAST 7.3: Arendrup et al., 2015a). 
None of the compounds have significant antifungal activity in the absence of blue 
light against both species. Since the tested compounds showed no measurable 
effect on the growth of cells in the absence of blue light, any possible antifungal 
efficacy will be due to blue light treated flavins. 
The data shows that the blue light treated flavins had limited effect on the growth 
of S. cerevisiae or C. albicans, with growth inhibition determined to be ≤ 50% 
compared to the compound-free control. As such, the MIC could not be 




























Although the MIC value was not reached, the flavin Compounds 25, 30 and 31 
showed the highest growth inhibition among all the 12 compounds after 20-
minute blue light illumination (Figures 4.7, 4.12 and 4.13). The highest 
percentage growth inhibition was obtained at a concentration of 25 μg/ml with 
maximum growth inhibition levels of between 30-40% in S. cerevisiae and C. 
albicans. There was no significant difference in the susceptibility of S. cerevisiae 
and C. albicans to the activated flavins. The nine remaining flavins demonstrated 
slightly more growth inhibition when excited by 20-minute blue light when 
compared to the unactivated compounds against the both species (Figures 4.5, 
4.6, 4.8, 4.9, 4.10, 4.11, 4.14, 4.15 and 4.16). Compounds 23 and 24, for 
example, showed growth inhibition of 15%, and 13% against C. albicans in the 
absence of blue light which increased to 25% and 23% respectively when 
exposed to 20-minute blue light (Figures 4.5 and 4.6). In all cases, growth 
inhibition of less than 12% was seen in the no blue light control. 
 
A. fumigatus was also screened using the EUCAST antifungal MIC microdilution 
method for moulds (EUCAST 9.3: Arendrup et al., 2015a). Due to the growth of 
A. fumigatus, instead of using the optical density to determine percentage growth 
inhibition, a visual inspection was undertaken. In this case the MIC was 
determined to be the first well where the concentration of compound resulted in 
complete absence of growth. It has been demonstrated that amphotericin B is 
effective against A. fumigatus showing MIC of 0.125 μg/ml, which matched the 
MIC EUCAST breakpoint in A. fumigatus. The antifungal screening demonstrated 
that flavins, following exposure to blue light, did not exhibit any efficacy against 
A. fumigatus at the concentrations tested (0 to 250 μg/ml) by checking the growth 









4.2.3 Antibacterial screening 
The flavin compounds were then screened using the European Committee for 
Antimicrobial Susceptibility Testing (EUCAST) microbroth dilution method, for 
antibacterial activity following blue light illumination for 20 min against two 
clinically important bacterial species, S. aureus and E. coli. 
 The antibacterial drug gentamicin was used as a control due to its broad 
antibacterial activity against both Gram-negative and Gram-positive bacteria (Jao 
et al., 1964). The bacterial species were exposed to a range of concentrations of 
the flavin compounds (0 to 256 μg/ml) in the presence and absence of blue light. 
A 20-minute illumination period was used due to the release of most singlet 
oxygen from the compounds during that time. The MIC was determined, by visual 
inspection, to be the lowest concentration that completely inhibits growth. The 
experiments were repeated two times in duplicate. 
EUCAST antibacterial susceptibility testing of S. aureus and E. coli to the control 
gentamicin was performed and the resultant MICs of 0.25 and 0.125 μg/ml 
corresponded with EUCAST Antibacterial Clinical Breakpoints which confirms the 
accuracy of the assay.  
All the compounds showed little effect on bacterial growth after blue light 
exposure and no MIC was reached at the maximum concentration tested of 256 













In this study, the aim was to evaluate the antimicrobial activity of a set of novel 
photoactivated flavins using blue light irradiation. Flavin compounds, previously 
characterised photochemically, were tested in the absence and presence of blue 
light against a range of clinically important fungi including S. cerevisiae, C. 
albicans and A. fumigatus, and the bacteria S. aureus and E. coli, using the 
European Committee for Antimicrobial Susceptibility Testing (EUCAST) method 
(EUCAST 7.3: Arendrup et al., 2015a). 
4.3.1 Flavins are photosensitised following exposure to blue 
light and release singlet oxygen 
Due to the reported photosensitising activity of flavins, such as riboflavin 
(Khaydukov et al., 2016; Ha et al., 2009; Huang et al., 2006), a set of novel 
synthesised flavins has been characterised photochemically.  
The absorption spectrum between the wavelengths 250-800 nm was taken for 
each flavin compound to determine the wavelength of maximum absorbance, 
λmax, which identified the visible light source required to photoactivate the 
flavins. Although flavins absorbed maximally in the UV light region, as λmax 
ranges between 260-269 nm (Table 4.2), the absorption spectrum consists of two 
additional peaks centred in the blue light region at around 415 and 435nm, which 
can activate flavins. This finding supports the results of Heelis et al., (1982), who 
found that riboflavin was absorbed in the UV-blue light region as four maximum 
peaks centred at 446, 375, 265 and 220nm. This is also consistent with other 
published data conducted on flavins, flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN), which show their longest absorption wavelengths in the 
range between 400-500 nm at the λmax of 450 and 446 nm, respectively. 
Absorption peaks of a compound can be obtained by electron jump from π-
bonding orbitals to π-anti-bonding orbitals, non-bonding orbitals to π-anti-
bonding orbitals and non-bonding orbitals to sigma anti-bonding orbitals. This 
means that in order to absorb light in the region from 200- 800 nm, the molecule 
must contain at least one π bond or atom with a non-bonding orbital (Huang et 
al., 2006). The carbon-oxygen double bond in flavins obviously has π electrons 
as part of the double bond, and also has a non-bonding orbital. The non-bonding 
orbital has higher energy than a π-bonding orbital which means that flavins can 
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absorb light of different wavelengths. The structures of flavins tested within this 
study have two carbon-oxygen double bonds, producing additional absorption 
peaks. The substitutions added to the basic flavin structure did not affect the 
λmax. 
Flavins are suggested to be involved in two photochemical reactions, Type 1 and 
Type 2, producing free radicals and singlet oxygen, respectively. These released 
species are highly reactive and thus can cause cellular damage (Martins et al., 
2008; Sauer et al., 2010). Therefore, singlet oxygen release following activation 
by blue light over a 60-minute period was quantified using the TPCPD assay, 
which demonstrated that most singlet oxygen species were produced from flavins 
following 20 min of blue light illumination (Table 4.2). 
The 12 flavin derivatives, following 20 min of blue light illumination, all released 
more singlet oxygen than the standard, alloxazine. The relative singlet oxygen 
values for the novel flavins ranged between 3 and 29 (Table 4.2). This finding 
was in agreement with a study by Sikorska et al., 1998, who found that derivatives 
of alloxazine also showed higher levels of singlet oxygen production, when 
compared to alloxazine alone. However, the 1O2 measurements between the 
studies are difficult to compare, owing to the use of two different measurement 
methods of 1O2 as well the use of UV light instead of blue light. 
These results indicate that the flavins tested in this study can act as effective 
singlet oxygen producers. The most important method of generating 1O2 is via 
the photosensitising process, which is triggered by the absorption of photons by 
the photosensitiser (PS). The resultant singlet excited state can decay via 
intersystem crossing (ISC) to generate the excited triplet state (T1). 
Subsequently, the energy of the excited triplet state of PS is transferred directly 
to molecular oxygen, resulting in the generation of 1O2. Consequently, the 
quantum yield of 1O2 strongly depends on the efficiency of ISC and the triplet 
excited state T1 (Jeong et al., 2016). Therefore, enhancing the ISC process is 
considered a fundamental approach for producing a high T1 population of PS and 
thus more 1O2. This can be achieved by incorporation of heavy atoms (such as 
halogens) onto the photosensitiser, which can be explained using the principles 
of spin-orbit coupling, which leads to a bathochromic shift in absorption maxima, 
the first important step in the photosensitising process (Abrahamse et al., 2016). 
This method supports the observations obtained in this study, which 
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demonstrated that flavin structures which have halogen atoms, such as iodine, 
bromine and chlorine, incorporated into the alloxazine moiety increased the 
singlet oxygen yield at least threefold when compared to compounds without 
halogens. It has been demonstrated that Compounds 29 and 24 which contain 
the halogens iodine and bromine released the most relative 1O2 at values 29 and 
27.5, respectively. It was followed by compounds incorporating the halogens 
chlorine and fluorine, which produced relative 1O2 at 21.7 and 20.4, respectively 
(Table 4.2). The effect seen with halogenated substituents is consistent with 
several studies which demonstrated the same relationship between induction of 
halogens and amount of singlet oxygen release following the order F < Cl < Br < 
I (Mehraban et al., 2015; Pereira et al., 2010; Azenha et al., 2002). This suggests 
that halogens with a higher atomic mass induce a significant enhancement of the 
ISC, the excited triplet yield, and the quantum yield of 1O2 generation (Jeong et 
al., 2016).  
Following the UV or blue light illumination, flavins such as riboflavin are converted 
into triplet excited state riboflavin. Radical O2·− (a precursor of H2O2 and 
hydroxyl radical .OH) and 1O2  are then produced through the reaction of the triplet 
excited state riboflavin (Liang et al., 2017; Nielsen et al., 2015). Various studies 
have investigated irradiation of riboflavin with blue light and determined the 
generation of radical species (O2·−) by measuring the reduction of nitro blue 
tetrazolium (NBT). This release can be detected at 560 nm as the absorbance of 
NBT reduction increases with the generation of (O2·−) (Yang et al., 2018; Choi et 
al., 2002; Apak et al., 2007). This NBT method points to the significant generation 









4.3.2 Flavins have no significant effect on microbial growth in 
the absence of blue light 
All flavin compounds screened in this study demonstrated insignificant growth 
inhibition activity in the absence of blue light. At the highest concentrations tested 
(250 μg/ml), growth inhibition of less than 12% in S. cerevisiae and C. albicans 
was observed in the no blue light control. Additionally, no visual growth effect was 
observed against the fungus A. fumigatus and the bacteria S. aureus and E. coli. 
The finding in this study was in agreement with a number of other studies that 
have found that riboflavin had no effect on cell viability in the absence of light. 
This includes both fungi (C. albicans, Fusarium sp and Aspergillus fumigatus) 
and bacteria (E. coli, S. aureus and P. aeruginosa) (Makdoumi et al., 2010; 
Martins et al., 2008; Nielsen et al., 2015). In all cases, the concentration of 
riboflavin was significantly lower than that used in this study, ranging from 1 μg/ml 
to 150 μg/ml. 
  
When flavins are taken up into the cell by flavin importers, the FMN and FAD 
enzymes inside the microbial cell, which have a relatively broad substrate 
specificity, will accept a variety of flavin analogues as substrates; among them 
are riboflavin (RF) and roseoflavin (RoF). The imported flavin analogues are 
phosphorylated and adenylated and consequently flavin-FMN and flavin-FAD 
rather than flavins will be the toxic compounds in the cytoplasm of target cells 
due to significantly altered redox potential (Biscaro Pedrolli et al., 2013). 
However, some flavoenzymes may still be active after accepting flavin analogues 
without a decrease in activity. In bacteria, the flavin transporters, YpaA, RibZ, 
RibM and RibF, can uptake these flavin analogues, where they are 
phosphorylated and adenylated within the cytoplasm (Vogl et al., 2007, 
Hemberger et al., 2011; Gutiérrez-Preciado et al., 2015). For fungi, transporters 
Mch5p, RibZ and RibE catalyse the uptake of riboflavin (Vogl et al., 2007).  
The impact of the absence of tested flavins in this study against fungal and 
bacterial cells is suggestive that these microorganisms did not recognise the 
tested flavins and thus no enzymatic conversion occurred. Furthermore, upon 
addition of the flavin compounds to the media, they could be taken up into the 
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cells and converted into flavin-FAD and flavin-FMN, which are potentially still 
active or marginally affected. To provide more antimicrobial activity to the flavins 
it has been suggested to make them more hydrophobic (through a methylation 
process), such as roseoflavin, which facilitates their binding to the target enzymes 
and fully inactivates flavoenzymes (Biscaro Pedrolli et al., 2013; Kasai et al., 
1979). Since flavins tested in the present study lack methylation (making them 
less hydrophobic), this may give indication why no effect was observed against 
fungal and bacterial cells.  
 
4.3.3 Three blue light activated flavins have a significant effect 
on microbial growth when compared to that of untreated 
flavins 
To confirm that any effect on microbial cell growth is the result of blue 
light/compound combination rather than exposure to the activating light source, 
the effect of blue light alone (470 nm) on growth of fungal and bacterial cells, over 
20-minute period of irradiation at 96 mW/cm2, was investigated. The data 
presented in Chapter 3 demonstrated that 60-minute blue light illumination did 
not have a significant effect on the the growth of S. cerevisiae, C. albicans, A, 
fumigatus, S. aureus and E. coli when compared to that of untreated microbial 
cells (Figures 3.3-3.6).  
Based on the blue light results, any growth inhibition observed following 
illumination of the novel flavin compounds, would be attributed to photoactivation 
of these compounds. Following photochemical screening of the 12 flavin 
compounds, the photoantimicrobial activity of these compounds was assessed 
against a range of fungi and bacteria and the minimum inhibitory concentration 
(MIC) values were measured using the EUCAST method (EUCAST 7.3: Arendrup 
et al., 2015a). 
 
Each of the controls in each individual species tested, fell within the published 
range, indicating that the assay was consistent.  
Following microbiological screening, nine of the twelve flavin-based compounds 
showed no effect on growth in either S. cerevisiae or C. albicans (Figures 4.5 to 
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4.16). Only three of the light activated flavin compounds, 25, 30 and 31, showed 
significant growth inhibition in S. cerevisiae and C. albicans when compared with 
no blue light control (Figures 4.7, 4.12 and 4.13). However, no MIC could be 
determined as, at the highest concentration tested (250 μg/ml), total growth 
inhibition was less than 50%. In contrast, no growth inhibition was observed in 
either A. fumigatus or the bacterial species, E. coli and S. aureus, following 
exposure to the 12 flavin compounds.  
Photoactivated riboflavin, by UV and visible light, has been extensively studied 
as an antimicrobial agent in a range of different microorganisms. Cellular damage 
occurs via ROS, which causes non-specific oxidative stress, and via intercalation 
of the molecule into the nucleic acids of the cell. In this study, nine of the light 
activated compounds showed no antimicrobial activity against fungi or bacteria.  
This is supported by previous studies where various concentrations of 
photoactivated riboflavin exhibited no effect on growth in C. albicans, A. 
fumigatus, S. aureus or E. coli (Martins et al., 2008; Nielsen et al., 2015; Sauer 
et al., 2010). However, it should be noted that the concentrations used were lower 
than this study (i.e. below 100 μg/ml versus 250 μg/ml) and the wavelengths of 
the activating light sources varied. There is no published data on the effect of 
activated flavin molecules on S. cerevisiae, thus this result could not be 
confirmed. 
This effect was observed only in S. cerevisiae and C. albicans and not in bacteria 
within this study, suggesting that flavins did not experience metabolism 
(enzymatic conversion) inside fungi and thus they are activated by blue light and 
release ROS, which significantly impact growth. Whereas in bacteria, it is 
possible that the substituted flavins are converted so there are no molecules 
available to be photoactivated. Also, the weak effect of blue light treated flavins 
on bacteria may be explained also by the uncharged state of flavins, which may 
reduce the interaction with bacterial cell membrane (Maisch, 2007). Regarding A. 
fumigatus, it is generally accepted to be more resistant than bacteria and other 
fungi to compound penetration and ROS effect due to the presence of trehalose 
and mannitol in the spores which play a protective role by scavenging reactive 




Compounds 25, 30 and 31 had the lowest release of singlet oxygen release of 
the 12 flavins compounds tested, but caused the greatest level of fungal growth 
inhibition (Table 4.2; Figures 4.7, 4.12 and 4.13). As such, the levels of singlet 
oxygen production were not proportional to their respective photoantimicrobial 
activity. Indeed, Compounds 28 and 32 produced the highest level of singlet 
oxygen but had no effect on growth following blue light illumination (Figures 4.9 
and 9.13). This means that the increased in vitro singlet oxygen release for 
Compounds 46 and 50 was not reflected in their respective photoantimicrobial 
activity.  
The low half-life of flavins obtained in in vitro photochemical studies indicated that 
singlet oxygen release from flavins is high (Table 4.2), as the lower the half-life 
value, the greater the singlet oxygen production. Although flavins released more 
singlet oxygen photochemically, no MIC was observed at the maximum 
concentration following blue light activation. This is may be due to the lack of 
singlet oxygen release inside the microbial cell, which may be attributed to the 
rapid transportation of flavins into the cells, which employ them directly as 
enzyme cofactors. The absence of effective photoantimicrobial properties may 
be explained by the concept that in vitro photochemical investigation, which 
measures relative singlet oxygen released from flavins, may not reflect exact 
behaviour in the real microbiological systems. Since the production of singlet 
oxygen depends on the molecular environment of the photosensitiser, 
investigations in solution may not reflect exact behaviour in the microbiological 
situation. Both singlet oxygen and radical species can result in damaging effects 
on microbial cells, suggesting that photoantimicrobial effects may be influenced 
mainly by electron transfer/redox mechanism of action (Type 1 
photosensitisation) represented by radicals such as .OH, which could not be 
measured, as previously mentioned in this study. Significant NBT reduction by 
flavin in the presence of light can confirm photosensitivity of the compound 
whereas an increased dichlorofluoroscein (DCF) level in the microbial cells 
treated with photoactivated flavin shows significant intracellular ROS generation 
(Khan et al., 2019). Furthermore, addition of radical scavenger to microbial 
solution will lead to hindrance in terms microbial inactivation, thus providing a 
clear evidence that the antimicrobial effect is mediated by radicals. 
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The present study shows that the flavins tested are not suitable as photoactivated 
compounds in photoantimicrobial therapy. This was because no antimicrobial 
efficacy was observed by using the combination of flavins and blue light against 

























5. Acridine-isoalloxazine  
5.1 Introduction 
Acridine-isoalloxazine based compounds are composed of a combination of two 
moieties, acridine and isoalloxazine. As previously described in Chapter 3, 
acridine compounds are one of many groups of photosensitisers that are 
intensively studied in antimicrobial photodynamic therapy due to their ability to 
generate reactive oxygen species (ROS) and inactivate microbial cells under blue 
light illumination. 
The most significant isoalloxazine derivatives are called flavins, (7,8-dimethyl 
substituted isoalloxazines), they are considered an important group of 
compounds in regard to their biological functions, photosensitisation activity and 
nutritional role. They can be seen in most cell types, mainly as riboflavin (vitamin 
B2) and two electron carriers, flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD). The wavelengths of maximum absorbance of isoalloxazine 
derivatives range between 326 and 460 nm, which match the UV and blue light 
regions (Sikorska et al., 1998) 
Isoalloxazine derivatives’ photochemical and photophysical properties have been 
studied intensively over the past forty years (Penzer et al., 1967). Isoalloxazine 
derivatives, including lumiflavin, riboflavin, flavin mononucleotide (FMN) and 
flavin adenine dinucleotide (FAD), demonstrated photosensitising activities in 
vitro by reacting with a number of substrates under illumination with a tungsten 
halogen lamp of 420-480 nm for 30 min. The production of singlet oxygen and 
radical species is due to the highly delocalised π-orbitals capable of transferring 
electrons or energy to molecular oxygen (Heelis, 1982).  
Initial tests have found that photoactivated isoalloxazines have antimicrobial 
efficacy against several microorganisms. Riboflavin (RB) has been revealed to 
have a sensitising effect on DNA in E. coli when activated with UV light as this 
effect was observed by showing increased genomic DNA degradation (Kumar et 
al., 2004).  
 
Additionally, photoactivated riboflavin demonstrated in vitro antimicrobial activity 
by inhibiting growth of a range of pathogenic microorganisms including both 
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Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis) and Gram-
negative (Pseudomonas aeruginosa) bacteria under one hour-UV illumination 
(365 nm) and using a disk diffusion susceptibility test (Martins et al., 2008). 
Due to the well-established photosensitising and antimicrobial activities of both 
acridine and isoalloxazine, a range of novel acridine-isoalloxazine conjugates 
was synthesised by a chromatography-free route to determine their applicability 
for photodynamic antimicrobial treatment (Johns et al., 2014).  
This study will utilise these novel substituted acridine-isoalloxazine compounds, 
which have previously been characterised photochemically, to determine their 
potential use as effective PDT agents for microbial infections following blue light 
illumination. The European Committee for Antimicrobial Susceptibility Testing 
(EUCAST) microbroth dilution method was utilised to evaluate the antimicrobial 
activity against bacteria, including S. aureus and E. coli and the fungi S. 
cerevisiae, C. albicans and A. fumigatus. 
 
5.2 Results 
Acridine moieties have been of interest to medicinal chemists for many years and 
they exhibit significant pharmaceutical importance due to their potential 
photodynamic biological activities (Wainwright, 2001). Isoalloxazine derivatives 
absorb in the visible region and show photoantimicrobial activity through Type 1 
and Type 2 photosensitisation (Ruane et al., 2004). Inspired by the biological 
activity of both, a series of novel acridine-isoalloxazine conjugates was previously 







                    Figure 5.1 Chemical structures of novel acridine-isoalloxazine derivatives.
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R1 R2 R3 R4 R5 R6 
35 H H H H H H 
36 Cl H OCH3 OCH3 H H 
37 Cl H H Fused 
Phenyl 
CH3 CH3 
38 Cl H OCH3 H H H 
39 H H H OCH3 CH3 CH3 
40 Cl H H Fused 
Phenyl 
H H 
41 Cl H OCH3 H CH3 CH3 
42 H H OCH3 H CH3 CH3 
43 Cl H CH3 H CH3 CH3 
44 H H CH3 H H H 
45 Cl H H OCH3 H H 
46 H H H H Cl Cl 
47 Cl H H CH3 H H 
48 H H H OCH3 H H 
49 Cl OCH3 H H Cl Cl 
50 NO2 H OCH3 H H H 
51 H H OCH3 H CH3 CH3 






5.2.1 Photochemical characterisation of acridine-isoalloxazine 
compounds 
5.2.1.1 Singlet oxygen (1O2) data  
The acridine-isoalloxazine compounds were previously characterised by Dr Rob 
Smith’s group at UCLan using the 2,3,4,5-tetraphenylcyclopentadienone 
(TPCPD) assay to measure the relative singlet oxygen of the compounds against 
alloxazine as a standard. 
Firstly, the wavelength of maximum absorbance, λmax, was determined for each 
of the compounds in order to identify the corresponding visible light range for best 
excitation. As such, the absorption spectrum between the wavelengths 250-800 
nm was taken for each of the compounds (Table 5.2). For all the novel acridine-
isoalloxazine compounds, the λmax of the compounds ranged between 300-443 
nm, which means they absorb in the UV-blue light region and thus are activated 
by blue light. 
The radical and 1O2 species released from photosensitisers, under visible light 
illumination, can inactivate microbial infections (Hamblin et al., 2004; Jori et al., 
2006). Therefore, to measure singlet oxygen species released following the 
exposure of acridine-isoalloxazine compounds to blue light, they were assayed 
using the decolourisation of 2,3,4,5-tetraphenylcyclopentadienone (TPCPD) in 
DMSO. The absorbance of TPCPD alone and the active mixture, at a wavelength 
of 506 nm, was monitored over time using a UV-Visible spectrophotometer 
(Shimadzu-UV-3600) in the presence of blue light. It was assumed that the 
resultant drop in absorption of TPCPD in DMSO at 506 nm, due to 
decolourisation, is proportional to its reaction with singlet oxygen species. As 
such, the level of singlet oxygen release from each of the compounds could be 
determined. An example set of data is shown in Table 5.2, where the absorbance 
of TPCPD decreases over a period of 5 min following exposure of Compound 45 
to blue light. By determining the gradient of the linear portion of the graph, the 





The illuminated compounds were ranked according to the half-life resultant from 
blue light illumination. It was assumed that the lower the half-life of TPCPD 
following exposure to acridine-isoalloxazine compounds and blue light, the 
greater its 1O2 yield. Fourteen acridine-isoalloxazine compounds did not show a 
half-life over 20-minute illumination except Compounds 37, 45, 47 and 49. This 
data suggests that Compound 45 released the most singlet oxygen within the 
acridine-isoalloxazine compounds tested. It was followed by Compounds 47 (t1/2 
= 6.5 min), 49 (t1/2 = 8 min) and 37 (t1/2 = 12 min), which showed lower half-life 
(Table 5.2). Following excitation with blue light over a 60-minute period, it was 
noted that most singlet oxygen was released from the tested compounds after 




















Table 5.2 Acridine-isoalloxazine compounds characterised according to the half-
life obtained following 20 min blue light exposure. As the decrease of absorption of 
TPCPD at 506 nm is directly proportional to singlet oxygen release and the lower the 
half-life the more singlet oxygen production. λmax is determined to be the wavelength at 
which absorbance is highest.  
 





Alloxazine 391 145 1 
35 343 137 1.23 
36 421 45 3.78 
37 401 12 14.430 
38 380 52.5 3.298 
39 345 76.06 2.28 
40 401 45 3.78 
41 348 27.5 6.297 
42 353 210 0.85 
43 443 39 4.2 
44 365 245 0.73 
45 350 5 34.633 
46 348 47 3.4 
47 360 6.5 26.64 
48 343 105.87 1.636 
49 367 8 21.645 
50 388 218 0.81 
51 300 166 0.92 








5.2.1.2 Radical species data 
Data on radical species, another damaging factor released within PDT, could not 
be measured in vitro using both assays DPPH and ABTS for the same reasons 
mentioned in Chapter 3. 
5.2.1.2.1 DPPH assay 
The absorbance of DPPH. has been degraded directly following the addition of 
compounds dissolved in DMSO. For instance, the DPPH. absorbance was 1.45, 
which decreased dramatically to 0.1 when adding Compound 36 in the presence 
or absence of blue light. The problem is that all tested acridine-isoalloxazines 
caused dramatic degradation of the absorbance of DPPH. when added to it in the 
absence and presence of blue light.  
5.2.1.2.2 ABTS assay 
After the compounds were added to ABTS.+, they were exposed to blue light and 
then absorbance readings taken. It has been shown that the absorbance of the 
ABTS.+ was degraded directly after the addition of acridine-isoalloxazines in the 
presence and absence of blue light. For instance, the ABTS.+ absorbance was 
1.52, which decreased markedly to 0.89 when Compound 40 was added in the 














5.2.2 Antifungal screening 
The 18 candidate compounds, based on acridine-isoalloxazine, were screened 
using the EUCAST microbroth dilution method for antifungal activity against S. 
cerevisiae, C. albicans and A. fumigatus. These species were exposed to a range 
of concentrations of the candidate compounds (0 to 250 μg/ml) in the presence 
and absence of blue light. This range of concentrations of acridine-isoalloxazine 
compounds was chosen because higher concentrations of compounds showed 
limited solubility. Growth was determined by measuring the OD at 530 nm for S. 
cerevisiae and C. albicans and visually for A. fumigatus.  
Growth inhibition percentage for each concentration of compound, in the 
presence and absence of blue light, was calculated against the OD530nm of the 
drug-free control (100%). The well-characterised antifungal agents, fluconazole 
and amphotericin B, were used as positive controls. All compounds were tested 
on two separate occasions in duplicate. However, if a compound was identified 
as having antimicrobial activity based on these two assays, it was tested for a 
third time.   
The heat maps shown in Figures 5.2 and 5.3 summarise the percentage growth 
inhibition determined from the OD530nm readings for fungal growth for 
concentrations of fluconazole and compounds exposed to blue light for 20 min at 
24 h incubation. The concentrations of fluconazole (control) used were 0 to 64 
μg/ml, while concentrations of the compounds were 0 to 250 μg/ml. The colour in 
the heatmap indicates the percentage growth, with black indicating complete 
growth (0% inhibition), and red indicating no growth (100% inhibition). Yellow 
indicates 50% growth inhibition, which aligns with the minimal growth inhibition 
(MIC), as determined by the EUCAST method (EUCAST 7.3: Arendrup et al., 
2015a)(Figures 5.2 and 5.3).  
Previous data in Chapter 3 demonstrated that blue light alone has no significant 
effect on the growth of fungal and bacterial species (Figures 3.3 to 3.6). 










       Growth Inhibition % (OD530nm) 
 
Figure 5.2 Heatmap illustrating OD530nm levels for varying concentrations of a list of 18 acridine-isoalloxazine compounds (0 to 250 
μg/ml) against S. cerevisiae. The yellow bar shows 50% growth inhibition while the red bar illustrates the maximum growth inhibition 
 % inhibition, as determined by OD530nm , following 24 h incubation at 30˚C 
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Growth Inhibition % (OD530nm) 
Figure 5.3 Heatmap illustrating OD530nm levels for varying concentrations of a list of 18 acridine-isoalloxazine compounds (0 to 250 
μg/ml) against C. albicans. The yellow bar shows 50% growth inhibition while the red bar illustrates the maximum growth inhibition.
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The minimum inhibitory concentration MIC of the tested compounds was 
identified to be the first concentration showing 50% growth inhibition compared 
to the drug-free control (EUCAST 7.3: Arendrup et al., 2015a). To determine 
percentage growth inhibition, the optical density OD530nm readings for fungal 
growth were taken for each concentration of fluconazole and compounds 
exposed to blue light for 10 and 20 min at 24 h incubation. 
Following the EUCAST microdilution method, for each of the compounds the 
maximum growth inhibition was seen at 25 μg/ml in the presence of blue light, 
after 10 and 20-minute exposure. Regarding fluconazole, the maximum growth 
inhibition seen was at the concentration of 64 μg/ml. All graphs show the mean 
±SEM (standard error of the mean) of the antifungal screening experiments in the 
presence and absence of blue light (Figures 5.4 to 5.21) and Table 5.3 shows the 
determined MIC (50% growth inhibition compared to the control) of each of the 
tested compounds in S. cerevisiae and C. albicans. In all cases, growth inhibition 
of less than 14% was seen in the no blue light control. 
 
 
Figure 5.4 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 35 in absence and presence of blue light. Comparison of Compound 35 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 





























Figure 5.5 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 36 in absence and presence of blue light. Comparison of Compound 36 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 
The experiment was conducted in duplicate, n=3. Values are the mean ±SEM.  
 
Figure 5.6 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 37 in absence and presence of blue light. Comparison of Compound 37 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 






















































Figure 5.7 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 38 in absence and presence of blue light. Comparison of Compound 38 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 
The experiment was conducted in duplicate, n=2. Values are the mean ±SEM. 
 
Figure 5.8 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 39 in absence and presence of blue light. Comparison of Compound 39 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 






















































Figure 5.9 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 40 in absence and presence of blue light. Comparison of Compound 40 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 
The experiment was conducted in duplicate, n=3. Values are the mean ±SEM. 
 
Figure 5.10 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 41 in absence and presence of blue light. Comparison of Compound 41 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 






















































Figure 5.11 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 42 in absence and presence of blue light. Comparison of Compound 42 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 
The experiment was conducted in duplicate, n=2. Values are the mean ±SEM. 
 
Figure 5.12 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 43 in absence and presence of blue light. Comparison of Compound 43 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 























































Figure 5.13 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 44 in absence and presence of blue light. Comparison of Compound 44 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 
The experiment was conducted in duplicate, n=2. Values are the mean ±SEM. 
 
Figure 5.14 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 45 in absence and presence of blue light. Comparison of Compound 45 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 






















































Figure 5.15 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 46 in absence and presence of blue light. Comparison of Compound 46 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 
The experiment was conducted in duplicate, n=3. Values are the mean ±SEM. 
 
Figure 5.16 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 47 in absence and presence of blue light. Comparison of Compound 47 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 























































Figure 5.17 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 48 in absence and presence of blue light. Comparison of Compound 48 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 
The experiment was conducted in duplicate, n=3. Values are the mean ±SEM. 
 
Figure 5.18 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 49 in absence and presence of blue light. Comparison of Compound 49 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 























































Figure 5.19 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 50 in absence and presence of blue light. Comparison of Compound 50 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 
The experiment was conducted in duplicate, n=2. Values are the mean ±SEM. 
 
Figure 5.20 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 51 in absence and presence of blue light. Comparison of Compound 51 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. The experiment was conducted using 
EUCAST broth microdilution method and standardised inoculum of 0.5-2.5 x 105 cfu/ml. 























































Table 5.3 Summary of the minimum inhibitory concentrations (MICs) of the 18 
acridine-isoalloxazine compounds in S. cerevisiae and C. albicans using the 
EUCAST method after 10 and 20 min blue light exposure. MIC is the concentration 
at which 50% growth inhibition is seen. (-) means MIC value could not be determined at 



















Fluconazole 0.25 1 0.25 1 
Compound 35 - - - - 
Compound 36 16.5 25 12.5 25 
Compound 37 25 25 16.5 25 
Compound 38 - - - - 
Compound 39 - - - - 
Compound 40 25 - 25 - 
Compound 41 12.5 12.5 12.5 12.5 
Compound 42 - - - - 
Compound 43 12.5 16.5 12.5 12.5 
Compound 44 - - - - 
Compound 45 - - - - 
Compound 46 21 21 21 21 
Compound 47 - - - - 
Compound 48 25 25 16.5 25 
Compound 49 - - - - 
Compound 50 - - - - 








To ensure consistency of the results, EUCAST antifungal susceptibility testing of 
S. cerevisiae and C. albicans to the control fluconazole was performed. The 
average MIC of fluconazole obtained was 0.25 μg/ml against S. cerevisiae and 1 
μg/ml against C. albicans. In regard to S. cerevisiae, the resultant MIC of 0.25 
μg/ml (Table 5.3) was located in the region of published data (MIC and zone 
distributions and ECOFFs; EUCAST 7.3: Arendrup et al., 2015a). The resultant 
MIC of 1 μg/ml against C. albicans corresponded with the EUCAST Antifungal 
Clinical Breakpoints (EUCAST 7.3: Arendrup et al., 2015a). 
None of the compounds have a significant antifungal activity in the absence of 
blue light against both species. Since the tested compounds showed no 
significant effect on growth of cells in the absence of blue light, any possible 
antifungal efficacy will be due to blue light treated compounds. 
A lower MIC value means that less amount of drug is required for inhibiting growth 
of microbes, therefore the lower the MIC, the more effective antimicrobial drugs. 
By analysing the MIC results in Table 5.3, it can be noted that among all the eight 
studied compounds, Compounds 36 (12.5, 25 μg/ml), 37 (16.5, 25 μg/ml), 40 
(12.5, 12.5 μg/ml), 41 (12.5, 12.5 μg/ml), 43 (21, 21 μg/ml), 46 (21, 21 μg/ml), 48 
(16.5, 25 μg/ml) and 51 (21, 21 μg/ml), showed antifungal efficacy following 20-
minute blue light exposure against S. cerevisiae and C. albicans, respectively. 
The data shows that Compound 40 showed antifungal activity against S. 
cerevisiae with MIC of 25 μg/ml but showed no effect on C. albicans at the 
maximum concentration tested. Compounds 41, 46 and 51 showed a similar 
susceptibility against both species over 10 and 20-minute blue light exposure 
(Table 5.3). S. cerevisiae showed more susceptibility to Compounds 36, 37 and 
48 than C. albicans following 20-minute blue light illumination. While under 10-
minute blue light exposure, the susceptibility of S. cerevisiae to Compounds 36 
and 43 was more than C. albicans, showing MIC of 16.5, 12.5 μg/ml for 
Compound 36 and 12.5, 16.5 μg/ml for Compound 43, respectively (Table 5.3). 
A. fumigatus was also screened using the EUCAST antifungal MIC microdilution 
method for moulds (EUCAST 9.3: Arendrup et al., 2015b). Due to the growth of 
A. fumigatus, instead of measuring the optical density to determine percentage 
growth inhibition, a visual inspection was undertaken. In this case the MIC was 
determined to be the first well where the concentration of compound resulted in 
complete absence of growth. The concentrations range tested for the control drug 
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amphotericin B was 0-16 μg/ml. The control drug amphotericin B was effective 
against A. fumigatus showing MIC of 0.125 μg/ml, which matched the MIC 
EUCAST breakpoint in A. fumigatus. The antifungal screening demonstrated that 
acridine-isoalloxazine compounds, following exposure to blue light, did not exhibit 
any efficacy against A. fumigatus at the concentrations tested (0 to 250 μg/ml) by 
visual determination of growth (data not shown). 
 
5.2.3 Antibacterial screening 
Following antifungal screening of the acridine-isoalloxazine compounds, these 
compounds were then screened in vitro for their antibacterial efficacy under blue 
light exposure against two clinically important bacteria Gram-positive S. aureus 
and Gram-negative E. coli. 
The acridine-isoalloxazine compounds were screened, using the European 
Committee for Antimicrobial Susceptibility Testing (EUCAST) microbroth dilution 
method, for antibacterial activity (EUCAST 5.1: EUCAST, 2003).  
 The antibacterial drug gentamicin, was used as a control due to its broad 
antibacterial activity against both Gram-negative and Gram-positive bacteria (Jao 
et al., 1964).The bacterial species were exposed to a range of concentrations of 
the compounds (0 to 256 μg/ml) in the presence and absence of blue light. A 20-
minute illumination period was used due to the release of most singlet oxygen 
from the compounds. The MIC was determined, by visual inspection, to be the 
lowest concentration that completely inhibited growth. The experiments were 
repeated two times in duplicate, except for the active compounds (36, 37, 40, 41, 









Table 5.4 Summary of the minimum inhibitory concentrations (MICs) of the 
acridine-isoalloxazine compounds in S. aureus and E. coli using the EUCAST 
method after 10 and 20 min blue light exposure. (-) means MIC value could not be 


















Gentamicin 0.5 0.25 0.5 0.25 
Compound 35 - - - - 
Compound 36 8 16 8 16 
Compound 37 24 32 8 64 
Compound 38 - - - - 
Compound 39 - - - - 
Compound 40 32 - 24 64 
Compound 41 8 64 32 64 
Compound 42 - - - - 
Compound 43 8 8 24 32 
Compound 44 - - - - 
Compound 45 24 24 24 24 
Compound 46 32 128 32 128 
Compound 47 - - - - 
Compound 48 24 128 24 128 
Compound 49 128 - 24 - 
Compound 50 - - - - 





EUCAST antibacterial susceptibility testing of S. aureus and E. coli to the control 
gentamicin was performed and the resultant MICs of 0.5 and 0.25 μg/ml 
corresponded with EUCAST Antibacterial Clinical Breakpoints (EUCAST 9.3: 
Arendrup et al., 2015b), which confirms the accuracy of the assay (Table 5.4). 
Since the acridine-isoalloxazine compounds did not exhibit a significant 
antibacterial efficacy in the absence of blue light, any bacterial inactivation 
observed following blue light illumination must be due to photosensitisation of the 
compounds. 
By analysing the MIC results (Table 5.4) ten acridine-isoalloxazine compounds 
showed little effect on bacterial growth after 20-minute blue light irradiation. 
Compound 36 showed the lowest MICs of all the compounds tested against S. 
aureus and E. coli with 8 and 16 μg/ml, respectively. Following 20-minute blue 
light exposure, only Compound 49 exhibited an antibacterial activity against S. 
aureus at 24 μg/ml without activity against E. coli.  
S. aureus was more susceptible than E. coli against Compound 36 at 8, 16 μg/ml, 
Compound 37 at 8, 64 μg/ml, Compound 40 at 24, 64 μg/ml, Compound 41 at 32, 
64 μg/ml, Compound 43 at 24, 32 μg/ml, Compound 46 at 32, 128μg/ml, 
Compound 48 at 24, 128 μg/ml and Compound 51 at 24, 64 μg/ml after 20-minute 
blue light exposure. Based on the data in Table 5.4, it is apparent that the Gram-
positive bacterium, S. aureus, is more sensitive to the compounds, following 
exposure to blue light, than the Gram-negative bacterium, E. coli. 
By combining the MIC values of the acridine-isoalloxazine compounds against 
bacterial and fungal species in Table 5.5, it can be noted that there is a difference 
in the sensitivity of fungi and bacteria to the tested compounds. Compound 45, 
for instance, showed only antibacterial activity at MIC 24 μg/ml without any 
antifungal effect while Compound 49 exhibited only antibacterial activity against 
S. aureus at MIC 24 μg/ml after 20-minute blue light exposure without any effect 







Table 5.5 Summary of the minimum inhibitory concentrations (MICs) of the active 
acridine-isoalloxazine compounds in S. cerevisiae, C. albicans and S. aureus, E. 
coli using the EUCAST method after 20 min blue light exposure. (-) means MIC 

























Fluconazole 0.25 1   
Gentamicin   0.5 0.25 
Compound 36 12.5 25 8 16 
Compound 37 16.5 25 8 64 
Compound 40 25 - 24 64 
Compound 41 12.5 12.5 32 64 
Compound 43 12.5 12.5 24 32 
Compound 45 - - 24 24 
Compound 46 21 21 32 128 
Compound 48 16.5 25 24 128 
Compound 49 - - 24 - 




In this chapter, the aim was to screen a series of novel synthesised acridine-
isoalloxazine compounds for their possible antimicrobial activity in the presence 
of blue light.  
These compounds had previously undergone photochemical characterisation. 
This included identifying the relevant activating light source by examining the 
absorption spectrum of each compound between the wavelengths 250-800 nm. 
The wavelength of maximum absorbance, λmax, was then determined for each 
of the compounds tested to choose the light that can photosensitise them. It has 
been shown that λmax of the acridine compounds ranges between 300-443 nm, 
which corresponds with the blue light region (400-500 nm) (Table 5.2). The 
obtained values of acridine-isoalloxazine conjugates are consistent with other 
published acridines, which generally show their longest absorption wavelengths 
in the range between 400-500 nm (Albert, 1951) and isoalloxazines (flavins) 
which absorb also in the UV-blue light range (Baier et al., 2006). The method of 
conjugating two photoactivated compounds in this study has not been previously 
investigated, so there is no literature to support this observation.   
 
5.3.1 Acridine-isoalloxazines are photosensitised following 
exposure to blue light and release singlet oxygen 
Due to the well-established photosensitising activity of various acridine 
compounds, such as acridine orange (Iwamoto et al., 1987; Iwamoto et al., 1993), 
and isoalloxazine derivatives, such as riboflavin (Heelis et al. 1982), a set of novel 
synthesised acridine-isoalloxazine derivatives has been synthesised and 
characterised photochemically to quantify singlet oxygen release following 
activation by blue light over a 60-minute period. 
The photochemical reactions of the triplet state of photosensitiser such as 
acridine-isoalloxazines following blue light exposure can be divided into two 
different pathways, either the Type 1 mechanism that leads to the production of 
radical species or the Type 2 mechanism that results in 1O2 release. Both these 
species, radicals and 1O2, can inactivate microbial cells (Castano et al., 2004). 
Therefore, this current work has tried to measure these species under 60-minute 
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blue light irradiation. Within this work, two radical scavenging assays, DPPH and 
ABTS, were chosen as described previously in Chapter 3 in order to measure the 
amount of radicals released following blue light illumination. As with previous 
data, neither of these two assays was able to measure radicals’ production from 
these compounds, as explained in Chapter 3. Solvent type could have a potential 
impact on radical production, however, both reagents exhibited stability when 
dissolved in DMSO in the presence and absence of blue light, yet were degraded 
following the addition of acridine-isoalloxazines. Alternative methods have been 
used as radical screening assays for other acridines and isoallxazines, including: 
D-mannitol, a scavenger of hydroxyl radicals or electron paramagnetic resonance 
(EPR) spectroscopy combined with spin trap probes (Spin-trapping) (Augusto et 
al., 2007). 
By measuring 1O2 under blue light excitation for 60 min it was shown that most 
singlet oxygen was released from acridine-isoalloxazine compounds after 20-
minute blue light excitation. It was established by using TPCPD assay, that 18 
acridine-isoalloxazine compounds released singlet oxygen upon exposure to blue 
light for 20 min when compared with the standard’s yield (alloxazine) in the in 
vitro photochemical test (Table 5.2). This finding is consistent with a study of 
Iwamoto et al., (1987), who found that several acridines such as acriflavine (AF), 
proflavine (PF), acridine orange (AO) and 9-aminoacridine (AA) showed singlet 
oxygen activity upon irradiation with an ultraviolet (UV) lamp for 30 min by 
measuring the signal intensity of TEMPO detected by (ESR) spectrometry 
(Iwamoto et al., 1987). This finding also supports findings by Baier et al., (2006), 
who proved that UVA light (320-400) nm has been shown to generate singlet 
oxygen by irradiating isoalloxazine derivatives such as flavin mononucleotide 
(FMN) and flavin dinucleotide (FAD).  
In this study, 14 acridine-isoalloxazine compounds (35, 36, 37, 38, 39, 40, 41, 43, 
45, 46, 47, 48, 49 and 52) were more efficient singlet oxygen producers than the 
standard alloxazine, which released 1O2 of value 1. The relative 1O2 values of the 
previous 15 acridine-isoalloxazine compounds ranged between 1.23 and 34.633 
(Table 5.2). However due to the structural differences between the standard 
compounds, comparison between the singlet oxygen production can only be 
done based on the 1O2 yield. Although there can be a direct comparison between 
compound half-lives, many papers do not include this information, instead only 
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presenting the 1O2 yield. The only conjugation which occurred was between 
photoactivated compounds in nanoparticles, which does not affect ROS release, 
but increases selectivity. 
 
Both the isoalloxazines and acridine orange have demonstrated their ability to 
produce both 1O2 and radicals (Iwamoto et al., 1987; Losi, 2007). Based on this 
evidence, it is expected that compounds tested in this study work via both 
mechanisms, Type 1 and 2, and thus release 1O2 and radicals under blue light 
exposure. Even though radicals could not be measured, it is assumed that they 
are being released in our study. The incorporation of halogens onto the acridine-
isoalloxazine structure was shown to exhibit significant increase in the singlet 
oxygen yield (a minimum twofold increase) when compared to non-halogenated 
compounds. Compounds 45 (t1/2 = 5 min), 47 (t1/2  = 6.5 min) and 49 (t1/2 = 8 min), 
all contain a chlorine, and show the highest release of of singlet oxygen (Table 
5.2). This result indicates that the heavy atom effect increases the possibility of 
the transition into the excited triplet state, causing an increase in the amount of 
singlet oxygen produced (Mehraban et al., 2015). Non-halogenated Compound 
44 (t1/2 = 245 min), 50 (t1/2 = 218 min), 51 (t1/2 = 166 min), produced the lowest 
amount of relative singlet oxygen among all the compounds tested (Table 5.2).  
 
5.3.2 Acridine-isoalloxazines have no significant effect on 
microbial growth in the absence of blue light 
Both acridines and isoalloxazines can penetrate bacterial and fungal cells as 
described previously in Chapters 3 and 4. The penetration of both moieties into 
the microbial cell may indicate how the acridine-isoalloxazine compounds tested 
in this work may behave. All compounds tested in this study demonstrated limited 
activity in the absence of blue light irradiation, with limited growth inhibition 
observed in the fungal and bacterial cells tested. A key requirement for potential 
photoantimicrobial compounds is to have a small molecular weight with cationic 
charge (Wainwright, 2015). Therefore, it can be assumed that although these 
compounds have cationic charge, their large molecular weight may prevent them 
from penetrating into the cell and thus a limited effect of these compounds was 
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observed on microbial growth in the absence of blue light. These compounds 
have not been previously investigated, consequently there is no literature to 
support these observations. 
 
5.3.3 Blue light activation of acridine-isoalloxazines has an 
effect on microbial growth 
Based on the blue light results and the absence of significant effect of acridine-
isoalloxazines alone on microbial growth, any growth inhibition observed 
following illumination with blue light would be attributed to photoactivation. 
Following photochemical characterisation of the 18 compounds, their 
photoantimicrobial activity under blue light illumination was measured against 
both fungi and bacteria.  
The growth inhibitory activity of tested compounds was determined by measuring 
minimum inhibitory concentration (MIC) values using the EUCAST broth 
microdilution method. To ensure consistency of the antimicrobial susceptibility 
testing and compare the obtained results across experiments, three control 
bioassays with fluconazole against S. cerevisiae and C. albicans and 
amphotericin B against A. fumigatus as well as gentamicin against S. aureus and 
E. coli were conducted. The obtained MIC of 0.25 μg/ml against S. cerevisiae 
was in the fluconazole wildtype distributions determined by the EUCAST broth 
microdilution method. Additionally, the resultant MIC of 1 μg/ml against C. 
albicans corresponded with the EUCAST Antifungal Clinical Breakpoints 
(EUCAST 7.3: Arendrup et al., 2015a). Finally, the MIC of amphotericin B against 
of 0.125 μg/ml matched the MIC EUCAST breakpoint in A. fumigatus. With 
respect to bacteria, the obtained MICs of 0.25 and 0.125 μg/ml against S. aureus 
and E. coli corresponded with EUCAST Antibacterial Clinical Breakpoints. All 
control assays were conducted on each run and all the results obtained were 
within the expected range. 
Based on photochemical data, the compounds were investigated for antimicrobial 
activity following 20 min of blue light illumination (470 nm, 115 J/cm2), using the 
EUCAST brothmicrodilution method.  The microbiological screening used in this 
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work identified eight compounds with photoantifungal activity (Table 5.3) and ten 
compounds with photoantibacterial activity (Table 5.4). 
A review of the antimicrobial results compared to the photochemical data 
indicated that there was no relationship between singlet oxygen release and MIC. 
For example, Compound 45, which released the highest amount of singlet oxygen 
with a half-life of 5 min, showed an MIC of 24 μg/ml against both S. aureus and 
E. coli but elicited no activity against fungi. However, Compound 37 released 
significantly lower 1O2 than Compound 45, in the spectrophotometric assay, yet 
showed antimicrobial activity in both bacteria and fungi (Tables 5.2 and 5.3). 
Interestingly, Compound 47 which produced the second highest amount of 1O2, 
showed no effect on bacterial and fungal growth following blue light illumination 
(Table 5.5). This suggests that measurement of singlet oxygen release is not an 
accurate reflection of antimicrobial activity of a compound. This is a theme that 
has been previously identified and can be attributed to the same reasons 
explained in detail within Chapter 3. These reasons include the possibility that 
Type 1 (radicals) has more antimicrobial impact than Type 2 (1O2) in this situation 
and the antioxidant capacity of RPMI 1640 and Mueller-Hinton media used in the 
photoantimicrobial screening assays (Lewinska et al., 2007). 
 
The photoantifungal results showed that C. albicans overall is more resistant than 
S. cerevisiae to the compounds tested (Table 5.3). This data is consistent with 
the data obtained for fluconazole, which is used as a control in this study, and 
other azole based antifungal agents (Anderson et al., 2014). Compared with S. 
cerevisiae, which often shows great sensitivity to hydrogen peroxide (Lewinska 
et al., 2007; Pedreño et al., 2002), C. albicans has a high natural resistance to 
oxidative agents. C. albicans has the ability to induce specific genes encoding 
antioxidant enzymes including superoxide dismutase (SOD) and glutathione 
reductase (GR), which is considered important factor in the resistance of C. 
albicans to oxidative stress (Hwang et al., 2002; Pedreño et al., 2002). In addition, 
C. albicans is a diploid microorganism, and contains two copies of the efflux pump 
genes CDR1, CDR2 and MDR1, which encode proteins responsible for 
resistance to accumulation of compounds inside the cells. This supports the 
higher resistance of C. albicans to photoactivated compounds observed in this 
study when compared to S. cerevisiae.   
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In the present study, no effect of acridine-isoalloxazines was seen against A. 
fumigatus under blue light illumination. A. fumigatus in general is more resistant 
than other fungi to antifungal drugs and ROS. This could be due to synthesis of 
high amounts of trehalose and mannitol intracellularly in conidia, these 
compounds work as antioxidant by quenching ROS (Ruijter et al., 2003). This can 
explain why A. fumigatus was resistant to the ROS produced following the 
exposure of acridine-isoalloxazine to blue light. In this study both flavins and 
acridines moieties that form acridine-isoalloxazines, did not show antifungal 
activity against A. fumigatus when exposed to blue light. There are reports of PDT 
being effective against conidial forms of A. fumigatus but at longer exposure time 
and higher wavelength than used in the study (Friedberg et al., 2001). 
It has been demonstrated that the tested acridine-isoalloxazine compounds 
demonstrated better photoantimicrobial activity when compared to flavins 
(isoalloxazines) separately, however this was not significantly different to that of 
the tested acridines.  
It has been shown in this study that the Gram-positive bacterium S. aureus was 
more sensitive to acridine-isoalloxazine compounds illuminated by blue light than 
the Gram-negative bacterium E. coli (Table 5.4). This finding was consistent with 
data obtained from several studies, which showed Gram-positive bacteria had 
increased susceptibility to PDT compared to Gram-negative bacteria (Nitzan et 
al., 2004; Maclean et al., 2009). The difference in susceptibility is due to the 
existence of lipopolysaccharides (LPSs) in the extra outer membrane of Gram-
negative bacteria, which may prevent the penetration of compounds and ROS 
into the cells (Hamblin et al., 2004). This finding is also consistent with other 
studies conducted with different PDT agents (Jori et al., 2006). Conversely, a 
study by Wainwright et al., 2015 showed no difference in susceptibility to PDT 
between Gram-positive and negative bacteria. This is suggested to be as a result 
of existence of more strongly constitutive cationic charges than that of our 
compounds which may increase the antibacterial activity against Gram-negative 
bacteria (Costa et al., 2012; Vatansever et al., 2013). This is because the use of 
cationic molecules would increase the susceptibility of Gram-negative bacteria 
due to their highly negatively charged surface.  
In the case of Gram-negative bacteria, photoinactivation does not occur with ease 
as they are relatively impermeable to neutral or anionic compounds due to their 
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highly negatively charged surface. This offers a beneficial property of broad-
spectrum activity as neutral and ionic compounds taken up by all classes of 
microbial cells; this can faciltate overcoming the hindrance of Gram-negative to 
the penetration process. 
 
It was apparent that there was a remarkable difference in the susceptibility of 
fungi and bacteria against our tested compounds. The compounds that showed 
antifungal activity also demonstrated antibacterial activity, with the exception of 
Compounds 45 and 49, which only demonstrated antibacterial activity. The higher 
resistance of fungi S. cerevisiae and C. albicans to photodynamic inactivation 
(PDI) in this present study may be attributed to the great difference in size and 
surface area between bacterial and fungal cells. As bacterial cells are significantly 
smaller than fungal cells, lower ROS are needed to kill them (Jori et al., 2006; 
Demidova et al., 2004). This suggests that the amount of ROS released by 
photoactivated Compounds 45 and 49 was sufficient only to inactivate the tested 
bacteria. Additionally, as described previously in this chapter, fungi generally 
have the ability to survive oxidative stress due to the presence of genes encoding 
antioxidant enzymes. 
 
In conclusion, the data reported here have shown the photosensitising activity 
and photoantimicrobial efficacy of some novel acridine-isoalloxazine compounds 
synthesised by combination of acridine and isoalloxazine moieties. The low 
toxicity of these compounds and their photoantimicrobial activity prompt further 










6. Anthraquinone  
6.1 Introduction 
Anthraquinone derivatives are a group of quinone-containing compounds based 
on a rigid, planar three-ring aromatic system ,9,10-dioxoanthracene, and have 
the appearance of a yellow or light grey solid crystalline powder (Dave et al., 
2012) . They are considered one of the largest groups of natural pigments found 
in fungi and plants (Chien et al., 2015, Gessler et al., 2013). An important feature 
of anthraquinones is their absorption spectrum. They have small absorption 
peaks at 405 nm and stronger absorption peaks in the ultra violet region due to 
the system of conjugated double bonds (Gessler et al., 2013, Uchimiya et al., 
2009). This property allows anthraquinones to be photosensitised under both UV 
and visible light region. 
 
Naturally occurring quinone compounds such as anthraquinones have been used 
widely in the textile industry as dyes for fibres and in microelectronics as 
semiconductors. Furthermore, several anthraquinones have a broad spectrum of 
bioactivities, for example laxative, diuretic and anticancer activities (Dave et al., 
2012; Gholivand et al., 2011; Uchimiya et al., 2009). They can be used also as 
catalysts in a wide variety of chemical and biogeochemical reactions, such as 
reductive degradation of contaminants, due to their redox activity (Malik et al., 
2016). Due to the wide range of applications, there is interest in and efforts to 
develop novel anthraquinone compounds with important biological properties 
(Malik et al., 2016). 
 
Anthraquinones have been demonstrated to possess antimicrobial activities 
against a range of common pathogens. It has been shown that two 
anthraquinones, aloe-emodin and chrysophanol (Figure 6.1) have antifungal 
activity against C. albicans and A. fumigatus in the absence of light activation 





Figure 6.1 Aloe-emodin R1 = COOH    R2 = H, Chrysophanol R1 = CH3     R2= H (Agarwal 
et al., 2000). 
 
A new anthraquinone compound, 1-methyl-2-(3 ̀-methyl-but-2 ̀-enyloxy)-
anthraquinone, isolated from the seeds of Aegle marmelos Correa showed 
significant antifungal activity against Aspergillus fumigatus and Candida albicans 
(Figure 6.2; Mishra, 2010). 
 
Figure 6.2 Structure of 1-methyl-2-(3̀-methyl-but-2̀-enyloxy)-anthraquinone 
(Mishra, 2010). 
 
Anthraquinone derivatives have also been shown to have antibacterial activity 
against both Gram-positive and negative bacteria in the absence of light (Wu et 
al., 2006; Mohanlall et al., 2013). Two anthraquinones, soranjidiol and rubiadin 
were shown to have antibacterial activity on S. aureus with MICs of 32-64 μg/ml 
(Comini et al., 2011). The mechanism of action of these compounds was 
suggested to be directly linked to the increase of O2.- and/or 1O2 levels resulting 
from the interaction between anthraquinones and bacteria without a 
photosensitising process (Comini et al., 2011). Several mechanisms of actions of 
anthraquinones in microbes were reported in the absence of light including the 
inhibition of cell wall synthesis and membrane function by reducing membrane 
fluidity and integrity (Lu et al., 2011) .Additionally, anthraquinones can inhibit 
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nucleic acid synthesis by binding with phosphate groups of DNA and affecting 
replication and transcription. Finally, production of singlet oxygen and radicals 
can occur in the presence and absence of light (Lu et al., 2011). 
It has been established that anthraquinones can have photosensitising activities 
and mediate one electron transfer to the oxygen molecule to produce the 
superoxide anion radical and form reactive oxygen species under visible light 
illumination (Comini et al., 2011). 
Two anthraquinones, barleriaquinone-I (BQ-I) and barleriaquinone-II (BQ-II), 
have been demonstrated to have photosensitising activity by releasing O2.- and 
1O2 on visible illumination via Type 1 and 2 reactions (Figure 6.3; Inbaraj et al., 
1999) . 
 
Figure 6.3 Chemical structures of BQ-I and BQ-II (Inbaraj et al., 1999). 
 
Naturally occurring anthraquinone hypericin was reported to have 
photoantibacterial activity when illuminated by 593 nm. Hypericin-mediated 
phototoxicity was found to be active against methicillin-susceptible S. aureus 
(MSSA), methicillin-resistant S. aureus (MRSA) and E. coli through 
photodynamic therapy (Liu et al., 2015). 
 
Additionally, the in vitro photodynamic production of superoxide radicals by 
quinone-containing compounds, such as doxorubicin, has been demonstrated by 
Comini et al., (2011) upon visible light (300-600 nm) exposure. 
Photoantibacterial efficacy of three anthraquinone compounds, rubiadin, 
soranjidiol and 5,5 ́-bisoranjidiol, have been shown on Gram-positive bacterium 
S. aureus under visible light illumination (410 nm, 0.65 mW/cm2) for 20 min due 
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to the detected increase in the levels of singlet oxygen and superoxide anion 
(Comini et al., 2011). 
 A combination of two anthraquinones, rubiadin and rubiadin-1-methyl ether, with 
blue light (420 nm, 0.65 mW/cm2) was shown to produce superoxide radical anion 
O2.- and singlet oxygen and 1O2 (Figure 6.4). The photosensitisation of 15 μg/ml 
for each anthraquinone was capable of inactivating C. tropicalis biofilms (Marioni 
et al., 2017). 
 
Figure 6.4 Chemical structures of rubiadin and rubiadin-1-methyl ether (Marioni et 
al., 2017). 
 
Based on the reported in vitro photosensitising and phototoxicity effect of 
anthraquinones (Gessler et al., 2013) and to search for potential compounds for 
photodynamic antimicrobial treatment, a set of structures of novel anthaquinones 
was synthesised.  
The work shown in this chapter illustrates the possible photochemical inactivation 
of selected microbes using the novel anthraquinone derivatives and blue light 
illumination. The singlet oxygen (1O2) released from these anthraquinone 
compounds was measured previously and these compounds were then tested to 
determine their photoantimicrobial activities.   
In this present work, the susceptibility of fungi S. cerevisiae, C. albicans and A. 
fumigatus and bacteria including S. aureus and E. coli to these new 
anthraquinones was tested following blue light irradiation. The European 
Committee for Antimicrobial Susceptibility Testing (EUCAST) microbroth dilution 
method was utilised to test the antimicrobial activity of these blue light treated 
and untreated anthraquinones and their potential use in photodynamic therapy 




A series of quinone-based compounds, including anthraquinone (Table 6.1), 
anthrone (Table 6.2) and bianthrone (Table 6.3) was previously synthesised by 
Dr Rob Smith, UCLan. These compounds absorbe in the UV range and have 
chemical structures shown in (Figure 6.5). Due to the anthraquinones having 
three different structures, the singlet oxygen levels will be discussed separately. 
These compounds were screened for singlet oxygen production when compared 
to their standards and then screened for antimicrobial activities in the presence 




















Table 6.1 Structures of substituted anthraquinone containing different R groups 
R1, R2, R3, R4, R5, R6, R7 and R8. 
 
 
Table 6.2 Structures of substituted bianthrone containing different R groups R1, 
R2, R3, R4, R5, R6, R7 and R8. 
Compound R1 R2 R3 R4 R5 R6 R7 R8 
61 H H H H H H H H 
60 OH H H H H H H OH 
 
 
Table 6.3 Structures of substituted anthrone containing different R groups R1, R2, 
R3, R4, R5, R6, R7 and R8. 
Compound  R1 R2 R3 R4 R5 R6 R7 R8 










Compound R1 R2 R3 R4 R5 R6 R7 R8 
57 OH H H H H H H OH 
58 OCH3 H H H H H H OCH3 
59 NO2 H H H H H H NO2 
63 NH2 H H H H H H NH2 
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6.2.1 Photochemical characterisation of anthraquinone 
compounds 
6.2.1.1 Singlet oxygen (1O2) data 
The photochemical data was collected and analysed by Dr Rob Smith’s group, 
UCLan, and then characterised biologically in this study. For all anthraquinone 
compounds, two λmax were identified, the first in the UVC region between 223-
265 nm and the second in the blue light visible region between 400-450 nm. This 
information confirms that all anthraquinones can be activated in the blue light 
range (400-495 nm) (Tables. 6.1 to 6.3). 
The 1O2 release for the prepared anthraquinones was assayed using the 
decolourisation 2,3,4,5-tetraphenylcyclopentadienone (TPCPD assay)  in DMSO 
under visible light illumination. The illuminated compounds were ranked 
according to the half-life. 
The half-life and singlet oxygen of anthraquinones were measured after blue light 
exposure. All anthraquinone compounds demonstrated a half-life, with a shorter 
half-life indicating increased singlet oxygen release. The data suggests that both 
Compounds 57 and 60 produced the most singlet oxygen within the compounds 
tested due to showing the lowest half-life of 2 min (Table 6.5). Compound 63 
showed the longest half-life, which means it released the least amount of singlet 
oxygen among all compounds tested (Table 6.4).  
By measuring singlet oxygen release following excitation with blue light over a 
60-minute period, it was noted that no further increase in singlet oxygen release 









Table 6.4 Anthraquinone compounds characterised according to the half-life 
obtained following 20 min blue light exposure. As the decrease of absorption of 
TPCPD at 506 nm is directly proportional to singlet oxygen release and the lower half-
life the more singlet oxygen production. λmax is determined to be the wavelength at 
which absorbance is highest. 






57 253 2 52.94 
58 254 4 26.5 
59 247 7 16 
63 251 16 6.625 
 
Table 6.5 Bianthrone compounds characterised according to the half-life obtained 
following 20 min blue light exposure. As the decrease of absorption of TPCPD at 506 
nm is directly proportional to singlet oxygen release and the lower half-life the more 
singlet oxygen production. λmax is determined to be the wavelength at which 
absorbance is highest. 






61 228 7 1 
60 223 2 3.5 
 
Table 6.6 Anthrone compound characterised according to the half-life obtained 
following 20 min blue light exposure. As the decrease of absorption of TPCPD at 506 
nm is directly proportional to singlet oxygen release and the lower half-life the more 
singlet oxygen production. λmax is determined to be the wavelength at which 
absorbance is highest. 






62 265 7 1 
 
6.2.1.2 Radical species data 
The measurement of radicals released from anthraquinones following blue light 




6.2.2 Antifungal screening 
The anthraquinone compounds, which have previously been characterised 
photochemically, were then screened in vitro to determine their photoantifungal 
activity against a range of fungal species. 
 
The seven anthraquinone compounds were screened using the EUCAST 
microbroth dilution method for antifungal activity against, S. cerevisiae, C. 
albicans and A. fumigatus.These species were exposed to a range of 
concentrations of the anthraquinone compounds (0 to 500 μg/ml) in the presence 
and absence of blue light. This range of concentrations is different to the 
previously studied groups because this group showed higher solubility. Growth 
was determined by using OD at 530nm for S. cerevisiae and C. albicans and 
visually for A. fumigatus.  
 
The percentage growth inhibition for each concentration of the anthraquinones, 
in the presence and absence of blue light, was calculated against the OD530nm of 
the drug-free control (100%). The well-characterised antifungal agents, 
fluconazole and amphotericin B, were used as the controls. Data on percentage 
growth inhibition of S. cerevisiae and C. albicans with the highest concentration 
used of fluconazole and anthraquinone compounds in presence and absence of 
blue light are shown as means ±SEM (Figures 6.8 to 6.14). Experiments were 
repeated on two separate occasions (n=2) in duplicate. 
 
The heat maps shown in Figures 6.6 and 6.7 show the percentage growth 
determined from the OD530nm readings for fungal growth after 24 h incubation for 
concentrations of fluconazole and the compounds following exposure to blue light 
for 20 min. The concentrations of fluconazole (control) used were 0-64 μg/ml, 
while concentrations of the compounds were 0-500 μg/ml. The colour in the heat 
map indicates the percentage growth, with black indicating complete growth (0% 
inhibition), and red indicating no growth (100% inhibition). Yellow indicates 50% 
growth inhibition, which aligns with the minimal growth inhibition (MIC), as 








       Growth Inhibition % (OD530nm) 
 
Figure. 6.6 Heatmap illustrating OD530nm levels for varying concentrations of a list of seven anthraquinone compounds (0 to 500 
μg/ml) against S. cerevisiae. The yellow bar shows 50% growth inhibition while the red bar illustrates the maximum growth inhibition. 
 
    
                                                                                                                             % inhibition, as determined by OD530nm, following 24 h incubation at 30oC 
      
Compounds       500  μg/ml   25   μg/ml 12.5   μg/ml 6.25   μg/ml 3.125   μg/ml 1.56  μg/ml   0.78  μg/ml   0.39  μg/ml   0.195  μg/ml   0.097  μg/ml   0  μg/ml   
57          2.98 3.025 
58          3.38 3.505 
59          3.24 3.28 
60          2.8 2.875 
61          3 3.05 
62          3.065 3.11 
63          2.8 2.875 
           Flu            
 64 μg/ml 32 μg/ml 16 μg/ml 8 μg/ml 4 μg/ml 2 μg/ml 1 μg/ml 0.5 μg/ml 0.25 μg/ml 0.125 μg/ml 0 μg/ml 
             Flu            
          4 




% inhibition, as detemined by OD530nm, following 24 h incubation at 35oC 
Compounds 500  μg/ml 25 μg/ml  12.5  μg/ml 6.25 μg/ml  3.125  μg/ml 1.56 μg/ml  0.78  μg/ml 0.39  μg/ml 0.195  μg/ml 0.097 μg/ml  0  μg/ml 
57            
58            
59            
60            
61            
62            
63            
Flu 




     Growth Inhibition % (OD530nm) 
 
Figure. 6.7 Heatmap illustrating OD530nm levels for varying concentrations of a list of 7 anthraquinone compounds (0 to 500 μg/ml) 
against C. albicans. The yellow bar shows 50% growth inhibition while the red bar illustrates the maximum growth inhibition. 
                                                                                                            
 64 μg/ml 32 μg/ml 16 μg/ml 8 μg/ml 4 μg/ml 2 μg/ml 1 μg/ml 0.5 μg/ml 0.25 μg/ml 0.125 μg/ml 0 μg/ml 
             Flu            
          4 
100%     50%     0% 
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The graphs (Figures 6.8 to 6.14) show the mean ±SEM (standard error of the 
mean) of highest percentage growth inhibition that has been recorded at 
concentration 64 (μg/ml) fluconazole and 50 (μg/ml) anthraquinones in the 
absence and presence of blue light, after 20-minute exposure in S. cerevisiae 
and C. albicans (Figures 6.9 to 6.15). In all cases, growth inhibition of less than 
23% was seen in the no blue light control. 
 
Figure 6.8 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 57 in absence and presence of blue light. Comparison of Compound 57 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 min means no blue light exposure. 
The experiment was conducted using EUCAST broth microdilution method and 
standardised inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in 






























Figure 6.9 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 58 in absence and presence of blue light. Comparison of Compound 58 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 min means no blue light exposure. 
The experiment was conducted using EUCAST broth microdilution method and 
standardised inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in 
duplicate, n=2. Values are the mean ±SEM. 
 
Figure 6.10 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 59 in absence and presence of blue light. Comparison of Compound 59 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 min means no blue light exposure. 
The experiment was conducted using EUCAST broth microdilution method and 
standardised inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in 
























































Figure 6.11 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 60 in absence and presence of blue light. Comparison of Compound 60 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 min means no blue light exposure. 
The experiment was conducted using EUCAST broth microdilution method and 
standardised inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in 
duplicate, n=2. Values are the mean ±SEM. 
 
Figure 6.12 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 61 in absence and presence of blue light. Comparison of Compound 61 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 min means no blue light exposure.  
The experiment was conducted using EUCAST broth microdilution method and 
standardised inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in 























































Figure 6.13 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 62 in absence and presence of blue light. Comparison of Compound 62 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of blue light. 0 min means no blue light exposure. 
The experiment was conducted using EUCAST broth microdilution method and 
standardised inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in 
duplicate, n=2. Values are the mean ±SEM. 
 
Figure 6.14 Percentage growth inhibition of S. cerevisiae and C. albicans with 
Compound 63 in absence and presence of blue light. Comparison of Compound 63 
with fluconazole on both S. cerevisiae and C. albicans growth inhibition percentage 
obtained in the absence and presence of red light. 0 min means no blue light exposure. 
The experiment was conducted using EUCAST broth microdilution method and 
standardised inoculum of 0.5-2.5 x 105 cfu/ml. The experiment was conducted in 























































To ensure consistency of the results, EUCAST antifungal susceptibility testing of 
S. cerevisiae and C. albicans to the control antifungal agent, fluconazole, was 
performed. The resultant MIC of 1 μg/ml against C. albicans corresponded with 
the EUCAST Antifungal Clinical Breakpoints (EUCAST 7.3: Arendrup et al., 
2015a). Regarding S. cerevisiae the resultant MIC of 1 μg/ml was identified to be 
within the published MIC range (MIC and zone distributions and ECOFFs; 
EUCAST 7.3: Arendrup et al., 2015a). 
Only Compound 57 had a significant effect in the absence of blue light against 
both species (Figure 6.8). None of the six remaining compounds (58, 59, 60, 61, 
62 and 63) showed significant antifungal activity in the absence of blue light. As 
such, for these compounds, any antifungal efficacy will be due to blue light treated 
anthraquinones.  
The data shows that none of the blue light treated anthraquinones showed growth 
inhibition of ≥50% compared to that of the compound-free control, which means 
that no MIC could be determined against both S. cerevisiae and C. albicans. 
 
Although the MIC value was not reached, the anthraquinone Compounds 57, 58 
and 60 showed the highest growth inhibition among all the seven compounds 
after 20-minute blue light exposure. The highest percentage growth inhibition of 
Compounds 57, 58 and 60 was recorded at a concentration of 50 μg/ml, with 
maximum growth inhibition levels of 40%, 41% and 42% against S. cerevisiae 
and 36%, 33% and 36% against C. albicans, respectively. In general, the 
sensitivity of S. cerevisiae was more than that of C. albicans (Figures 6.8, 6.11 
and 6.13). 
All the four remaining anthraquinones exposed to 20-minute blue light exhibited 
slightly more growth inhibition than the no-light control against both species. For 
example, Compound 59 inhibited growth of S. cerevisiae and C. albicans at 20% 
and 16%, in the absence of blue light that increased to 28% and 24%, 
respectively, when light activated (Figures 6.9).  
A. fumigatus was also screened using the EUCAST antifungal MIC microdilution 
method for moulds. Due to the growth of A. fumigatus, instead of measuring the 
optical density to determine percentage growth inhibition, a visual inspection was 
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undertaken. In this case the MIC was determined to be the first well where the 
concentration of compound resulted in complete absence of growth. The 
concentrations range tested for the control drug amphotericin B was 0-16 (μg/ml). 
It has been demonstrated that amphotericin B was effective against A. fumigatus 
showing MIC of 0.125 μg/ml, which matched the MIC EUCAST breakpoint in A. 
fumigatus. The antifungal screening demonstrated that anthraquinones, following 
exposure to blue light, did not exhibit any efficacy against A. fumigatus at the 
concentrations tested (0 to 500 μg/ml) by checking the growth visually (data not 
shown). 
 
6.2.3 Antibacterial screening 
The anthraquinone compounds were then screened, using the European 
Committee for Antimicrobial Susceptibility Testing (EUCAST) microbroth dilution 
method, for antibacterial activity following 20-minute blue light exposure against 
two clinically important bacterial species S. aureus and E. coli (EUCAST 7.3: 
Arendrup et al., 2015a). 
 The antibacterial drug gentamicin, was used as a control due to its broad 
antibacterial activity against both Gram-negative and Gram-positive bacteria (Jao 
et al., 1964). The bacterial species were exposed to a range of concentrations of 
the anthraquinone compounds (0-500 μg/ml) in the presence and absence of blue 
light. The MIC was determined, by visual inspection, to be the lowest 
concentration that completely inhibits growth. The experiments were repeated 
twice in duplicate. 
EUCAST antibacterial susceptibility testing of S. aureus and E. coli to the control 
gentamicin was performed and the resultant MICs of 0.25 and 0.125 (μg/ml) 
corresponded with EUCAST Antibacterial Clinical Breakpoints, which confirms 
the accuracy of the assay.  
Compounds 57, 58 and 60 showed effect on visible growth against S. aureus and 
E. coli following 20-minute blue light exposure. The remaining compounds did not 







In this study, the aim was to evaluate the antimicrobial effectiveness of a set of 
novel photoactivated anthraquinones using blue light illumination. The 
anthraquinone compounds had previously been characterised photochemically 
and, in this study, they were investigated biologically against a range of clinically 
important microorganisms.  
 
6.3.1 Anthraquinones are photosensitised following exposure to 
blue light and release singlet oxygen 
Due to the studied photosensitising activity of anthraquinones and their ability to 
release free radicals and singlet oxygen within Type 1 and Type 2 reactions, a 
set of novel synthesised anthraquinones was characterised photochemically 
(Comini et al., 2011). 
To identify the required light source to photoactivate anthraquinones, the 
wavelength of maximum absorbance, λmax, was determined by taking the 
absorbance spectrum between the wavelengths 250-800 nm. The tested 
anthraquinones absorbed maximally in the UV light region, with the λmax located 
between 223 to 265 nm. The photophysical properties of the anthraquinone 
compounds can be seen in Table 6.4. The reduction of one of the carbonyl groups 
causes an increase in the absorption spectra. In the case of Compound 62, when 
compared to Compound 57 there is an increase of 12 nm and this could be a 
result of the reduction in the polarity of the molecule, which affects the interaction 
with the microbial cell membrane. This result is supported by another study which 
found that anthraquinones, such as rubiadin and rubiadin-1-methyl ether, 
absorbed in UV and blue light regions of the spectrum, showing maximum 
absorbance at 360 nm and 411 nm, respectively. This is also consistent with 
various published studies conducted on bis(4-oxybenzoic acid)-1,8-
anthraquinone and bis(3-oxybenzoic acid)-1,8-anthraquinone, sornjidiol and 
damnacanthal, which demonstrate their maximum absorption in the range 




The studied anthraquinones have been demonstrated to absorb mainly in the UV 
light region between 220-300 nm (Tables 6.1, 6.2 and 6.3). Due to the UV-based 
mutagenesis effect, blue light can potentially be a safer activating light source. 
However, blue light has the associated disadvantages of potentially not activating 
the anthraquinone tested compounds.  
 
Following anthraquinones exposure to 20-minute blue light in the present study, 
singlet oxygen species were produced and relative 1O2 calculated when 
compared to their unsubstituted standards. The data suggests that most singlet 
oxygen species were released from the anthraquinones following 20-minute blue 
light exposure. All anthraquinone derivatives produced higher singlet oxygen than 
their relevant standards, anthraquinone and bianthrone. The relative singlet 
oxygen values for these derivatives ranged between 3.5 and 53 (Table 6.4 and 
6.5), with the singlet oxygen yield of Compound 57 showing the highest increase 
at 53-fold. Similarly, the singlet oxygen of Compound 60 also showed an increase 
when compared to the standard bianthone, at a 3.5-fold increase.  
Compounds which produced high levels of singlet oxygen were hydroxyl and 
methoxyl derivatives (Compounds 57, 58 and 60; Tables 6.4 and 6.5). The 
TPCPD assay for singlet oxygen measurement showed that light activation of 
Compounds 57 and 60 resulted in a half-life of 2 min, when compared with 
standards anthraquinone and bianthrone, respectively (Tables 6.1 and 6.2). 
These observations indicate that the addition of hydroxyl groups to the parental 
compound increases singlet oxygen production (Tables 6.4 and 6.5). This data is 
supported by data from four anthraquinones, erythroglaucin (ERG), teloschistin 
(TEL), 1-hydroxy-2-methylanthraquinone (HYQ) and 1-methoxy-2-
hydroxyanthraquinone (MEQ), which contain both hydroxyl and methoxyl 
substitute groups and have exhibited effective photosensitising activity 
(Rajendran et al., 2004). These results cannot be compared with the data shown 
in this study because of the different reference standards and also due to the data 





6.3.2 The majority of anthraquinones have no significant effect 
on microbial growth in the absence of blue light 
Anthraquinones have been shown to possess antimicrobial activity against a 
range of common pathogens in the absence of activating light (Wu et al., 2006, 
Mohanlall et al., 2013, Rhea et al., 2012). In this study, the anthraquinones alone 
were tested against the fungi and bacteria. Only Compound 57 showed a 
significant growth inhibition activity against S. cerevisiae and C. albicans when 
compared to the untreated control, however the MIC was not reached. The 
remaining compounds showed some growth inhibition in fungi, but it was less 
than 23% at the highest concentrations tested (500 μg/ml). No visual growth 
effect was observed against the fungus A. fumigatus and the bacteria S. aureus 
and E. coli in the absence of blue light. 
 
Both anthraquinones, rhein and emodin, were shown to be inactive against E. 
coli and C. albicans at the highest concentration tested (500 μg/ml) 
(Chukwujekwu et al., 2006, Malmir et al., Ayo et al., 2007). Additionally, the 
antimicrobial activity of a popular anthraquinone, emodin, was studied and the 
MIC was found to be 2,000 μg/ml against S. aureus, 3,000 μg/ml against E. coli 
and 4,000 μg/ml against C. albicans using the disk diffusion method (Ayo et al., 
2007) . These findings support the observations made in this study that the MIC 
was higher than the maximum concentration tested at 500 μg/ml. 
Comparison of the activities of the anthraquinones revealed that the effects of 
emodin, rhein and physcion against all microbial species were significant while 
our compounds showed no antimicrobial activity. It is suggested that antibacterial 
activity of the anthraquinone derivatives may be related to the type of substituent 
groups on the molecular structure. All of the anthraquinones tested in this study 
and the various reported studies have the same hydroxyanthraquinone nucleus 
composed of two ketone groups at C9 and C10, while different groups are 
substituted at C1, C3, C6 and C8 of the phenyl ring. The active anthraquinones, 
including rehin and emodin, have polar substituent carboxyl, hydroxyl, and 
hydroxymethyl groups at these positions. This is because these polar functional 
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groups can increase antibacterial activity due to the ability of these groups to bind 
strongly to the polar phospholipids region in the microbial membrane (Echeverría 
et al., 2017; Lu et al., 2011). This is consistent with the results for Compound 57 
within this study, which contains two hydroxyl groups. In comparison with the 
other anthraquinone compounds tested, this seems to increase the growth 
inhibition effect.  
This means Compound 57 could enter the cell and, as described for other 
anthraquinones, bind and insert into the cell membrane, leading to loss of 
cytoplasmic membrane integrity. Additionally, these compounds may also bind 
with the phosphate group of DNA and intercalate into the base pairs of the DNA 
helix, which may affect replication and transcription, repress expression and even 
lead to cell death. Other mode of actions might be involved in the observed 
antimicrobial activity of anthraquinones including the inhibition of activity of 
nicotinamide adenine dinucleotide (NADH) oxidase and succinate oxidase of 
mitochondria and thus this could lead to uncoupling of oxidative phosphorylation, 
restraining of active transport, and loss of pool metabolites (Lu et al., 2011). The 
six remaining tested anthraquinones lack these polar groups, which may limit 
their ability to enter the cell and, therefore, explain why they have no antimicrobial 
effect in the absence of light. 
The activity of anthraquinones in the absence of activating light may be improved 
by having a long unsaturated aliphatic chain methoxy group substituted in 
position C2 of the basic anthraquinone structure to facilitate interaction and 
disruption of cell walls (Sikkema et al., 1995; Kemegne et al., 2017). This is the 
case of 1-methyl-2-(3′-methyl-but-2′-enyloxy)-anthraquinonem, which showed 
significant efficacy against both C. albicans and A. fumigatus at MIC of 31.25 
μg/ml (Mishra et al., 2010), while our compounds tested in this study do not 








6.3.3 Blue light activation of three tested anthraquinones 
showed a significant effect on microbial growth when 
compared to that of untreated-anthraquinones 
It has been demonstrated in Chapter 3 that 60-minute blue light illumination did 
not have a significant effect on the the growth of any of the test microorganisms 
when compared to that of untreated microbial cells, due to the wavelength and 
irradiance dose (Figures 3.3-3.6). Based on the blue light results and the 
observations of no-light effect, any growth inhibition observed following 
illumination of the novel anthraquinones other than Compound 57, would be 
attributed to the of photoactivation of the compounds. 
The results for all the control bioassays undertaken within this study against each 
of the species tested were within the published ranges, which ensured the 
accuracy and consistency of the antimicrobial susceptibility testing (EUCAST 7.3: 
Arendrup et al., 2015a). 
  
The phototoxicity effect of these anthraquinones using blue light irradiation was 
investigated against a range of clinically important microorganisms. The minimum 
inhibitory concentration (MIC) were determined for each compound using the 
EUCAST method (EUCAST 7.3: Arendrup et al., 2015a). 
Following microbiological screening of seven quinone-based compounds, four 
compounds demonstrated no significant effect on growth in either S. 
cerevisiaeand C. albicans (Figures 6.10, 6.12, 6.13 and 6.14). Only Compounds 
57, 58 and 60 of the light activated compounds exhibited significant growth 
inhibition in S. cerevisiae and C. albicans when compared with no-light 
compounds (Figures 6.8, 6.9 and 6.11). However, no MIC could be determined 
as, at the highest concentration tested (500 μg/ml), total growth inhibition was 
less than 50%. No growth inhibition was observed in either A. fumigatus or the 
bacterial species, E. coli and S. aureus, following exposure to the seven 
anthraquinone compounds. It has been demonstrated that two anthraquinones, 
rubiadin and rubiadin-1-methyl ether, showed significant antifungal activity 
against Candida species when exposed to blue light (Marioni et al., 2017). 
However, the previous study used a shorter wavelength than that used in this 
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research (420 nm versus 470nm), which may have had a cumulative effect on 
Candida. The two tested anthraquinones have been substituted with methoxyl 
and methyl groups as well as two hydroxyl groups, which may increase the 
polarity, facilitating penetration into the microbial cells. The test compounds are 
less polar, possibly reducing their ability to enter the cell. Although not measured 
in this study, a number of other anthraquinone-related compounds, such as 
rubiadin and rubiadin-1-methyl ether, have also been shown to release both 
radical and 1O2 species following light activation. As such, we can predict that 
lack of penetration into the cell of the test compounds is reducing their ability to 
affect the microbial cells and reduce their growth (Marioni et al., 2017).  
 
Three blue light activated anthraquinones, Compounds 57, 58 and 60, have 
significantly greater photoantimicrobial activity against S. aureus and E. coli 
compared to the controls. However, although they were tested up to 500 μg/ml, 
the MIC was not reached. In comparison, the blue light activation of 
anthraquinones soranjidiol and rubiadin showed in vitro bactericidal effect against 
S. aureus using a different method, the agar diffusion method, with a minimum 
reduction of 103 cfu/ml (3.0 log10). The higher antibacterial activity of soranjidiol 
and rubiadin in comparison to the compounds tested in this research is suggested 
to be related to hydroxyl and methyl groups substituted at C2, C3 and C4 of the 
basic phenyl ring, which increase the penetration into the cells. 
The aforementioned anthraquinones are different to our compounds in respect to 
position of hydroxyl groups and including a substituent methyl group, which are 
suggested to have influence on activity due to additional polarity obtained (Wang 
et al., 2010). 
 
One of the limitations regarding using anthraquinones as drugs is the possible 
toxicity associated with quinone-containing derivatives that could lead to 
mammalian cell damage (Malik et al., 2016). Anthraquinones are widely used as 
laxatives, however several side effects, such as; electrolyte imbalance, metabolic 
alkalosis, hypotension and dehydration are generally associated with their use 
(Malik et al., 2016) . The toxicity associated with quinones is caused by their 
ability to interact with essential nucleophiles inside the cell as well as the result 
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of taking part in redox reactions, which produce damaging reactive oxygen 
species (ROS) mainly 1O2 as well as radicals, however radicals were not 
measured in this present study (Malik et al., 2016). Therefore, the limited 
photoantimicrobial activity and potential toxicity of the novel anthraquinones 

























7. Characterisation of candidate compounds 
7.1 Introduction 
The treatment of infectious diseases is one of the most challenging problems in 
medicine due to the increased resistance of microbes to current antimicrobial 
drugs, their side effects and their spectrum of activity (Liang et al., 2016; Cieplik 
et al., 2018). Therefore, there is a requirement to develop new therapeutic 
strategies which target unique characteristics of bacterial and fungal cells, without 
affecting the patient. Photodynamic therapy is a potential alternative therapy that 
can be utilised to treat microbial infections. 
There are certain characteristics required of an ideal PDT antimicrobial agent: 
1. Broad spectrum of antimicrobial activity at a low MIC, which indicates that 
less of the drug is required to inhibit growth of the microbe. 
2.  They cannot easily induce the development of microbial resistance. Many 
current antimicrobial therapies target a limited number of sites within the 
microbial cell, which increases the chances that resistance may develop. 
Multiple targets will increase efficacy of the PDT agent and limit the 
development of resistance against the compound.  
3. Effective antimicrobial activity against biofilms that often have reduced 
susceptibility towards conventional antimicrobial treatments and are linked 
to various human diseases. 
4. Selective toxicity so that the compound is lethal to microorganisms without 
causing significant damage to the mammalian host cells. This will help 
reduce side effects within the patient.   
 
Following biological screening of all acridine, flavine, acridine-isoalloxazine and 
anthraquinone compounds (Chapters 3, 4, 5 and 6), a shortlist of five compounds 
showing the lowest MICs values against fungi and bacteria was chosen. The 
shortlisted compounds were acridine (Compounds 1, 2 and 11) and acridine-
isoalloxazine (Compounds 36 and 43), which have the lowest MICs of all the 
compounds tested for both antifungal and antibacterial activity following 
photoactivation (Table 7.1). In order to determine their clinical potential, the 
shortlisted compounds need to be further characterised to determine whether 
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they meet the characteristics required for an effective antimicrobial agent in a 
clinical setting. 
A common dogma in the medical field is that cidal drugs are more efficient than 
static agents, because they eliminate bacteria rather than limiting their growth. 
Knowing the mechanism of action of any novel antimicrobial is important to 
determine its clinical use. The majority of PDT agents show cidal effects on 
microbial cells by releasing ROS, which disrupts multiple cellular targets. 
Therefore, the shortlisted compounds will be reviewed for cidial or static effects 
following treatment of microbial cells.  
Photosensitisers work via the release of ROS (.OH and H2O2) via Type 1 or/and 
(1O2) via Type 2 reactions, which is able to kills cells as a result of oxidative stress 
(Baltazar et al., 2015). The initial chemical characterisation of these compounds 
within this study demonstrates no biological relevance to their antimicrobial 
activity. Therefore, an alternative method is required to determine their biological 
effect. A large number of stresses are signalled through the high osmolarity 
glycerol (HOG) pathway, including the general stress response. One of the 
targets of this pathway are a key set of transcription factors, Msn2/4p, which are 
activated in response to oxidative stress. Deletion of the MSN2/4 genes encoding 
these proteins results in sensitivity of cells to oxidative stress (Pascual-Ahuir et 
al., 2007; Martinez Pastor et al., 1996). Therefore, the MIC of the candidate 
compounds within these mutant strains can help inform the mechanism of action 
of these compounds. 
 
The mechanism of action of these compounds is important as this may impact on 
the development of resistance within treated microbial cells. There is an 
increasing resistance to traditional antimicrobial treatments, which has resulted 
in the persistence of a number of infections (Alanis, 2005, Hawkey, 2008). 
Therefore, an important effort is being made to find alternative antimicrobial 
therapies, where development of resistance is limited. Various studies have 
shown that no development of resistance is observed in fungal and bacterial cells 
in response to PDT due to the absence of a specific target (Jori et al., 2006; 
Vandeputte et al., 2012; Vatansever et al., 2013). Therefore, any new PDT agents 
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will need to be reviewed to determine the possibility of resistance developing in 
the treated microorganisms.  
Microorganisms can cause persistent infections in clinical situations despite 
showing susceptibilities to antimicrobial treatment when testing in vitro. It has 
been suggested a parameter termed perseverance correlates with the clinical 
responses and is defined by the ability of fungal cells to grow at drug 
concentration above the MIC (Rosenberg et al., 2018). This parameter is 
measured as the degree of supra-MIC growth (SMG) in broth microdilution 
assays. The SMG and MIC of the examined compounds were studied to check 
the proportion of cells that form colonies at SMG concentration and compared 
with the MIC, which is often not sufficient to explain clinical outcomes.  
 
The clinical effectiveness of a potential antimicrobial compound is influenced by 
the external environment (Şen et al., 1997; Sherrington et al., 2017). This 
includes availability of metal ions and changes in pH, which can occur at the 
treatment site or intracellularly (Mayer et al., 2013; Weckwerth et al., 2012). For 
example, to treat microbes found in the vagina (pH 4-4.5), the compound must 
retain activity within acidic conditions (George et al., 2009). Further, medium pH 
and EDTA have been shown to have an effect within in vitro susceptibility testing 
against microbial species (Marr et al., 1999). These aspects can be assessed by 
testing the novel antimicrobial compounds in combination with EDTA, a 
magnesium and calcium metal chelator, and at varying pHs to determine their 
effectiveness.  
To investigate if the different medium conditions could have effects during PDT 
(Carvalho et al., 2009), the antimicrobial susceptibility testing of the PDT 
shortlisted compounds was investigated in buffered and unbuffered medium 
using MOPS as a buffer.  
 
Many PDT agents have been shown to have an effect on fungal and bacterial 
sessile cells of biofilms, which are often resistant to conventional antimicrobial 
therapies and host immune defences (Pereira et al., 2010). Therefore, in this 
chapter the photoantifungal activity of the shortlisted compounds against C. 
185 
 
albicans biofilms following exposure to 20-minute blue light was evaluated by 
conducting a colorimetric method using XTT reduction assay.  
 
As any new antimicrobial reagent would be required to have minimal effect in host 
cells, the shortlisted compounds were tested to determine their toxicity in 
mammalian cells. The assays were performed using HeLa cells, an immobilised 
human cell line derived from cervical cancer cells, which have been used widely 
in toxicity testing due to their ability to thrive indefinitely and easily in biomedical 
research and their susceptibility to infections (Limban et al., 2008; Franchini et 
al., 2009; Wasson et al., 2012). The toxicity in mammalian cells has been 
evaluated by investigating cell viability in the presence of the photosensitisers.   
This chapter will present data from a range of experiments utilised to assess 
whether the shortlisted compounds have the characteristics required to enable 
them to move forward as potential antimicrobial compounds for clinical use. 
 
7.2 Results 
Following photoantimicrobial screening of all tested compounds under 20-minute 
blue light illumination, a shortlist of compounds with the lowest MIC against the 
fungi S. cerevisiae and C. albicans and bacteria S. aureus and E. coli was chosen 
and moved through into further characterisation (Figure 7.1, Table 7.1). The five 
shortlisted compounds were three acridine-based compounds (1, 2 and 11) as 
well as two acridine-isoalloxazine based compounds, 36 and 43 (Figure 7.1). The 
MICs of S. aureus were lower than those of E. coli bacteria while C. albicans 










Table 7.1 Summary of the minimum inhibitory concentrations (MICs) of shortlisted 
compounds, which have been chosen according to the compounds showing the 


















Fluconazole 0.25 1   
Gentamicin   0.25 0.125 
Compound 1 4.2 4.2 2 24 
Compound 2 5.2 8.3 8 24 
Compound 11 12.5 25 8 24 
Compound 36 12.5 25 8 16 












Figure 7.1 Chemical structures of novel shortlisted acridine and acridine-isoalloxazine derivatives.
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7.2.1 All shortlisted compounds are static against the tested 
fungi, S. cerevisiae and C. albicans, and bacteria, S. aureus 
and E. coli. 
Based on the phototoxicity of the shortlisted compounds against fungal species 
S. cerevisiae and C. albicans and bacterial species S. aureus and E. coli (Table 
7.2), it was investigated whether this effect was static or cidal. 
Following treatment with the shortlisted compound and a 24 h incubation, 
samples were taken from the first well where no visible growth could be observed. 
These samples were diluted into the corresponding fresh broth media and 
incubated for 24 h. The regrowth was determined by observing turbidity visually, 
with samples treated with compound where growth was seen classified as static 
and those with no further growth determined to be cidal.  
The experiment was conducted on the shortlisted compounds, fluconazole and 
gentamicin three times in duplicate, n=3. 
 
Table 7.2 Determination if the compounds and control drugs are cidal or static to 
microbial cells. It has been determined by investigating their growth visually after 20 
min blue light exposure. 
Compounds 
Fungi Bacteria 
S. cerevisiae C. albicans S. aureus E. coli 
Compound 1 Static Static Static Static 
Compound 2 Static Static Static Static 
Compound 11 Static Static Static Static 
Compound 36 Static Static Static Static 
Compound 43 Static Static Static Static 
Fluconazole Static Static   






As expected, fluconazole showed a static effect against all fungal cells, with 
gentamicin showing a cidal effect against all bacterial cells (Lewis et al., 1998; 
Natarajan et al., 1998). 
The data suggests that compounds treated with blue light were static to bacterial 
























7.2.2 Development of resistance of PDT 
The emergence and spread of resistance to antimicrobial drugs is becoming an 
increasingly serious threat to global public health (Vandeputte et al., 2012; 
Hawkey, 2008). As a result, traditional and standard treatments become 
ineffective, and microbial infections persist and may spread to others, which lead 
to prolonged illness and death (Cosgrove et al., 2003; Hurley, 2005). Therefore, 
there is always a demand for new antimicrobial approaches where cells have a   
limited ability to develop resistance. 
 
In this study the development of microbial resistance following repeated exposure 
to the blue light activated compounds was investigated. The well before that 
showing MIC was chosen to move into the next round, and over three rounds of 
repeated exposure, the MICs of the cells to each shortlisted compound were 
determined. This is consistent with a study by Rosenberg who measured the MIC 
change throughout three successive exposures (Rosenberg et al., 2018).   
The determined minimum inhibitory concentrations of blue light treated 
compounds are shown as means ±SEM (Figures 7.2 to 7.5). The experiments 
were repeated on three separate occasions, n=3. Two-way ANOVA analysis was 
performed, and a significant result was determined to have a p value of < 0.05. 
 
7.2.2.1 No development of fungal resistance to the candidate compounds                                      
Two fungal species, S. cerevisiae and C. albicans, were repeatedly treated with 
five blue light activated compounds to evaluate the probability of resistance 
developing to the tested compounds. EUCAST antifungal susceptibility testing 
was performed and the MICs determined after repeated exposure to Compounds 
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Figure 7.2 Development of resistance to Compound 1, 2, 11, 36 and 43 in S. 
cerevisiae. Comparison of the MICs of five shortlisted compounds against S. cerevisiae 
following three exposures with excitation with blue light for 20 min. The MIC was defined 
by broth dilution (EUCAST method) as the lowest concentration, recorded in μg/ml, of a 
compound that gives inhibition of growth of ≥50% of that of the drug-free control. n=3 
(pooled from duplicate experiments). Values are the means ±SEM. ANOVA analysis of 
results shows no significant effect of repeated blue light exposure on the development 
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Figure 7.3 Development of resistance to Compounds 1, 2, 11, 36 and 43 in C. 
albicans. Comparison of the MICs of five shortlisted compounds against C. albicans 
following three exposures with excitation with blue light for 20 min. The MIC was defined 
by broth dilution (EUCAST method) as the lowest concentration, recorded in μg/ml, of a 
compound that gives inhibition of growth of ≥50% of that of the drug-free control. n=3 
(pooled from duplicate experiments). Values are the means ±SEM. ANOVA analysis of 
results shows no significant effect of repeated blue light exposure on the development 
of resistance to these shortlisted compounds in C. albicans. 
 
S. cerevisiae and C. albicans suspensions were serially passaged three times on 
20-minute blue light illumination and Figures 7.2 and 7.3 demonstrate the 
changes in MIC obtained with increasing numbers of passages. Two-way 
ANOVA analysis exhibited no significant difference in the photoantifungal activity 
between 1st and 3rd passage. 







7.2.2.2 No development of bacterial resistance to the candidate 
compounds                                                             
Two bacterial species, S. aureus and E. coli, were repeatedly treated with five 
blue light activated compounds to evaluate the probability resistance developing 
to the examined compounds. EUCAST antibacterial susceptibility testing of S. 
aureus and E. coli was performed and the MICs determined after repeated 
exposures to Compounds 1, 2, 11, 36 and 43 in the presence of blue light for 
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Figure 7.4 Development of resistance to Compounds 1, 2, 11, 36 and 43 in S. 
aureus. Comparison of the MICs of five shortlisted compounds against S. aureus 
following three exposures with excitation with blue light for 20 min. The MIC was defined 
by broth dilution (EUCAST method) as the lowest concentration, recorded in μg/ml, of a 
compound that completely inhibits the growth of S. aureus. n=3 (pooled from duplicate 
experiments). Values are the means ±SEM. ANOVA analysis of results shows no 
significant effect of repeated blue light exposure on the development of resistance to 
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Figure 7.5 Development of resistance to Compounds 1, 2, 11, 36 and 43 in E. coli.  
Comparison of the MICs of five shortlisted compounds against E. coli following three 
exposures with excitation with blue light for 20 min. The MIC was defined by broth dilution 
(EUCAST method) as the lowest concentration, recorded in μg/ml, of a compound that 
completely inhibits the growth of E. coli. n=3 (pooled from duplicate experiments). Values 
are the means ±SEM. ANOVA analysis of results shows no significant effect of repeated 
blue light exposure on the development of resistance to these shortlisted compounds in 
E. coli. 
 
S. aureus and E. coli suspensions were serially passaged three times on 20-
minute blue light illumination and Figures 7.4 and 7.5 demonstrate the changes 
in MIC obtained with increasing numbers of passages. However, two-way 
ANOVA analysis exhibited no significant difference in the photoantibacterial 
activity between 1st and 3rd passage. 







7.2.3 Effect of pH and EDTA on in vitro susceptibility to 
photoactivated compounds 
7.2.3.1 S. cerevisiae and C. albicans susceptibility decreases when pH 
reduces  
The treatment of vulvovaginal candidiasis (VVC) due to Candida species is 
challenging, with limited therapeutic options. Various studies have found a 
frequent in vivo failure of antifungal drugs in women with vaginitis caused by 
Candida species, which is possibly due to the decrease in susceptibility of 
Candida species to antifungals with more acidic vaginal pH (4 to 4.5) (Marr et al., 
1999; Danby et al., 2012). The exact mechanism of pH-induced reduced 
susceptibility has not been established yet and could be attributed to the pH 
impact on chemical structure of antifungal drug or on microbial cell. This study 
evaluated whether a change in media pH had an effect on in vitro susceptibility 
of S. cerevisiae and C. albicans to fluconazole and blue light treated shortlisted 
compounds, in order to explain the effectiveness of the compounds under 
conditions of reduced pH. 
The antifungal susceptibility testing was conducted using the broth microdilution 
EUCAST method and the concentrations tested were 0-64 µg/ml for fluconazole 
and 0-25 µg/ml for shortlisted compounds, as the MICs obtained for these 
compounds were within these concentration ranges as shown in Chapters 3 and 
4. The MICs were determined as the lowest concentration giving inhibition of 
growth of ≥50% compared to growth in compound-free growth wells for all tested 
compounds. 
Antifungal susceptibility testing was conducted for S. cerevisiae and C. albicans 
by adjusting the pH to 4, 5, 6 and 8, using either 1M hydrochloric acid or sodium 
hydroxide. The resultant antifungal activities were then compared with the pH of 
initial experiments that identified the shortlisted compounds (pH=7). This 
experiment was conducted in the presence and absence of MOPS buffer solution 
to identify the relationship between the photoantifungal results and the ability of 
the medium to permit changes in the pH values. The experiments were conducted 
three times, n=3, in duplicate. Two-way ANOVA analysis was carried out and a 
significant result was determined to have a p value of < 0.05. 
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Regarding fluconazole, it has been demonstrated that S. cerevisiae and C. 
albicans species showed MICs located in the published region, which means that 
no change in susceptibility was determined. However, as the pH decreased an 
obvious increase in MIC was noted. For example, in the presence of MOPS, the 
MIC of fluconazole against S. cerevisiae was 0.33 µg/ml at both pH 7 and 8, 
before increasing approximately threefold, to 0.83 µg/ml at pH 4 (Figure 7.6). 
While against C. albicans, the MIC of fluconazole in the presence of MOPS was 
0.21 µg/ml at pH 7 and 8, which increased twofold at pH 4 to 0.42 µg/ml (Figure 
7.8). 
The results of testing compounds in S. cerevisiae and C. albicans in in vitro 
exhibited that blue light treated compounds behaved similarly with a drop in pH 
and showed an increase in MIC, particularly at pH 4. This was a trend noted for 
all five of the shortlisted compounds, with MIC increasing with a decrease in pH.  
With a decrease in pH from 8 to 4 it was seen a 3-fold rise in MIC of Compound 
2 in the presence of MOPS from 5.21 to 16.67 µg/ml against S. cerevisiae and 
twofold rise in MIC of Compound 2 from 5.21 to 10.42 µg/ml against C. albicans. 
In general, for both fluconazole and the shortlisted compounds, the MICs in the 
absence of MOPS were not significantly different from those in the presence of 








Figure 7.6 Minimum inhibitory concentrations MICs50 susceptibility results for S. 
cerevisiae at pH 8, 7, 6, 5 and 4 in the presence of MOPS buffer solution. The 
experiment was conducted in duplicate, n=3. Values are the means ±SEM. Data 
analysed by two-way ANOVA analysis and significance indicated between susceptibility 
in pH 4 and pH 7 *p >0.01.  
 
Figure 7.7 Minimum inhibitory concentrations MICs50 susceptibility results for S. 
cerevisiae at pH 8, 7, 6, 5 and 4 in the absence of MOPS buffer solution. The 
experiment was conducted in duplicate, n=3. Values are the means ±SEM. Data 
analysed by two-way ANOVA analysis and significance indicated between susceptibility 
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Figure 7.8 Minimum inhibitory concentrations MICs50 susceptibility results for C. 
albicans at pH 8, 7, 6, 5 and 4 in the presence of MOPS buffer solution. The 
experiment was conducted in duplicate, n=3. Values are the means ±SEM. Data 
analysed by two-way ANOVA analysis and significance indicated between susceptibility 
in pH 4 and pH 7 *p > 0.01. 
 
 
Figure 7.9 Minimum inhibitory concentrations MICs50 susceptibility results for C. 
albicans at pH 8, 7, 6, 5 and 4 in the absence of MOPS buffer solution. The 
experiment was conducted in duplicate, n=3. Values are the means ±SEM. Data 
analysed by two-way ANOVA analysis and significance indicated between susceptibility 
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7.2.3.2 EDTA addition increases the susceptibility of S. cerevisiae and C. 
albicans to the shortlisted compounds 
The antibacterial effects of EDTA have been investigated widely and proved to 
be limited (Orstavik et al., 1990; Heling et al., 1998). However, EDTA may have 
antifungal potential with its chelating property because calcium ions have a critical 
role in morphogenesis and pathogenesis of C. albicans. Additionally, EDTA can 
reduce the fungal growth by removing calcium from the cell wall and causing 
collapse in the cell wall, and by inhibiting enzyme reactions (Holmes et al., 1991).  
 
Therefore, the aim of this study was to determine the susceptibility of S. 
cerevisiae and C. albicans to the combination of photoactivated compounds and 
fluconazole with and without 10 mM EDTA. The MOPS buffer solution effect was 
studied to investigate the influence of pH change on the photoantifungal results. 
The susceptibility testing using the broth microdilution method was performed 
according to EUCAST guidelines. The concentrations tested were 0-64 µg/ml for 
fluconazole and 0-25 µg/ml for shortlisted compounds, as the MICs obtained for 
these compounds were within these concentration ranges as shown in Chapters 
3 and 4. The MICs were determined as the lowest concentration giving inhibition 
of growth of ≥ 50% compared to growth in compound-free growth wells for all 
tested compounds. The experiments were conducted on three different 
occasions, n=3. ANOVA analysis was conducted to determine the significant 
results. 
 
The S. cerevisiae and C. albicans cells were exposed to 10 mM EDTA alone at 
pH 7 in the absence of the compounds. No significant impact on growth was 
observed. 
Fluconazole showed MICs located in the region of published results against S. 
cerevisiae and C. albicans strains, which means that strains remained 
susceptible to fluconazole in the presence and absence of EDTA regardless of 
the presence of MOPS buffer. However, the presence of EDTA resulted a slight 
decrease in MIC values. For example, in the presence of MOPS, MIC of 
201 
 
fluconazole was 0.42 µg/ml, when EDTA was not present, which decreased to 
0.21 µg/ml after addition of EDTA (Table 7.3). 
The results of testing compounds in S. cerevisiae and C. albicans in vitro 
exhibited that blue light treated compounds behaved similarly with addition of 
EDTA and showed a drop in MICs. In general, for both fluconazole and the 
shortlisted compounds, the MICs in the absence of MOPS were not significantly 
different from those in the presence of MOPS (Figures 7.6 to 7.9).  
 
It has been demonstrated that addition of 10 mM EDTA increases the 
susceptibility of both S. cerevisiae and C. albicans to fluconazole. A similar trend 
is seen when EDTA is used in combination with the blue light activated 
compounds, in the presence and absence of MOPS. The MIC of light activated 
Compound 1 in S. cerevisiae was 5.21 µg/ml in the presence of MOPS, which 
dropped to 2.6 µg/ml when EDTA was added. Similarly, Compound 43, showed 
a lower MIC in C. albicans in the presence of MOPS when EDTA was added 
(10.42 µg/ml) than without EDTA at a (25 µg/ml). As shown in Table 7.3, EDTA 
addition decreased the susceptibility of both species S. cerevisiae and C. 














Table 7.3 Minimum inhibitory concentrations MICs50 susceptibility results for S. 
cerevisiae and C. albicans in the presence and absence of 10 mM EDTA with and 
without MOPS (a final concentration of 0.165 M). 
 
Compounds 
S. cerevisiae C. albicans 
MICs with   
MOPS (µg/ml) 
MICs without 
MOPS                
(µg/ml) 
















Fluconazole 0.42 0.21 0.42 0.33 0.42 0.33 0.42 0.33 
Compound 
1 
5.21 2.6 5.21 4.16 
   
10.42 
4.16 10.42 5.21 
Compound 
2 
10.42 4.16 10.42 8.33 16.67 5.21 16.67 8.33 
Compound 
11 
16.67 16.67 16.67 8.33 20.83 16.67 20.83 16.67 
Compound 
36 
25 10.42 25 16.67 20.83 16.67 20.83 16.67 
Compound 
43 














7.2.4 Photoactivated antimicrobial compounds decreased 
significantly the viability of HeLa cell line 
Most photoactivated compounds work via the release of ROS (Radicals via Type 
1 reactions reactions and singlet oxygen via Type 2), which is able to kill cells as 
a result of oxidative stress (Baltazar et al., 2015). In vitro studies have only 
allowed measurement of singlet oxygen production in a non-biological 
environment and radical species could not be measured, as discussed in Chapter 
3. Therefore, an alternative method was required to determine if the antimicrobial 
effect of the compounds was a result of ROS release.  
The cellular response of fungi to oxidative stress has been well characterised, 
especially in the yeast S. cerevisiae. As such, mutant strains of S. cerevisiae, 
deleted for key genes involved in the stress response, were utilised to help 
understand the mechanism of action of the shortlisted compounds. S. cerevisiae 
was selected as a model organism due to the ability to delete genes from the 
genome and the high level of homologue to C. albicans pathways, especially in 
regard to stress (Pascual-Ahuir et al., 2007). 
The compounds were tested against S. cerevisiae strains deleted for Hog1, a key 
component of the stress activated MAPK pathway, and Msn2/4p, transcription 
factors that are downstream targets of the oxidative stress response. Deletion of 
the genes encoding these proteins results in sensitivity of cells to oxidative stress. 
Therefore, this phenotype was used to investigate the effect of the blue light 
treated compounds against HOG1 and MSN2/4 genomic deletion strains 
compared to the wildtype MIC values. The strains were tested using the EUCAST 
antifungal susceptibility method, following 20-minute blue light activation of the 
compounds (EUCAST 7.3: Arendrup et al., 2015a). The experiment was 
conducted twice in duplicate. Two-way ANOVA analysis was conducted to 
determine significance of results. The data presented in Figure 7.10 compares 
the MICs for wildtype S. cerevisiae and the deletion strains, hog1 and msn2/4, 
when exposed to each of the light activated shortlisted compounds. Increased 
sensitivity of the deletion strains to the compounds when compared to the 
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Figure 7.10 Comparison of the MICs of shortlisted compounds according to 
EUCAST method against wildtype, hog1 deletion and msn2/4 deletion strains of 
S. cerevisiae after 20 min blue light exposure. The experiment was conducted in 
duplicate, n=2. Values are the means ±SEM. Two-way ANOVA analysis of results was 
conducted. 
 
Three control bioassays with hydrogen peroxide, blue light alone and untreated 
compounds against wildtype, hog1 deletion and msn2/4 deletion strains of S. 
cerevisiae were carried out. The level of growth inhibition for the control, 
hydrogen peroxide H2O2, against msn2/4 was significantly higher than wildtype 
strain (at 37% versus 19%) without reaching MIC. While hog1 deletion did not 
show a significant difference when compared with wildtype (data not shown). No 
growth inhibition was observed for the wildtype or deletion strains following 
exposure to blue light alone. 
Following blue light activation of Compounds 11 and 43, no significant change in 
the MIC was observed between the wildtype control and the deletion strains. The 
MIC for the light treated Compounds 1, 2 and 36 showed no significant reduction 
in the hog1 deletion when compared to wildtype, 7.81 µg/ml versus 4.69 µg/ml, 
14.06 µg/ml versus 9.375 µg/ml and 15.63 µg/ml versus 14.06 µg/ml, respectively 
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(Figure 7.10). However, a significant decrease in MIC was seen in the msn2/4 
deletion when compared to wildtype S. cerevisiae for Compound 1 (7.81 µg/ml 
versus 1.7 µg/ml), Compound 2 (14.06 µg/ml versus 3.515 µg/ml) and Compound 
36 (15.63 µg/ml versus 4.688 µg/ml) (Figure 7.10). 
 
7.2.5 Only Compounds 1, 2 and 43 show an antifungal activity 
against C. albicans biofilms 
It has previously been reported that the five shortlisted compounds have 
photoantifungal activity against C. albicans following activation by blue light 
(Table 7.1). EUCAST guidelines utilise free planktonic cells for the in vitro 
susceptibility test. However, C. albicans infections can be associated with biofilm 
formation, which is difficult to fully eradicate using normal therapy approaches. 
As the EUCAST method does not provide an accurate in vitro–in vivo correlation, 
C. albicans biofilms were prepared in flat bottom 96-well microtiter plates 
(Ramage et al., 2001). Concentrations of fluconazole (0 to 64 μg/ml), 
amphotericin B (0 to 16 μg/ml) and the five shortlisted compounds (0 to 25 μg/ml) 
were added to the biofilm cells. These concentrations were chosen as they were 
within the MICs ranges previously obtained in Chapters 3 and 4. Following 
exposure to blue light for 20 min the plates were incubated for 48 h at 35˚C.   
To evaluate the effects of the control drugs and the blue light activated 
compounds against biofilm sessile cells, a colorimetric method using the XTT 
reduction assay was performed. The metabolic activity of biofilm cells was 
determined in a microtiter plate reader at 490 nm and the MICs of fluconazole, 
amphotericin B and tested compounds were defined as the first drug 
concentrations leading to 50% reduction of C. albicans metabolic activity. 
The metabolic activity calculated was: (OD490nm sample/ OD490nm drug-free 
control)* 100%. 
The graphs show the means ±SEM (standard error of the mean) of the percent 
metabolic activity for the concentrations series of fluconazole, amphotericin B and 
blue light treated compounds against C. albicans biofilm cells (Figures 7.11 to 
7.17). Fluconazole was used as a control in C. albicans planktonic cells and 
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Figure 7.11 Effect of fluconazole on the metabolic activity of C. albicans and C. 
albicans biofilms. Comparison of the MICs of fluconazole against C. albicans and C. 
albicans biofilm. The metabolic activity calculated was: (OD490nm sample/ OD490nm drug-
free control)* 100%. Minimum inhibitory concentrations were determined to be the first 
concentration showing ≥ 50% reduction of C. albicans and C. albicans biofilm metabolic 
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Figure 7.12 Effect of amphotericin B on the metabolic activity of C. albicans and 
C. albicans biofilms. Comparison of the MICs of amphotericin B against C. albicans 
and C. albicans biofilm. The metabolic activity calculated was: (OD490nm sample/ OD490nm 
drug-free control)* 100%. Minimum inhibitory concentrations were determined to be the 
first concentration showing ≥ 50% reduction of C. albicans and C. albicans biofilm 
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Figure 7.13 Effect of 20 min blue light treated Compound 1 on the metabolic 
activity of C. albicans and C. albicans biofilms. The metabolic activity calculated was: 
(OD490nm sample/ OD490nm drug-free control)* 100%. Minimum inhibitory concentrations 
were determined to be the first concentration showing ≥ 50% reduction of C. albicans 
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Figure 7.14 Effect of 20 min blue light treated Compound 2 on the metabolic 
activity of C. albicans and C. albicans biofilms. The metabolic activity calculated was: 
(OD490nm sample/ OD490nm drug-free control)* 100%. Minimum inhibitory concentrations 
were determined to be the first concentration showing ≥ 50% reduction of C. albicans 
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Figure 7.15 Effect of 20 min blue light treated Compound 11 on the metabolic 
activity of C. albicans and C. albicans biofilms. The metabolic activity calculated was: 
(OD490nm sample/ OD490nm drug-free control)* 100%. Minimum inhibitory concentrations 
were determined to be the first concentration showing ≥ 50% reduction of C. albicans 
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Figure 7.16 Effect of 20 min blue light treated Compound 36 on the metabolic 
activity of C. albicans and C. albicans biofilms. The metabolic activity calculated was: 
(OD490nm sample/ OD490nm drug-free control)* 100%. Minimum inhibitory concentrations 
were determined to be the first concentration showing ≥ 50% reduction of C. albicans 
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Figure 7.17 Effect of 20 min blue light treated Compound 43 on the metabolic 
activity of C. albicans and C. albicans biofilms. The metabolic activity calculated was: 
(OD490nm sample/ OD490nm drug-free control)* 100%. Minimum inhibitory concentrations 
were determined to be the first concentration showing ≥ 50% reduction of C. albicans 
biofilm metabolic activity. Data shown as means of duplicates ±SEM 
 
 
As shown in Figure 7.11, fluconazole reduced the fungal metabolic activity in a 
concentration-dependent manner in planktonic C. albicans. Exposure of 
planktonic C. albicans suspensions to concentrations of 0.5 µg/ml decreased 
their metabolic activity by more than 50% (MIC of 0.5 µg/ml). When exposed to a 
C. albicans biofilm, fluconazole was less effective, reaching a total inactivation of 
metabolic viability of 38%. 
Regarding amphotericin B, as shown in Figure 7.12, it significantly reduced the 
metabolic activity of planktonic C. albicans suspensions in a concentration-
dependent way, with a determined MIC of 0.125 µg/ml. A higher concentration of 
2 µg/ml was required to inhibit the C. albicans biofilms and this value was 16-fold 




None of the light activated shortlisted compounds were able to decrease the 
metabolic activity of C. albicans biofilms to the threshold percentage of 50% 
(Figures 7.13 to 7.17). In all cases metabolism inactivation was noted, with only 
a significant decrease in metabolic activity seen with Compound 1 (26 %), 
Compound 2 (30 %) and Compound 36 (35%), at the maximum concentrations 
tested (Figures 7.13 to 7.17). While testing all the light activated compounds 
exhibited a significant decrease in the metabolic activity of planktonic C. albicans 
to the threshold percentage of 50% (Figures 7.13 to 7.17).  
The compounds alone showed no significant effect on the metabolic activity of 




















7.2.6 S. cerevisiae and C. albicans exhibited growth at drug 
concentration above the MIC (SMG), with no MIC change 
between 24 and 48 h 
Antifungal MIC measurements determined by the EUCAST method can inform 
about the resistance or sensitivity of a microorganism to the drug and help in 
making treatment decisions. However, this does not necessarily predict the 
fungal response to the treatment within a clinical situation. To better correlate 
antifungal response in vitro with that seen in the clinic, the term perseverance 
was defined (Rosenberg et al., 2018). Perseverance is the ability of fungal cells 
to grow at a drug concentration above the MIC and is measured as the degree of 
supra-MIC growth (SMG) in the broth microdilution assay. Perseverance may be 
considered a useful parameter for predicting clinical persistence and choosing 
appropriate antifungal therapies as it correlates with the success or failure of 
treatment in the clinic. 
In general, the MICs of photoactivated compounds do not change when analysed 
on consecutive days (Giuliani et al., 2010; Tavares et al., 2010). To reinforce the 
idea that susceptibility/resistance is not time-dependent, the MICs of the 
shortlisted compounds were measured and then compared with the SMG. The 
MICs of blue light treated compounds were determined against S. cerevisiae and 
C. albicans following 24 and 48 h incubation to provide information about 
resistance. MIC values were measured using the EUCAST broth microdilution 
method and determined to be the first well giving growth inhibition of ≥ 50% of 
that of drug-free control. Fluconazole was used as a control drug and the 




Figure 7.18 Effect of incubation time on MIC values measured in S. cerevisiae at 
24 and 48 h. MICs values were determined using the EUCAST broth microdilution assay 
following 24 and 48 h incubation with the light activated compound. The MIC was 
determined to be the compound concentration at which 50% of the growth in the absence 
of compound is inhibited. The five shortlisted blue light treated compounds were used in 
a twofold serial dilution (0-25 µg/ml). Data shown as means of triplicates ±SEM. Two-
way ANOVA analysis was used to determine significant results. 
 
 
Figure 7.19 Effect of incubation time on MIC values measured in C. albicans at 24 
and 48 h MICs values were measured at 24 and 48 h to be the compound concentration 
at which 50% of the growth in the absence of compound is inhibited. The five shortlisted 
blue light treated compounds were used in serial twofold dilutions (0-25 µg/ml). Data 






































Results shown in Figures 7. 18 and 7.19 demonstrate that, following blue light 
activation of the compounds, the MICs against S. cerevisiae and C. albicans did 
not change between 24 and 48 h. Two-way ANOVA analysis of results was 
carried out to dhow significant differene. 
 
Supra-MIC growth (SMG) for tested compounds was quantified using the optical 
density method as the average growth per well obtained above the MIC at 24 and 




Figure 7.20 Effect of incubation time on SMG values measured in S. cerevisiae at 
24 and 48 h. Supra-MIC Growth (SMG) values were measured at 24 and 48 h as the 
average growth per well above the MIC divided by the compound-free growth control. 
The five shortlisted blue light treated compounds were used in serial twofold dilutions (0-
25 µg/ml). Data shown as means of triplicates ±SEM. ANOVA analysis of results shows 
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Figure 7.21 Effect of incubation time on SMG values measured in C. albicans at 24 
and 48 h. Supra-MIC Growth (SMG) values were measured at 24 and 48 h as the 
average growth per well above the MIC divided by the compound-free growth control. 
The five shortlisted blue light treated compounds were used in serial twofold dilutions (0-
25 µg/ml). Data shown as means of triplicates ±SEM. ANOVA analysis of results shows 
significant difference between SMG at 24h and 48 h for Compounds 1, 2 and 43 *p >0.05.  
 
SMG values were measured at 24 and 48 h by measuring SMG in the broth 
microdilution assay (Figures 7.20 and 7.21). For all compounds tested, S. 
cerevisiae and C. albicans showed growth at concentrations above the MIC and 
there was a significant increase in the calculated SMG between 24 h and 48 h.  
Both fungal species exhibited growth at a drug concentration above the MIC, 
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7.2.7 Effect of blue light and activated compounds on 
mammalian cells 
7.2.7.1 Optimisation of the cell viability protocol 
The candidate compounds have all demonstrated antimicrobial activity, however, 
their effect on mammalian cells has not been determined. As any new 
antimicrobial reagent would be required to have minimal affect in host cells, the 
shortlisted compounds were tested to determine their toxicity in mammalian cells. 
The assays were performed using HeLa cells, an immobilised human cell line 
derived from cervical cancer cells. To determine the best time range for 
evaluating the effects of the compounds, a growth curve was performed over a 
period of four days. 
HeLa cells were seeded in 12-well plate at a density of 5,000 cells per well in 
EMEM. After 24, 48, 72 and 96 h incubation at 37˚C, three wells were trypsinised 
and the cell number determined by a manual cell count using a haemocytometer, 
and via trypan blue, to determine cell viability. This process was repeated three 
times in triplicate (Figure 7.22). The growth curve shows an increase in cell 
numbers over time, with a reduced growth rate at 96 h, indicating that compounds 
should be tested throughout 96 h post treatment. 
  
Figure 7.22 Growth curve for HeLa cells over a period of 24, 48, 72 and 96 h 
incubation. 5,000 cells/ml were seeded in EMEM and the cell number was determined 
by counting cells manually using haemocytometer. The experiments were conducted on 




















7.2.7.2 2,000 cells/well is the appropriate initial seeding density for the 
toxicity experiments 
PrestoBlue® is a resazurin-based cell permeable viability indicator that is quickly 
reduced by metabolically active cells (living cells). Production of the fluorescent 
reduced form can be measured (Ex 535 nm / Em 612 nm), providing a 
quantitative measure of viability and cytotoxicity. To optimise the assay for 
determining cell viability following exposure to the compound, the optimal cell 
number had to be identified. This was determined by measuring the linearity of 
fluorescence versus cell number to find a suitable working cell density. Cells were 
seeded into a 96 well plate at a final concentration of 500, 1,000, 2,000, 2,500, 
5,000 and 10,000 cells in EMEM complete medium and incubated for 24, 48, 72 
and 96 h. PrestoBlue®, at ratio 1:10, was then added to the cells for one hour 
and the fluorescence measured using a Tecan GENius PRO plate reader (Ex 535 
nm / Em 612 nm) (Figure 7.23). This process was repeated three times in 
triplicate. The graph obtained (Figure 7.22) illustrates the change in fluorescent 




Figure 7.23 The relationship between fluorescence and increasing HeLa cell 
number. The linearity assay was performed for HeLa cells after 24, 48, 72 and 96 h of 
incubation at 37˚C using the PrestoBlue® reagent. The initial seeding density was 500, 
1,000, 2,000, 2,500, 5,000 and 10,000 cells in EMEM complete media. Fluorescence 
represents mean values generated from three independent experiments in triplicate. 
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Figure 7.23 indicates that an initial seeding density of between 5,000 and 10,000 
cells/well, results in a consistent fluorescence signal across the time points, 
indicating saturation of the signal. When the initial cell seeding density is 
decreased to between 500 and 1,000 cells/well, there is a linear increase in the 
fluorescence signal over time, but the readings are relatively low (less than 3,000 
RFU). However, when the initial cell seeding density is 2 500 cells/well, there is 
a linear relationship between fluorescence and time which is consistent until it 
starts to plateau at 80 h. A linear increase in signal without the saturation plateau 
is seen with 2,000 cells/well, indicating that this is the appropriate initial seeding 
density for the toxicity experiments.  
 
7.2.7.3 Blue light alone has no effect on HeLa cells viability 
All of the candidate compounds have antimicrobial activity following exposure to 
20 min of blue light. Before investigating the effect of the activated compounds 
on the HeLa cells, experiments were undertaken to investigate the effect of blue 
light alone. The PrestoBlue® assay was used to provide a quantitative measure 
of cell viability in the presence and absence of blue light. 
To characterise the effect of blue light illumination alone on HeLa cells, HeLa 
cells were seeded at 2,000 cells per well, then incubated for 24 h before being 
exposed to blue light for 20 min (Figure 7.24). 20 min was used as, in the 
antimicrobial studies; this was determined to be the optimal time for compound 
activation. The cell viability was then measured using the PrestoBlue® assay at 
24 h, 48 h and 72 h post exposure, three times in triplicate. Data is shown as 
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Figure 7.24 Cell viability in HeLa cells following 20 min exposure to blue light. The 
viability assay was performed for HeLa cells after 24, 48, and 72 h of incubation at 37˚C 
using the PrestoBlue® reagent. Cell viability was expressed by fluorescence values. The 
experiment was conducted in triplicate, n=3. Data shown as means ±SEM. ANOVA 
analysis of results shows no significant effect of blue light treatment in comparison with 
the control. 
 
It can be noted that there was no significant difference in viability between the 
treated and non-treated samples after 24, 48 and 72 h (Figure 7.24).  
  
7.2.7.4  All candidate compounds significantly reduced HeLa cells’ 
viability  
The five shortlisted compounds with antimicrobial activity (Table 7.1), were 
studied in HeLa cells to assess their toxicity at the MICs determined in microbial 
cells. 
HeLa cells were seeded at 2,000 cells per well and incubated for 24 h before 
treatment with the blue light activated compounds. The concentrations used were 
the highest MICs obtained following the antimicrobial studies, 25 µg/ml and 32 
µg/ml. The cell viability was measured using the PrestoBlue® assay at 24 h, 48 
h and 72 h following treatment. As controls, HeLa cells were both left untreated 
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and treated with a vehicle control, 0.625% DMSO, which was the highest DMSO 
concentration used in antimicrobial testing. The experiment was conducted in 
triplicate, n=3. Two-way ANOVA analysis of results was conducted. Data is 
presented as relative fluorescence intensity (RFU) following exposure of the cells 
to different conditions.  























































1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
U n t r e a t e d
D M S O  0 . 6 2 5 %
C o m p o u n d  1  ( 2 5  g / m l )
C o m p o u n d  1  ( 3 2  g / m l )
*
* * * *
 
Figure 7.25 Cell viability of HeLa cells treated with blue light activated Compound 
1. HeLa cells were seeded at an initial density of 2,000 cells. Following 24 h incubation 
cells were either untreated, treated with 0.625% DMSO or activated Compound 1. The 
viability assay was performed for HeLa cells after 24, 48, and 72 h of incubation at 37˚C 
using the PrestoBlue® reagent. Cell viability was expressed by fluorescence values. The 
experiment was conducted in triplicate, n=3. Data shown as means ±SEM. ANOVA 
analysis of results shows no significant effect of the control cells treated with 0.625% 
DMSO and an overall significant effect of treatment with Compound 1 in comparison with 
untreated cells. *p >0.05 comparing viability of untreated and compound treated HeLa 



















































1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0 U n t r e a t e d
D M S O  0 . 6 2 5 %
C o m p o u n d  2  ( 2 5  g / m l )
C o m p o u n d  2  ( 3 2  g / m l )
* * * *
 
 
Figure 7.26 Cell viability, determined by PrestoBlue, in HeLa Cells treated with two 
varying concentrations (25, 32 μg/ml) of Compound 2, HeLa cells treated with 
0.625% DMSO and untreated HeLa cells. The viability assay was performed for HeLa 
cells after 24, 48, and 72 h of incubation at 37˚C using the PrestoBlue® reagent. Cell 
viability was expressed by fluorescence values. The experiment was conducted in 
triplicate, n=3. Data shown as means ±SEM. ANOVA analysis of results, show no 
significant effect of the cells treated with 0.625% DMSO and two concentrations (25, 32) 
μg/ml of Compound 2 in comparison with untreated cells after 24 h of treatment. ****p > 
0.0001 comparing viability of untreated and compound treated HeLa cells after 48 and 

















































1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0 U n t r e a t e d
D M S O  0 . 6 2 5 %
C o m p o u n d  1 1  ( 2 5  g / m l )
C o m p o u n d  1 1  ( 3 2  g / m l )
* * * **
 
Figure 7.27 Cell viability, determined by PrestoBlue, in HeLa Cells treated with two 
varying concentrations (25, 32 μg/ml) of Compound 11, HeLa cells treated with 
0.625% DMSO and untreated HeLa cells. The viability assay was performed for HeLa 
cells after 24, 48, and 72 h of incubation at 37˚C using the PrestoBlue® reagent. Cell 
viability was expressed by fluorescence values. The experiment was conducted in 
triplicate, n=3. Data shown as means ±SEM. ANOVA analysis of results, show no 
significant effect of the cells treated with 0.625% DMSO and two concentrations (25, 32) 
μg/ml of Compound 11 in comparison with untreated cells after 24 h of treatment. 
****p>0.0001 comparing viability of untreated and compound treated HeLa cells after 48 




















































1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
U n t r e a t e d
D M S O  0 . 6 2 5 %
C o m p o u n d  3 6  ( 2 5  g / m l )
C o m p o u n d  3 6  ( 3 2  g / m l )
* * * *
*
 
Figure 7.28 Cell viability, determined by PrestoBlue®, in HeLa Cells treated with 
Two varying concentrations (25, 32 μg/ml) of Compound 36, HeLa cells treated with 
0.625% DMSO and untreated HeLa cells. The viability assay was performed for HeLa 
cells after 24, 48, and 72 h of incubation at 37˚C using the PrestoBlue® reagent. Cell 
viability was expressed by fluorescence values represent. The experiment was 
conducted in triplicate, n=3. Data shown as means ±SEM.  ANOVA analysis of results, 
show no significant effect of the control cells treated with 0.625% DMSO and an overall 
significant effect of treatment with Compound 24 in comparison with untreated cells. 
*P>0.05 comparing viability of untreated and compound treated HeLa cells after 24 h of 




















































1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
U n t r e a t e d
D M S O  0 . 6 2 5 %
C o m p o u n d  4 3  ( 2 5  g / m l )
C o m p o u n d  4 3  ( 3 2  g / m l )
* * * * *
 
Figure 7.29 Cell viability, determined by PrestoBlue, in HeLa Cells treated with two 
varying concentrations (25, 32 μg/ml) of Compound 43, HeLa cells treated with 
0.625% DMSO and untreated HeLa cells. The viability assay was performed for HeLa 
cells after 24, 48, and 72 h of incubation at 37˚C using the PrestoBlue® reagent. Cell 
viability was expressed by fluorescence values. The experiment was conducted in 
triplicate, n=3. Data shown as means ±SEM. ANOVA analysis of results, show no 
significant effect of the control cells treated with 0.625% DMSO and an overall significant 
effect of treatment with Compound 31 in comparison with untreated cells. *p>0.05 
comparing viability of untreated and compound treated HeLa cells after 24 h of treatment, 
while ****p>0.0001 after 48 and 72 h of treatment. 
 
 
At the concentration tested (0.625%), DMSO showed no toxicity against HeLa 
cells as their viability had not changed significantly when compared to that of 
untreated cells (Figures 7.25 to 7.29) after 24, 48 and 72 h of incubation.  
Following treatment with all five shortlisted compounds in the presence of blue 
light the fluorescence values dropped significantly after 24, 48 and 72 h 
incubation when compared to the controls. This demonstrates a significant 
reduction in the viability of HeLa cells, with little difference observed between the 
two test concentrations (Figures 7.25 to 7.29). 
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When testing the compounds alone in the absence of blue light fluorescence, 
values also reduced significantly when compared to untreated cells (data not 
shown).  
7.3 Discussion 
Based on their antimicrobial activity, five compounds were shortlisted for further 
testing including acridine based Compounds 1, 2 and 11 and acridine-
isoalloxazine based Compounds 36 and 43. All of these compounds had MICs 
below 32 μg/ml against the tested bacterial and fungal species (Table 7.1). These 
compounds were further characterised to determine whether they had the 
potential for clinical use.  Further, additional information on these shortlisted 
compounds could inform further formulation improvements. 
 
7.3.1 All shortlisted compounds are static against the tested 
fungal and bacterial species  
Antimicrobial agents are classified as either static, which inhibit microbial growth, 
or cidal, that actively kill microbes. 
Analysis of the shortlisted compounds within this study have indicated that they 
are all static to both fungi and bacteria (Table 7.2). This contrasts with other 
studies using photoactive acridine compounds, specifically acridine orange, 
where a bactericidal effect against S. aureus and E. coli was observed 
(Wainwright et al., 1997). The discrepancy between results is possibly due to the 
bactericidal activity of acridine orange in the absence of light, which was not 
observed in our tested compounds. Additionally, the effect of blue light alone (400 
-450 nm) was not investigated within this study. Therefore, the bactericidal results 
seen following light activation may have resulted from a cumulative effect. 
Other studies have also demonstrated that PDT has fungicidal effect against 
Candida species by using a viable cell counting method (Dovigo et al., 2011; 
Zhang et al., 2016). In contrast, the method utilised in this study relies on taking 
the sample from the first well with no visible growth, which may mean some viable 
cells are still present. The control drugs used in this study were shown to be static 
(fluconazole) and cidal (gentamicin), which agreed with Calderón et al., 2007 and 
confirmed that the method is accurate. 
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ROS generally have a reversible effect, which depends on the level of ROS and 
the target (Magder, 2006, Dharmaraja, 2017). This suggests that the ROS 
released from the PDT compounds in this study are probably at low enough levels 
that the cell can adapt. 
Various studies have found that cidal and static compounds have similar 
effectiveness when used to control clinical infections, with no differences 
observed in clinical responses or mortality (Nemeth et al., 2015; Wald-Dickler et 
al., 2017). This suggests that, although static to the microorganisms tested, these 
compounds may still be clinically effective. There are important factors affecting 
the response to antimicrobial therapy, including host defence systems, optimal 
dosing, pharmacokinetics and inadequate penetration of the infection site (Estes 
et al., 1998). 
 
7.3.2 Development of resistance of PDT 
The growing emergence of antimicrobial treatment resistance is spreading 
worldwide, threatening the effectiveness of antimicrobials and increasing 
mortality rates, for example methicillin-resistant Staphylococcus aureus (MRSA) 
infections cause 11,285 deaths per year in the USA (Alanis, 2005, Hawkey, 
2008). Microbial resistance usually occurs more rapidly with static agents than it 
does with cidal agents (Gould et al., 2002). As the shortlisted compounds are 
static, there may be an increased chance of resistance developing. Data 
presented in this chapter indicates that, following three repeated exposures to 
suboptimal concentrations of the shortlisted compounds, no obvious resistance 
was detected in the microorganisms tested. This is consistent with data from 
other studies in fungi and bacteria following repeated exposure to the PDT agents 
(Giuliani et al., 2010; Tavares et al., 2010).  
Microbes have developed many mechanisms to increase their resistance to 
antimicrobial agents. These mechanisms include a thickening of their outer wall, 
mutations within the target protein, encoding of new proteins which prevent the 
penetration of agents, and an increase in efflux transporters to remove 
compounds from the cell (Tavares et al., 2010). However, evidence suggests that 
resistance to PDT agent does not develop due to the absence of a specific target 
(Dougherty et al., 1998; Castano et al., 2004). In PDT, both types of reaction 
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release highly toxic reactive oxygen species (ROS) such as free radicals and 1O2, 
able to inflict damage in a multi-target process to cytoplasmic membrane, cell wall 
and DNA. Due to this property of PDT development of resistance to ROS is 
seldom observed (Giuliani et al., 2010) . Additionally, cell wall structures and 
membranes are the main targets of photoactivated compounds, and for this 
reason, the target cells have no chance to develop resistance by stopping uptake 
or influx of the drugs as proper adhesion to these structures is usually sufficient 
to damage the target cell without the need for penetration inside the cells. 
However, the number of exposures was significantly higher than that of our study, 
which should be considered in future work.  
 
7.3.3 Effect of pH and EDTA on in vitro susceptibility to 
photoactivated compounds 
7.3.3.1 pH effect 
The aim in this study is to investigate whether the external environment influences 
the efficacy of the tested PDT compounds in clinical situations, which may affect 
the optimal site of action for compounds. The medium conditions, including 
temperature and pH, result in phenotypic, metabolic and physical changes in 
fungi and bacteria (Carvalho et al., 2009; Sherrington et al., 2017). The site of 
action of a variety of fungi include the stomach, skin and vagina. Given that these 
sites vary greatly in pH, for example vaginal pH is 4-4.5 and the intestine pH 
ranges between 5.5 and 7, we studied the effect of pH on the in vitro activity of 
blue light shortlisted compounds and fluconazole against the fungi S. cerevisiae 
and C. albicans using EUCAST susceptibility testing in the presence of MOPS. 
The antifungal agent used to inactivate fungi grown in vagina of pH 4-4.5 should 
be effective at correspondingly acidic conditions. 
Acidic environments alone, particularly at pH 4 to 5, have exhibited a growth 
inhibition effect on fungi due to the increased sensitivity of β-glucanase, which 
breaks down the fungal cell wall by affecting β-glucan, the major component of 
the fungal cell wall (Sherrington et al., 2017; Mayer et al., 2013; Weckwerth et al., 
2012). However, the pH change can be overcome by the adaptive response 
induced in fungi, as fungi have the ability to actively modify the pH of their 
environment by secreting natural acids or alkali (Vylkova et al., 2011; Ramon et 
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al., 1999; Vylkova et al., 2017). Additionally, pH changes may trigger hyphal 
formation in fungi, which is generally accepted to be more resistant than the yeast 
form (Ceccato-Antonini et al., 2004; Ramon et al., 1999). This concept supports 
the findings observed in this study and might cause S. cerevisiae and C. albicans 
to become more resistant (Figure 7.6 and 7.8). 
In the present study, the MIC of fluconazole, Compound 1, Compound 2 and 
Compound 36 was mostly affected by a decrease in pH, in the presence of MOPs. 
These compounds showed at least a threefold increase in MIC against S. 
cerevisiae and a twofold increase in MIC against C. albicans, when the pH was 
decreased from 7 to 4. A similar trend was observed for Compounds 11 and 43, 
showing less than a twofold increase in MIC against S. cerevisiae and C. 
albicans, ranging between 16.67 and 25 µg/ml (Figure 7.6 and 7.8). In general, a 
decrease in pH resulted in a decrease in the susceptibility of S. cerevisiae and C. 
albicans to the photoactivated antimicrobial compounds. The presence of 
chlorine in the structures of Compounds 11 and 43 may indicate that they are 
less affected by the change in pH.  
 
The antifungal agent, fluconazole, used in this study showed a decrease in 
susceptibility of S. cerevisiae and C. albicans when pH was dropped from 7 to 4 
(Figures 7.6 and 7.8). This data supports the results of several reports conducted 
on different azole antifungals including fluconazole which exhibited a similar 
decreasing trend in the susceptibility of C. albicans when pH was reduced, as 
higher fluconazole concentration was necessary in an acidic environment (pH 4 
to 5.5) than in neutral condition (pH 7) to achieve the same growth inhibition 
extent. This may suggest to result from the fact that changes in pH instigate 
marked changes in the cell wall, which may influence the susceptibility of S. 
cerevisiae and C. albicans to fluconazole, or a potential consideration is the 
protonation of fluconazole, demonstrating reduced efficacy against fungal cells 
(Danby et al., 2012; Vasconcellos et al., 2014). Further to this, it has been shown 
that acidic pH decreases the susceptibilities of the Bacteroides fragilis group to 
several antibiotics including ciprofloxacin, ampicillin-sulbactam and clindamycin 
(Falagas et al., 1997). The effect of pH on in vitro susceptibilities of bacteria is 
suggested to be due the pH impact either on the permeability of bacteria to 




Studying the effect of pH change on the efficacy of PDT agent, polyethylenimine-
chlorin(e6) conjugates, showed that although pH decreased, the cellular uptake 
of the compound was not affected (Huang et al., 2011). In the case of the less 
susceptibility of bacteria S. aureus and E. coli to the previous PDT agent, which 
was observed when pH decreased, it is suggested that the pH drop influenced 
the compound itself (Huang et al., 2011) . This may potentially support the 
suggestion that PDT shortlisted compounds in this study are inactivated by pH 
drop. 
     
The impact of pH on decreasing in vitro susceptibilities of fungal and bacterial 
cells to antimicrobials by increasing the MIC may be mediated through a variety 
of mechanisms. Firstly, as pH can influence the permeability of microbes to 
antimicrobials (Cuchural et al., 1988) this suggests that the shortlisted 
compounds used in this study have been prevented, to some level, from the 
adhesion or penetration into the examined microbes which would reduce the ROS 
killing effect. Secondly, the stability and activity of enzymes which inactivate 
antimicrobials are influenced by pH. Finally, the stability and kinetics of the 
shortlisted compounds are suggested to be affected by pH change (Smith et al., 
1990). Additionally, pH effect may influence fungal growth and instigate 
conversion from the yeast to the hyphal form, which is more resistant to all 
antimicrobial compounds (Ramon et al., 1999). 
The EUCAST method to assess antimicrobial activity, involves the addition of a 
buffering agent, MOPS, to the media. Results presented in this chapter indicate 
that removal of MOPS from the media has no significant impact on the 
effectiveness of the compounds at the various pH levels tested. 
It has been shown that C. albicans cells grown in unbuffered medium are able to 
modulate pH changes, thus, the effect of the antifungal is negated via the 
manipulation of extracellular pH (Kulkarny et al., 2014; Vylkova, 2017).  
 
Using two PDT agents methylene blue (MB) and toluidine blue (TB) as 
photosensitising drugs, phototoxicity effects observed were not related to the 
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specific pH values of the medium, they were attributed to the ability of the medium 
to permit changes in the pH values (Carvalho et al., 2009). It has been found that 
in a saline buffered medium the phototoxicity effects with either MB or TB, 
significantly decreased compared to that of non-buffered saline, due to the ability 
of the saline medium to control the pH. MOPS was also the buffer used to resist 
pH changes, but the medium in our study was RPMI, which may potentially 
possess a reduced ability to control pH change. 
 
7.3.3.2 EDTA effect 
The aim in this study is to investigate the role of metal ions present in the external 
environment in the activity of the tested PDT compounds by using EDTA, an 
effective chelator of magnesium and calcium. EDTA was used in combination 
with antimicrobials to evaluate the resultant antimicrobial potency. 
This study has investigated the EDTA effect on in vitro susceptibility of S. 
cerevisiae and C. albicans to fluconazole and blue light treated shortlisted 
compounds in the presence of MOPS buffer. Comparison of the MIC values for 
S. cerevisiae and C. albicans following treatment with the photoactive 
compounds in the presence of 10 mM EDTA, resulted in a significant decrease 
in the MIC when compared to control groups and EDTA alone (Table 7.5). The 
presence or absence of MOPS did not exhibit any significant impact on these 
results.  
As 10 mM EDTA alone had no observable impact on the growth of the cells, it is 
suggested that the presence of the EDTA is affecting the susceptibility of the 
fungal cells to the photoactivated compounds. EDTA chelates the divalent cations 
Mg+2 and Ca+2 (George et al., 2009), which are present in the cell wall of both 
fungi and bacteria. Removal of these ions can result in damage, making S. 
cerevisiae and C. albicans cells more permeable, and therefore susceptible, to 
the photoactivated compounds. Although this study showed that EDTA alone had 
no significant effect on S. cerevisiae and C. albicans, there are studies which 
demonstrate that EDTA does itself have an antimicrobial effect. However, an 
effect was only seen with a concentration of EDTA significantly higher than 
utilised in this study, 0.6 M compared to 10 mM (Şen et al., 1997) . 
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It has been demonstrated that EDTA has potential antifungal activity against C. 
albicans using a broth microdilution method. This activity is attributed to its 
chelating property, as calcium ions play a critical role in the morphogenesis and 
pathogensis of C. albicans. Therefore, it may be expected that other chelating 
agents would also possess antifungal potential (Ates et al., 2005, Li et al., 2018).  
 
EDTA concentration at 17%, which is 200-fold higher than the concentration used 
in our study, exhibited significant antifungal activity against C. albicans when 
using an agar diffusion test, which has been related to the severe collapse in cell 
wall by removing calcium, inhibiting enzyme reactions and limiting nutritional 
conditions with this mechanism (Şen et al., 1997). When testing C. albicans 
biofilms EDTA alone was used at a concentration much higher than that used in 
our study at 25 mM against C. albicans biofilms At this concentration it was 
observed to demonstrate significant activity against C. albicans biofilms by 
employing the XTT assay to test viability of biofilms (Casalinuovo et al., 2017).  
 
Gram-negative bacteria occasionally exhibit resistance to PDT, consequently it 
was suggested to pre-treat them with EDTA, which can cause Gram-negative 
bacteria to lose up to 50% of their lipopolysaccharide and thus become more 
sensitive to PDT agents (Sperandio et al., 2013). This approach was used by 
treatment of S. epidermidis biofilms with EDTA followed by TBO as a PDT agent. 
The treatment with 89 mM EDTA helped to disrupt biofilm structure and increase 
the permeability of TBO and this thus enhanced the photodynamic efficacy of 
TBO (Fu et al., 2013). While the concentration of EDTA used in this study did not 
show any antimicrobial activity alone it is possible that increased susceptibility of 
the fungal cells to the compounds occurred in EDTA’s presence, due to a 
synergistic effect (Table 7.5). The reason for this finding is potentially related to 
the ability of EDTA to make the outer wall of S. cerevisiae and C. albicans more 
permeable, and allow photoactivated shortlisted compounds to penetrate and 
accumulate inside. These compounds are then photoactivated, thus releasing 




7.3.4 Mechanism of action of the photoactivated antimicrobial 
compounds 
The mechanism of action of photoantimicrobial therapy has been discussed 
extensively and demonstrated to result from the interaction of photons of visible 
light with photosensitising agents known as photosensitisers (Dougherty et al., 
1998). Following absorption of light photons of specific wavelengths, the 
photosensitisers produce free radicals and singlet oxygen via Type 1 and Type 2 
reactions, respectively. These resultant species have the ability to attack cellular 
targets and kill the microbial cells (Baltazar et al., 2015). 
In this study, photochemistry data demonstrated that the shortlisted compounds 
released singlet oxygen following exposure to blue light (Table 3.3). As these 
findings did not correlate with photobiological data and radical species could not 
be measured, this study attempted to determine the mechanism of action of the 
compounds using S. cerevisiae deletion strains.  
In S. cerevisiae, many stresses are signalled through the high osmolarity glycerol 
(HOG) MAPK pathway, including osmotic, metal and oxidative stress, pH and 
citric acid (Saito et al., 2004; Pascual-Ahuir et al., 2007; Bilsland et al., 2004). 
One of the downstream targets of the HOG pathway are the transcription factors, 
Msn2/4p, which are also activated in response to oxidative stress. Specifically, 
Msn2/4p are responsible for activation of oxidative stress response by binding to 
the stress response element (STRE) within specific genes (Hasan et al., 2002). 
For example, in response to hydrogen peroxide, they activate transcription of the 
antioxidant defence genes, CTT1 and SOD1 (Hasan et al., 2002). As a result, 
deletion of the genes encoding these proteins results in sensitivity of cells to 
oxidative stress and specifically to hydrogen peroxide, a resultant radical species 
(Pascual-Ahuir et al., 2007; Martinezpastor et al., 1996). Therefore, if the 
antimicrobial activity of the shortlisted compounds is via this mechanism, we 
would expect to see a decrease in the MIC of the relevant deletion strains when 
compared to the wildtype control.   
To confirm that the deletion strains exhibited sensitivity to ROS, hydrogen 
peroxide (H2O2) was used as a control. As expected, both deletion strains, 
msn2/4  and hog1, were more sensitive than the wildtype (Figure 7.10). This 
is consistent with other research findings, which demonstrated that the encoded 
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proteins, Hog1p and Msn2/4p have a significant role in resistance to H2O2, with 
the effect being more profound for Msn2/4p (Hasan et al., 2002; Bilsland et al., 
2004). 
 
The MICs for the photoactivated Compounds 1, 2 and 36, showed a similar trend, 
with both mutant strains showing increased sensitivity. However, msn2/4 was 
significantly more sensitive than hog1 when compared to the wildtype (Hasan 
et al., 2002).  
 
Compared to other stresses, Hog1p phosphorylation and accumulation in the 
nucleus following oxidative stress is delayed, which indicates a lesser role for this 
protein in the oxidative response (Bilsland et al., 2004) . Although the transcription 
factors Msn2/Msn4p are targets of the HOG pathway as part of the general stress 
response, they are also activated by oxidative stress via a number of other 
signalling pathways. This includes the negative regulators, Ras/protein kinase A 
pathway (PKA), which are down regulated following oxidative stress causing 
activation of Msn2/4 (Costa et al., 2001) . These findings are consistent with 
results following hydrogen peroxide stress, the msn2/4 strains are more 
sensitive to Compounds 1, 2 and 36 when compared to hog1, although the MIC 
is still reduced compared to the wildtype control. This suggests that Compounds 
1, 2 and 36 are inhibiting cell growth via oxidative stress resulting mainly from 
H2O2, a direct precursor of hydroxyl radicals (Hasan et al., 2002; Costa et al., 
2001). Testing the shortlisted compounds alone in the absence of light did not 
demonstrate any significant inhibitory effect against the examined strains. This 
current study and the aforementioned studies showed that the msn2/4 
transcription factors play an important role in the cellular response to these 
particular photoactivated chemicals. 
For Compounds, 11 and 43 no significant differences in the MICs were observed 
between wildtype S. cerevisiae and the mutant strains. This indicates that these 
compounds must inhibit growth via an alternative mechanism. The lack of 
response in the hog1 suggests that these compounds are not causing any level 
of detectable general stress to the cell. 
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This data has been obtained in S. cerevisiae, however, is it possible that a similar 
mechanism of action occurs in bacteria. In regard to bacterial response to 
oxidative stress, it is coordinated mainly by two regulons, SoxRS and OxyR, 
which respond to oxidative stress induced by ROS including superoxide anion, 
hydrogen peroxide and singlet oxygen (Netto et al., 2007, Lushchak, 2011). 
Bacteria show much less complicated pathways of response to oxidative stress 
than fungi (Lushchak et al., 2011). It was supposed that regulatory proteins SoxS 
and OxyR are sensors responding to increased hydrogen peroxide level in 
bacteria. Both forms bind to DNA but with different binding specificity, activating 
the expression of SoxRS and OxyR genes and resulting in increased protein 
levels (Hidalgo et al., 1997; Imlay, 2015). The sensing step involves the oxidation 
of sensor molecules. E. coli is the most widely model system studied to 
investigate the oxidative stress in bacteria (Imlay, 2015). To detect oxidative 
stress in bacteria E. coli mutants that lack oxyR have been shown more sensitive 
to hydrogen peroxide than wildtype strains. Additionally, mutants that lack either 
set of superoxide dismutases and catalases that degrade superoxide and 
hydrogen peroxide, cannot grow when reacted with ROS (Keyer et al., 1996; 
Touati et al., 1995) .   
In general fungi are more resistant to oxidative stress than bacteria which is 
reflected in the results obtained in our study, showing slightly more susceptibility 
of bacteria than fungi to the PDT shortlisted compounds. 
 
7.3.5 In vitro antifungal susceptibility testing of C. albicans 
biofilms 
As described earlier within this chapter, the shortlisted compounds exhibited 
antifungal activity against planktonic C. albicans cells, when activated with a dose 
of 115 J/cm2 470 nm blue light for 20 min (Table 7.1). C. albicans pathogens 
typically form biofilm structures in clinical situations, which exhibit increased 
resistance to antifungal agents. As a consequence, this study evaluated the 
photoantifungal activity of the shortlisted compounds against C. albicans biofilm 




One of the main features of biofilms is that they are more resistant to broad-
spectrum antimicrobial drugs when compared to planktonic cells (Tsang et al., 
2007; Punithavathy et al., 2012; Khan et al., 2011). In C. albicans, this decreased 
susceptibility is thought to be due to reduced penetration through the biofilm 
layers. These layers, which contain extracellular polymer matrix, in combination 
with the presence of efflux pumps, contribute to the increased resistance of C. 
albicans biofilms to antifungal drugs (Punithavathy et al., 2012).      
This supports the findings in this present study, which demonstrated that all the 
tested compounds, including the controls, exhibited a reduced effect on the 
metabolic activity of C. albicans biofilms when compared to planktonic C. 
albicans. For both control antifungal drugs, fluconazole and amphotericin B, the 
results (Figures 7.11 and 7.12) agreed with the published literature (Casalinuovo 
et al., 2017; Chamilos et al., 2005; Pierce et al., 2008).  
Overall, the biofilms were more sensitive to amphotericin B than fluconazole, with 
2 µg/ml of amphotericin B resulting in > 50% reduction in metabolic activity 
(Figure 7.12), while fluconazole showed no effect at any of the concentrations 
tested (Figure 7.11). The discrepancy in susceptibility of C. albicans biofilms to 
fluconazole and amphotericin B may be explained in two ways. Firstly, it is 
suggested that the cell viability of biofilms treated with fluconazole could be due 
to a selection of drug-resistant cells, or to the proliferation of pre-existing persister 
cells: specific gene expression patterns in biofilm mass after fluconazole 
treatment, may be implicated (Punithavathy et al., 2012). Secondly, the unique 
activity of amphotericin B can be attributed to its different mechanism of action, 
by forming pores in cell membrane following binding to membrane ergosterol, 
causing direct loss of cytosol and hence loss of viability, while fluconazole acts 
by inhibition of ergosterol synthesis without fungal cell disintegration (Van de 
Sande et al., 2010; Chamilos et al., 2005). 
All light activated shortlisted compounds screened in this study caused a 
decrease in the metabolic activity of the C. albicans biofilms. Only Compounds 1, 
2 and 36, at a concentration of 25 µg/ml, showed a significant reduction in 
metabolic activity (approx. 30 %) when compared with the untreated control 
(Figure 7.13 to 7.17). Neither the compounds nor blue light alone reduced 
significantly the metabolism of C. albicans biofilms (Figures 7.13 to 7.17). 
Compounds 1, 2 and 36 had approximately similar activity to Compounds 11 and 
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43 against tested fungi and bacteria; however, Compounds 11 and 36 did not 
significantly affect C. albicans biofilms. This indicates that the initial ranking of 
activity did not correlate with the results for biofilm data. 
The results of Compounds 1, 2 and 36 are consistent with data from a number of 
different PDT agents (methylene blue and toluidine blue), which showed activity 
against C. albicans biofilms (De Melo et al., 2013; Shi et al., 2016). Notably higher 
inactivation was achieved on the metabolism of planktonic C. albicans, when 
compared to biofilm data (Hu et al., 2018; Hosseini et al., 2016). This supports 
the findings for Compounds 1, 2 and 36, which affected planktonic C. albicans 
significantly more than C. albicans biofilm when using the same XTT viability 
method. 
The antimicrobial effect of aPDT is dependent both on cellular localisation of the 
photosensitiser and on the diffusion of ROS (radicals and 1O2) which should be 
sufficient to inactivate biofilm structure (Hosseini et al., 2016; Hu et al., 2018). 
Although Compounds 11 and 43 demonstrated relatively similar efficacy to 
Compounds 1, 2 and 36 in initial antimicrobial testing, their effect on biofilms was 
different. The reduced effect of Compounds 11 and 43 on the C. albicans biofilms 
is suggested to be due to the limited penetration of the compounds during the 
PDT process into biofilm structure, which leads to reduced photoantifungal 
activity. Additionally, ROS species (the damaging factors in PDT) cannot travel 
very far before disappearing (Vatansever et al., 2013), thus this may suggest that 
Compounds 11 and 43 did not localise close to the target. One important point is 
that Compounds 1, 2 and 36 are working via the activation of msn2/4 in oxidative 
stress while Compounds 11 and 43 have been suggested to work via another 
mechanism. This may suggest that the unknown mechanism of Compounds 11 
and 43 was affected negatively when testing biofilms.   
PDT can be used to treat bacterial biofilms as it has been demonstrated that 
methylene blue can be an effective PDT agent against S. aureus biofilms by 
inhibiting their growth (Briggs et al., 2018). Different sensitivity of microbial 




7.3.6 Measurement of supra-MIC growth (SMG), an indication of 
perseverance 
In the case of treatment of Candida infections, a new drug response parameter 
termed perseverance, defined as supra-MIC growth (SMG), has been identified. 
This correlates with clinical outcomes in patients treated with antifungal agents 
and reflects the possible persistence of C. albicans in clinical settings (Rosenberg 
et al., 2018). Perseverance relative to the minimum inhibitory concentration (MIC) 
was measured, using the standard EUCAST assay over two consecutive days, 
to provide information about both resistance and perseverance.  
 
Perseverance (SMG) is correlated with a subpopulation of cells (represented by 
OD) that grows at concentrations above the MIC. The SMG values of fluconazole 
in this study were slightly lower than that measured in the study conducted by 
Rosenberg et al., 2018. Blue light alone did not show any significant growth 
inhibition and did not have any impact on SMG. 
For all shortlisted compounds (1, 2, 11, 36 and 43) and fluconazole, the SMG 
values increased significantly between 24 and 48 h.  
Although the SMG increased for all the compounds tested, the MIC values 
determined against C. albicans did not change (Tables 7.18 and 7.19). It is 
suggested that perseverance is dependent upon pathways that do not affect the 
MIC and therefore can predict the possibility of failure or success of treatment in 
the clinic. This is reflected in our results, which showed that SMG increased 
significantly while the MIC of the shortlisted compounds did not change between 
24 and 48 h. The reason behind this is unclear as the mechanisms behind the 
development of SMG have not yet been determined (Rosenberg et al., 2017).  
It has been reported that strains with higher SMG levels may relate to the failure 
of antifungal compounds to clear an infection despite an isolate being compound 
susceptible (Rosenberg et al., 2018). This supports the suggestion that the 
significant increase in SMG values between 24 and 48 h in this study can predict 
that the studied C. albicans strain is more likely to give rise to persistent and/or 
recurrent infections.   
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Previous experiments, using mouse models and infection outcomes, have 
suggested that there was no relationship between the SMG phenomena and 
virulence (Rex et al., 2002; Bennett et al., 2003). However, it is believed that this 
discrepancy is due to the analysis of the immediate response rather than the 
clinical persistence or recurrence over long periods (Rosenberg et al., 2017). 
 
7.3.7 Effect of candidate compounds on mammalian cells 
As any new antimicrobial agent would be required to have minimal affect in host 
cells, the shortlisted compounds were tested to determine their effect on 
mammalian cells. HeLa cells, an immobilised human cell line derived from 
cervical cancer cells, were chosen for testing as they reproduce rapidly, easily 
and cheaply (Suchland et al., 2003; Limban et al., 2008). Despite being 
cancerous, HeLa cells still have several characteristics in common with normal 
cells, as they produce proteins, express and regulate genes, and are susceptible 
to infections, which allows them to be used widely in antimicrobial testing 
(Hammerschlag, 1994, Wasson et al., 2012). 
The cellular growth curve for HeLa cell line was established to define the growth 
characteristics and determine the best time range for evaluating the effects of 
biological compounds. To provide a quantitative measurement of viability and 
toxicity, PrestoBlue® was chosen as it is faster and more sensitive than other 
assays such as 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazonium bromide 
(MTT) cell viability assay (Boncler et al., 2014). The greatest variable in viability 
assays is cell number, thus linearity of fluorescence versus cell number was 
studied to identify the optimal cell number. This was determined to be an initial 
seeding density of 2,000 cells/well, which was used for all future experiments.  
The principle of PDT depends on the activation of the photosensitisers through 
an appropriate light source, in this case blue light. To determine whether the blue 
light alone effects HeLa cells, cell viability was determined following a 20-minute 
blue light exposure (470 nm, 115 J/cm2). Treatment of HeLa cells with blue light 
demonstrated no significant effect on viability measured after 24, 48 and 72 h 
(Figure 7.21). This finding was in agreement with a previous study that used the 
same blue light wavelength but at a lower final irradiance dose of 3.7 J/cm2 than 
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used in this experiment (Yang et al., 2017). This result is further confirmed by 
data in human primary retinal epithelial cells and fibroblast cells, exposed to a 
similar wavelength and irradiance dose (Lee et al., 2014; Mayer et al., 2013). 
However, this contrasts with human promyelocytic leukaemia cell lines (HL60) 
where blue light has been shown to reduce their viability significantly (Zhuang et 
al., 2018). However, although a similar blue light wavelength was used to this 
study (470 nm versus 456 nm), the irradiation period was much longer (10 to 56 
h) (Zhuang et al., 2018). It is well established that shorter blue light wavelengths 
(405-415 nm) significantly decrease the viability of mammalian cells, including 
immortalised osteoblasts (OST 5) and normal human skin fibroblast 
(Ramakrishnan et al., 2016; Mamalis et al., 2015; Lee et al., 2014). The 
suggested mechanism of action for these shorter wavelength (405 nm) involves 
the photo-excitation of endogenous porphyrins, which in turn produce ROS 
(Vandersee et al., 2015; Yoshida et al., 2015). ROS are reactive species causing 
oxidative damage to cell components including proteins, lipids and nucleic acids 
(Lubart et al., 2011; Ramakrishnan et al., 2016). Therefore, the use of a longer 
wavelength (approx. 470 nm) and limited irradiation (110 J/cm2) in this study may 
indicate why there is no significant reduction in cell viability with blue light alone 
(Lee et al., 2014; Mayer et al., 2013). 
As the shortlisted compounds were initially resuspended in DMSO the effect of 
the vehicle alone was assessed as a control. The highest DMSO concentration 
used in the antimicrobial testing was 0.625%, thus this was used in the control 
studies. No significant reduction in cell viability was detected in the vehicle control 
when compared to that of untreated HeLa cells (Figures 7.21, 7.22, 7.23, 7.24 
and 7.25) at 24, 48 and 72 h. Our findings support several studies conducted also 
on HeLa cells, which found that DMSO only exhibits a cytotoxic effect at 
concentrations above 2% (Trivedi et al., 1990; Forman et al., 1999) . This is also 
consistent with findings in other mammalian cell lines including a haematopoietic 
progenitor cells (HPCs) and human adipose-derived adult stem cells (ASCs) 
(Timm et al., 2013; Galmes et al., 2002). 
 
The ideal photosensitiser should not exhibit any significant effect on the host cell. 
However, in this study, the treatment of HeLa cells with two concentrations of the 
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shortlisted light activated compounds significantly decreased their viability 
(Figures 7.25 to 7.29). Additionally, compounds alone demonstrated a significant 
reduction in viability of HeLa cells. Our photoactivated findings are inconsistent 
with data from a blue light activated acridine-based compound, acridine orange 
(AO), where no significant reduction in cell viability of human immortalised 
uroepithelial cells (SV-Huc-1) was reported (Lin et al., 2017). This difference in 
effect may be due to compound concentrations and the level of light activation 
used in these studies. The acridine orange was tested at a much lower 
concentration, 1µg/ml, compared to this study where compounds were tested at 
a concentration of 32 µg/ml. Further, despite using a similar activation 
wavelength, the irradiance dose (6 versus115 J/cm2) and duration (30 s versus 
20 min) were higher in this current study. Additionally, blue light with similar 
wavelength to our study did not affect also the cell viability of human immortalised 
uroepithelial cells (SV-Huc-1) (Lin et al., 2017). 
 
Treatment with compounds alone was shown to elicit toxicity without blue light 
illumination. This suggests that the compounds are toxic to HeLa cells via a non-
light activated mechanism, suggesting it is not via ROS production. Acridine-
based compounds act at the level of DNA-coiling enzymes (topoisomerases) and 
the damage is caused by the stabilisation of the enzyme-DNA cleavage complex 
(Wainwright, 2015). Thus, its mechanism of action explains why HeLa cell line 
showed reduced viability at 24, 48 and 72 h following treatment with 25 and 32 
µg/ml acridine-based compounds.  
It has been reported in previous studies that the structure-activity relationship in 
acridines is of great importance, as they have been shown to localise and act in 
different regions/organelles depending on a combination of lipophilicity and 
degree of ionisation (Wainwright, 2015; Lin et al., 2017). The toxicity of the 
examined compounds in this study against HeLa cells supports the idea of 






8. General discussion  
8.1 Overview of discussion  
The rise in opportunistic microbial infections in immunocompromised patients and 
the reduction in efficiency of currently available treatments has resulted in an 
unmet medical need. As a result, photodynamic therapy has become an 
increasingly important area of research. This project utilised a library of novel 
photoactivated compounds, developed around a number of key molecules 
including acridine, flavine and anthraquinones. These compounds were then 
investigated to determine their antimicrobial activity against a range of clinically 
important pathogenic fungi, including Candida albicans, Saccharomyces 
cerevisiae and Aspergillus spp, and medically important bacteria, including 
Escherichia coli and Staphylococcus aureus. 
Compounds were ranked based on their antimicrobial activity and the top five 
compounds were further characterised to determine whether they had a clinical 
use. This included assessing development of resistance, their mechanism of 
action, their ability to treat biofilm and their toxicity against mammalian cells.  
Ultimately, compounds identified in this study may lay the foundation for the 
development of a new group of PDT antimicrobial drugs, which will help in the 
fight against a number of medically important pathogens. 
 
8.2 Development of novel PDT compounds for use as 
antimicrobials 
Research published previously has demonstrated that acridine, flavin and 
anthraquinone-based compounds may have potential photosensitising activity as 
they can release radical and singlet oxygen species via Type 1 and Type 2 
reactions, respectively. Furthermore, PDT is emerging as an area of interest in 
the discovery of novel antimicrobial therapeutic approaches. Therefore, a set of 
novel synthesised compounds based around these core parental molecules were 
characterised under blue light exposure, which has been identified to be the 
corresponding visible light range for best excitation. 
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The key target criteria for PDT sensitisers is the production of toxic reactive 
oxygen species (ROS), either 1O2 or free radicals. These molecular species are 
able to interact with multiple biological targets within the cell, effectively killing 
unwanted microbes. The ability to produce satisfactory levels of 1O2 correlates 
with increasing the triplet excited state lifetime of a PS that can be obtained by 
increasing intersystem crossing (ISC) efficiency (Mehraban et al., 2015; Azenha 
et al., 2002; Pereira et al., 2011). To enhance ISC of the synthesised compounds, 
enabling more 1O2 production, hydroxyl and halogen atoms including Cl, I, F and 
Br were incorporated into the structures. This approach is supported by the 
findings of 1O2 measurement in this current study, which demonstrated that the 
most efficient 1O2 producers were the compounds substituted with halogens and 
hydroxyl groups. 
 
8.3 Clinical use of novel PDT compounds as antimicrobials  
With the development of new compounds which potentially have antimicrobial 
activity, it is important to have an accurate method to assess their therapeutic 
use. This study utilised the EUCAST microdilution broth assay to assess the 
susceptibility of microbial cells to the developed novel PDT compounds. This 
method is widely used within the field because it allows a quantitative 
measurement of MIC for antimicrobial compounds and reproducibility. However, 
this method is not without its limitations, including its high cost and difficulties in 
setting it up.  
There are a number of alternative methods used to determine the effectiveness 
of antimicrobial agents. Currently, the solid media-based disk diffusion method 
utilised for the photoantimicrobial screening does not provide quantitative MIC 
values and should be read visually. However, the disk diffusion method allows 
susceptibility testing to be conducted for microorganisms that may not be able to 
grow in the microbroth dilution method, while the disk diffusion method is more 
accurate as it assesses accurate growth inhibition by measuring only viable cell 
count.  
Based on the EUCAST method, of the fifty-nine photoactive compounds tested 
(Chapters 3, 4, 5 and 6), only thirteen acridine-based compounds and ten 
acridine-isoalloxazine compounds showed activity against both fungi and 
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bacteria. Interestingly, these compounds showed no significant growth inhibition 
in the absence of blue light, although acridines, such as acridine orange, enter 
the S. cerevisiae cell and accumulate in lysosomes or mitochondria or bind to 
DNA (Iwamoto et al., 1987; Lin et al., 2017). This suggests that these compounds 
are unable to enter the cell and thus unable to affect it at an intracellular level. As 
such, the antimicrobial activity of these compounds appears to result from the 
photoactivation of the compounds.  
Following photoantimicrobial screening of all tested compounds three acridine-
based compounds (1, 2 and 11), as well as two acridine-isoalloxazine based 
compounds (36 and 43), were shortlisted for further characterisation to determine 
whether they could move forward for clinical use (Figure 7.1). Upon examination 
of the data of these shortlisted compounds it can be observed that these 
compounds can be used as broad-spectrum antimicrobial agents against bacteria 
and fungi as the MIC values obtained were similar. 
A key fungal pathogen is Aspergillus fumigatus. Although this study exhibited 
photoantifungal activity for a selection of compounds against S. cerevisiae and 
C. albicans, the effects of photoactivation of tested compounds on A. fumigatus 
were shown to be insignificant. The reasons for the absence of effect can be 
ascribed to the fact that the high concentrations of mannitol present in the conidia 
of A. fumigatus can act as an antioxidant to scavenge ROS released during 
photosensitising activity of tested compounds and thus prevent oxidative 
damage. This concept is supported by evidence that A. fumigatus accumulates 
terhalose and mannitol in its spores to survive under a variety of stress conditions 
and also use mannitol as a ROS scavenger (Ruijter et al., 2003; Smirnoff et al., 
1989; Jennings et al., 1998). 
 
A fundamental difference in susceptibility to PDT agents between fungi and 
bacteria has been demonstrated and can be explained by their physiology and 
morphology (Jori et al., 2006; Vatansever et al., 2013). Photodynamic therapy 
against microorganisms is considered to be affected by the mechanism of the 
production of radicals and singlet oxygen that react against several cell target 
molecules including membrane lipids, cytoplasmic enzymes and nucleic acids 
(Castano et al., 2004; Liu et al., 2015) . The great difference in size and surface 
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area between the bacterial and fungal cells means that the amount of ROS 
needed to kill fungi is much greater than the amount necessary to kill the bacterial 
cell (Zeina et al., 2001; Demidova et al., 2004). This is supportive of the 
suggestion that the difference in susceptibility observed in this study may reflect 
differences in cell size as S. cerevisiae and C. albicans species are approximately 
25-50 times larger than the bacterial species, S. aureus and E. coli, and may 
therefore require more ROS to inactivate them.   
One of the key clinical issues associated with currently utilised antimicrobials is 
the development of resistance. All the shortlisted compounds were shown to be 
static not cidal, which may increase the possibility of cells developing resistance 
(Gould et al., 2002). However, evidence suggests that microbial resistance does 
not develop to PDT agents because of having multi-target impact on cell wall, 
cytoplasmic membrane and DNA (Giuliani et al., 2010). This was assessed within 
this study, with no resistance observed following repeated exposures to the 
shortlisted compounds. Although this agrees with data in the literature, the 
number of exposures in this study was significantly lower. Previously mentioned 
studies regarding the development of resistance have been conducted in in vitro. 
The major limitation of this study is that antimicrobial compounds act in conditions 
so remote from those that exist in infected patients and so the purely antimicrobial 
properties may be profoundly influenced by pharmacologic considerations, by the 
underlying condition of the patient, and by patient’s immunologic status 
(Greenwood, 1981; Dufour et al., 2015). It is suggested that the in vivo 
environment may encourage the development of resistance, which might not be 
reflected in in vitro testing as it has been shown that tracking in vivo resistance 
evolution using whole-genome sequencing (WGS) revealed that resistant 
subpopulations could emerge which is most likely to occur in the case of high-
burden infections (Van Hal et al., 2013; Howden et al., 2011). 
The possibility of failure or success of fungal treatment in the clinic has been 
suggested to correlate with the perseverance parameter (SMG) (Rosenberg at 
al. 2017). The increasing trend of SMG values between 24 and 48 h in S. 
cerevisiae and C. albicans (Figures 7.17 and 7.18) may relate to the possible 
failure of antifungals to clear fungal infections clinically, despite the tested fungi 
being shown to be susceptible to the compound. 
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The PDT shortlisted compounds may be of clinical importance for patients with 
microbial infections if their effect on mammalian cells is minimal. It has been 
demonstrated in Chapter 7 that treatment with these acridine-based compounds 
was observed to elicit toxicity with and without blue light irradiation using 
PrestoBlue® assay. The toxicity of the tested compounds in this study against 
HeLa cells supports the idea of possible DNA intercalation causing the obtained 
toxicity. Treatment of human immortalised uroepithelial cells (SV-Huc-1) with 
acridine orange did not show a significant reduction in cell viability (Lin et al., 
2017). The difference in effect is probably due to using lower compound 
concentrations and different levels of light activation.  
 
Microbial biofilms often have high degree of complexity and are often challenging 
to treat due to their high resistance to traditional antimicrobial treatments. As 
described in Chapter 7, the photoantifungal activity of shortlisted compounds was 
studied against C. albicans biofilm and planktonic cells using the colorimetric 
metabolic XTT assay, which evaluates the viability of cells. It has been 
demonstrated in Chapter 7 that Compounds 1, 2 and 36, at a concentration of 25 
µg/ml, showed a significant drop in metabolic activity when exposed to blue light 
against C. albicans biofilms, however they exhibited a higher reduction in 
metabolic activity in planktonic C. albicans. The findings in this study support 
several studies using different PDT agents, which inactivated the viability of C. 
albicans biofilms and showed more susceptibility to these agents in planktonic C. 
albicans than C. albicans biofilms (Diogo et al., 2017; Shi et al., 2016; De Melo 
et al., 2013). The remaining shortlisted Compounds, 11 and 24, could inactivate 
the viability of planktonic C. albicans, however minimal effect was observed on 
the C. albicans biofilms. The antimicrobial effect of PDT is reliant on both cellular 
localisation of the compounds and on the diffusion of ROS that should be 
sufficient to reduce the viability of biofilm cells (Diogo et al., 2017; Hu et al., 2018). 
This highlighted the possibility that Compounds 11 and 43 could not penetrate 
well inside the biofilm cells, however, they were able to penetrate into the 
planktonic C. albicans cells and inactivate their metabolism. Although the effect 
of shortlisted compounds was not investigated in this current study against 
bacterial biofilms, various studies conducted on PDT agents have shown 
antibacterial activity against S. aureus biofilms (Pereira et al., 2011). This may 
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suggest that the PDT shortlisted compounds could have in vitro antimicrobial 
activity against bacterial biofilms. 
The acridine-based shortlisted compounds cannot be used clinically based on 
mammalian toxicity data obtained in this study. However, other PDT agents such 
as porphyrin related photosensitisers could be used widely clinically due to their 
antimicrobial effect with no toxicity against mammalian cells. 
 
8.4 Characterisation of novel PDT compounds 
To determine the mechanism of action of these compounds both in vitro and in 
vivo tools were utilised. Initially, screening using several in vitro 
spectrophotometric assays determined that 1O2 measurements were not 
consistent with antimicrobial data. Furthermore, free radicals, another key 
molecule produced by PDT agents, could not be measured.  
The mechanism of action of Compounds 1, 2 and 36 was identified using S. 
cerevisiae deletion strains, as demonstrated in Chapter 7, confirmed that the 
msn2/4 transcription factors play a significant role in the cellular response to the 
particular photoactivated Compounds (1, 2 and 36). The data in the current study 
is supported by the evidence that deletion of the genes encoding these Msn2/4 
proteins results in susceptibility of cells to oxidative stress and specifically to 
hydrogen peroxide, a resultant radical species (Pascual-Ahuir et al., 2007; Hasan 
et al., 2002; Martinez Pastor et al., 1996). Therefore, it is suggested that in vitro 
photochemical data for 1O2 in this study aligns with the mechanism of action of 
Compounds 1, 2 and 36, which means that oxidative stress through msn2/4 may 
be the meachanism of action of these compounds. For Compounds 11 and 43 
the mechanism of action may not be due to ROS and possibly they have 
alternative mechanisms of action as msn2/4 is not involved in the mechanism of 
action of these compounds.  
 
A major drawback of the in vitro spectrophotometric assay is its lack of biological 
relevance and poor alignment with the mechanism of action of compounds. The 
ROS including hydroxyl radical .OH and singlet oxygen 1O2 in vitro may not be 
easy to detect, because of their extremely short lifetimes. Additionally, the 
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reaction mechanisms in biological screening depend on different considerations. 
Firstly, the localisation of PS is critical as ROS are highly reactive and cannot 
travel far from their site of production before degrading. Secondly, penetration of 
the PS into the cell is also important, as the data did not confirm whether these 
compounds enter the cell or not. Thirdly, the amount of species released during 
PDT depends on the solvent and media used (Pérez-Jiménez et al., 2006) . 
An alternative detection method is the addition of .OH and 1O2 quenchers or 
scavengers in vivo to the illuminated microbial suspension containing the PSs 
during PDT may be more helpful in identifying the role of each species by 
monitoring the extent of microbial inactivation (Tavares et al., 2010). However, 
inherent difficulties with the commonly-used quencher methods include the ability 
of quenchers to react with any oxidising agent, as well as the possibility of the 
two agents involved in PDT (.OH and 1O2) to indiscriminately oxidise many of 
these quenchers. Further to this, the introduction of fluorescence probes to 
measure and characterise the identity of different ROS produced during PDT in 
vitro has become recently popular, Fluorescence probes, 3'-(p-hydroxyphenyl)-
fluorescein (HPF) and singlet oxygen sensor green reagent (SOSG) were used 
to determine .OH and 1O2, respectively. However, it is generally accepted that 
these probes (HPF and SOSG) are not very specific for .OH and 1O2 and also the 
approach is not biologically relevant (Price et al., 2010) . 
The in vitro chemical methods used in this project were not biologically relevant 
and were not easy to characterise PDT agents. The chemical data obtained does 
not match with antimicrobial activity, thus testing them biologically suggests that 
some of them work by PDT mechanism while others do not. 
 
8.5 Optimisation of PDT compounds for clinical use 
The data within this study found that Gram-negative E. coli were more resistant 
to tested photoactivated compounds than Gram-positive S. aureus by showing 
higher MIC values. In the case of Gram-negative bacteria, photoinactivation is 
difficult as they are relatively impermeable to neutral or anionic compounds due 
to their highly negatively charged surface. Therefore, it is desirable for clinical 
applications of these shortlisted compounds to introduce positive charge which 
make them more active against Gram-positive and negative bacteria as well as 
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fungi. Additionally, using disrupting agents such as polymixin nonapeptide in 
combination with the compounds can be an alternative to allow the penetration 
of the compound that can then cause killing damage to the cell when it is exposed 
to light.  
To obtain an effective irradiance dose it is suggested to use low power with long 
exposure time, which increases significantly the antimicrobial activity, when 
compared to high power with short illumination time (Murdoch et al., 2012). 
Furthermore, it is generally accepted that synergistic combinations of two or more 
agents can overcome possible toxicity and side effects associated with high 
doses of single drugs and increase the effect compared with using the individual 
drug in the equivalent dose (Yasukawa et al., 2012; Fila et al., 2017). Utilising 
shorter blue light wavelength with a higher irradiance dose achieves the best 
potential antimicrobial blue light efficacy (Murdoch et al., 2012). This suggests 
that combination of shorter antimicrobial blue light with the shortlisted compounds 
increased their activity. However, using shorter blue light may damage the DNA.  
Since these acridine-based shortlisted compounds have been absorbed in the 
blue light region, the best activating light is expected to be blue light. However, 
red light is more advantageous for the PS applications due to the better tissue 
penetration of red light than other light wavelengths.  
 
The toxicity prevents the use of these shortlisted compounds clinically. In order 
to make them less toxic and direct them to the intended location in the body, a 
nanoparticle drug delivery system could be a good option. The shortlisted 
compounds could be loaded onto polymer based nanoparticles which offer 
selectivity for microbial infections without affecting the host tissue (Sakima et al., 
2018). However, this approach might be expensive and time consuming.  
The purpose of this study was to develop photoactivated antimicrobial 
compounds; however, they did not show encouraging results. To make the 
compounds more effective, first of all we need to know whether they enter the 
cell or not. The shortlisted compounds are expected to enter the cell and could 
have two effects, by entering the cell and be activated or by having another 
unclear mechanism. Acridine-based compounds are expected to have the most 




The in vitro photochemistry methods used in this project have no biological 
relevance. Ultimately, unless we test the compounds in biological systems we will 
not have acceptable indication about the therapeutic potential. 
Among the photosensitisers tested in this thesis, five acridine-based compounds 
are the most active compounds biologically against the fungi S. cerevisiae and 
C. albicans and the bacteria S. aureus and E. coli, with no activity against A. 
fumigatus. The anti-biofilm effect observed in this study may serve as a strong 
base for further formulation development to form a promising approach in 
treatment of chronic biofilm infections.  
The present study has also confirmed that fungi and bacteria photosensitised by 
the shortlisted compounds do not develop resistance mechanisms against the 
photodynamic process following three repeated exposures. 
Through the investigation of the mechanism of action using deleted S. cerevisiae 
strains, a remarkable role for msn2/4 in oxidative cellular response has been 
determined for Compounds 1, 2 and 36. It has been further demonstrated that 
msn2/4 has not been activated in response to the Compounds 11 and 43 and 
thus other mechanisms could be involved.  
Since the observations that testing acridine-based shortlisted compounds 
inactivated significantly the viability of HeLa cells, utility of these compounds 
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